>A0A290U7C4|PF00931(198...417)|Disease resistance protein Roq1
MLTSSSHHGRSYDVFLSFRGEDTRKTFVGHLFNALIEKGIHTFMDDKELKRGKSISSELMKAIGESRFAVVVFSKNYASS
TWCLEELVKILEIHEKFELIVVPVFYDVDPSTVRKQNGEYAVCFTKFEANLVDDRDKVLRWREALTKVANISGHDLRNTY
NGDESKCIQQILKDIFDKFCFSISITNRDLVGIESQIKKLSSLLRMDLKGVRLVGIWGMGGVGKTTAARALFNRYYQNFE
SACFLEDVKEYLQHHTLLYLQKTLLSKLLKVEFVDCTDTEEMCVILKRRLCSKKVLVVLDDVNHNDQLDKLVGAEDWFGS
GSRIVITTRDMKLLKNHDVHETYEIKVLEKDEAIELFNLHAFKRSSPEKEFKELLNLVVDYTGGLPLALKVLGSLLYKED
LDVWISTIDRLKDNPEGEIMATLKISFDGLRDYEKSIFLDIACFFRGYNQRDMTALFHASGFHPVLGVKTLVEKSLIFIL
EDKIQMHDLMQEMGRQIAVQESPMRRIYRPEDVKDACIGDMRKEAIEGLLLTEPEQFEEGELEYMYSAEALKKTRRLRIL
VKEYYNRGFDEPVAYLPNSLLWLEWRNYSSNSFPSNFEPSKLVYLTMKGSSIIELWNGAKRLAFLTTLDLSYCHKLIQTP
DFRMITNLERLILSSCDALVEVHPSVGFLKNLILLNMDHCISLERLPAIIQSECLEVLDLNYCFNLKMFPEVERNMTHLK
KLDLTSTGIRELPASIEHLSSLENLQMHSCNQLVSLPSSIWRFRNLKISECEKLGSLPEIHGNSNCTRELILKLVSIKEL
PTSIGNLTSLNFLEICNCKTISSLSSSIWGLTSLTTLKLLDCRKLKNLPGIPNAINHLSGHGLQLLLTLEQPTIYERLDL
LRIIDMSWCSCISSLPHNIWMLKFLRILCISYCSRLEYLPENLGHLEHLEELLADGTGILRLPSSVARLNKLEVLSFRKK
FAIGPKVQYSSSMLNLPDDVFGSLGSLGSVVKLNLSGNGFCNLPETMNQLFCLEYLDITFCQRLEALPELPPSIKELYVD
EHLALRIMEDLVIKCKELNLIAVTKIEYQNFYRWLDSIWSDVSELLENSQKQQLDDMLQLIPFSYLSTAKREEVLKIVIH
GTRIPEWFRWQDRSATTMSVNLPEYWYTENFLGFAICCSCCFYHSARSYDVEFEGSMHHYNYDSSYWKEYEEPSYDFYER
DSIEITAKLTPRHKGMRTEELKKVCSFSMNVLRRATAVPNMCFAFFPFNSLCHISNLQANNPNDYGIFETCLSPGDIRHR
GKQWGFNLVYKDETGGSVTHEMLINR
>A7XGN8|PF00931(169...421)|Disease susceptibility protein LOV1
MAEGVVLFGVHKLWELLNRESARLNGIGEQVDGLKRQLGRLQSLLKDADAKKHESERVRNFLEDVRDIVYDAEDIIESFL
LNEFRTKEKGIKKHARRLACFLVDRRKFASDIKGITKKISEVIGGMKSLGIQEIIDGASSMSLQERQREQKEIRQTFANS
SESDLVGVEQSVEALAGHLVENDNIQVVSISGMGGIGKTTLARQVFHHDMVQRHFDGFAWVFVSQQFTQKHVWQRIWQEL
QPQNGDISHMDEHILQGKLFKLLETGRYLVVLDDVWKEEDWDRIKAVFPRKRGWKMLLTSRNEGVGIHADPKSFGFKTRI
LTPEESWKLCEKIVFHRRDETGTLSEVRVDEDMEAMGKEMVTCCGGLPLAVKVLGGLLATKHTVPEWKRVYDNIGPHLAG
RSSLDDNLNSIYRVLSLSYEDLPMCLKHCFLYLAHFPEYYEIHVKRLFNYLAAEGIITSSDDGTTIQDKGEDYLEELARR
NMITIDKNYMFLRKKHCQMHDMMREVCLSKAKEENFLEIFKVSTATSAINARSLSKSRRLSVHGGNALQSLGQTINKKVR
SLLYFAFEDEFCILESTTPCFRSLPLLRVLDLSRVKFEGGKLPSSIGDLIHLRFLSLHRAWISHLPSSLRNLKLLLYLNL
GFNGMVHVPNVLKEMQELRYLQLPMSMHDKTKLELSDLVNLESLMNFSTKYASVMDLLHMTKLRELSLFITDGSSDTLSS
SLGQLRSLEVLHLYDRQEPRVAYHGGEIVLNCIHLKELELAIHMPRFPDQYLFHPHLSHIYLWCCSMEEDPIPILERLLH
LKSVILTFGAFVGRRMVCSKGGFPQLCFLKLEELEELEEWIVEEGSMPLLRALTICNCRKLKLPGGINYITSLKELTIVG
MKWKEKLVPGGEDYYKVQNIPNVQFINCDE
>A9QGV6|PF00931(169...421)|Inactive disease susceptibility protein LOV1
MAEGVVLFGVHKLWELLNRESARLNGIGEQVDGLKRQLGRLQSLLKDADAKKHESERVRNFLEDVRDIVYDAEDIIESFL
LNEFRAKEKGIKKHARRLACFLVDRRKFDSDIKGITKKISEVIGGMKSLGIQEIIDGASSMSLQERQREQKEIRQTFANS
SESDLVGVEQSVEALAGHLVENDNIQVVSISGMGGIGKTTLARQVFHHDMVQRHFDGFAWVFVSQQFAQKHVWQRIWQEL
QPQNGDISHMDEHILQGKLFKLLETGRYLVVLDDVWKEEDWDRIKAVFPRKRGWKMLLTSRNEGVGIHADPKSFGFKTRI
LTPEESWKLCEKIVFHRRDETGTLSEVRVDEDMEAMGKEMVTCCGGLPLAVKVLGGLLATKHTVPEWKRVYDNIGPHLAG
RSSLDDNLNSIYRVLSLSYEDLPMCLKHCFLYLAHFPEYYEIHVKRLFNYLAAEGIITSSDDGTTIQDKGEDYLEELARR
NMITIDKNYMFLRKKHCQMHDMMREVCLSKAKEENFLEIFKVSTATSAINARSLSKSSRLSVHGGNALQSLGQTINKKVR
SLLYFAFEDEFCILESTTPCFRSLPLLRVLDLSRVKFEGGKLPSSIGDLIHLRFLSLHRAWISHLPSSLRNLKLLLYLNL
GFNGMVHVPNVLKEMQELRYLQLPMSMHDKTKLELSDLVNLESLMNFSTKYASVMDLLHMTKLRELSLFITDGSSDTLSS
SLGQLRSLEVLHLYDRQEPRVAYHGGEIVLNCIHLKELELAIHMPRFPDQYLFHPHLSHIYLWCCSMEEDPIPILERLLH
LKSVILTFGAFVGRRMVCSKGGFPQLCFLKLEELEELEEWIVEEGSMPLLRALTICNCRKLKLPGGINYITSLKELTIVG
MKWKEKLVPGGEDYYKVQNIPNVQFINCDE
>B5UBC1|PF00931(282...487)|Disease resistance protein Pikm1-TS
MEAAAMAVTAATGALAPVLVKLAALLDDGECNLLEGSRSDAEFIRSELEAVHSLLTPNILGRMGDDDAACKDGLIAEVRE
LSYDLDDAVDDFLELNFEQRRSASPFGELKARVEERVSNRFSDWKLPAASLPPSSVHRRAGLPPPDAGLVGMHKRKEELI
ELLEQGSSDASRWRKRKPHVPLRIMGGEMQKIVFKIPMVDDKSRTKAMSLVASTVGVHSVAIAGDLRDQVVVVGDGIDSI
NLVSALRKKVGPAMFLEVSQVKEDVKEITAMLAPVKSICEFHEVKTICILGLPGGGKTTIARVLYHALGTQFQCRVFASI
SPSSSPSPNLTETLADIFAQAQLGVTDTLSTPYGGSGTGRALQQHLIDNISAFLLNKKYLIVIDDIWHWEEWEVIRKSIP
KNDLGGRIIMTTRLNSIAEKCHTDDNDVFVYEVGDLDNNDAWSLSWGIATKSGAGNRIGTGEDNSCYDIVNMCYGMPLAL
IWLSSALVGEIEELGGAEVKKCRDLRHIEDGILDIPSLQPLAESLCLGYNHLPLYLRTLLLYCSAYHWSNRIERGRLVRR
WIAEGFVSEEKEAEGYFGELINRGWITQHGDNNSYNYYEIHPVMLAFLRCKSKEYNFLTCLGLGSDTSTSASSPRLIRRL
SLQGGYPVDCLSSMSMDVSHTCSLVVLGDVARPKGIPFYMFKRLRVLDLEDNKDIQDSHLQGICEQLSLRVRYLGLKGTR
IRKLPQEMRKLKHLEILYVGSTRISELPQEIGELKHLRILDVRNTDITELPLQIRELQHLHTLDVRNTPISELPPQVGKL
QNLKIMCVRSTGVRELPKEIGELNHLQTLDVRNTRVRELPWQAGQISQSLRVLAGDSGDGVRLPEGVCEALINGIPGATR
AKCREVLSIAIIDRFGPPLVGIFKVPGSHMRIPKMIKDHFRVLSCLDIRLCHKLEDDDQKFLAEMPNLQTLVLRFEALPR
QPITINGTGFQMLESFRVDSRVPRIAFHEDAMPNLKLLEFKFYAGPASNDAIGITNLKSLQKVVFRCSPWYKSDAPGISA
TIDVVKKEAEEHPNRPITLLINAGYKEISTESHGSSENIAGSSGIDTEPAQAQHDNLPAVRDDYKGKGILLDGRCPTCGR
ATKIEEETQDRVADIEIQTETTS
>C4B7M5|PF00931(163...371)|Disease resistance protein RRS1
MTNCEKDEEFVCISCVEEVRYSFVSHLSEALRRKGINNVVVGVDSDDLLFKESQAKIEKAGVSVMVLPGNCDPSDVWLDK
FAKVLECQRNNKDQAVVPVLYGDSLLRDQWLSELDFKGLSRIHQSRKECSDSILVEEIVRDVYETHFYVGRIGIYSKLLE
IENMVNKQPIGIRCVGIWGMPGIGKTTLAKAVFDQMSSAFDASCFIEDYDKSIHEKGLYCLLEEQLLPGNDATIMKLSSL
RDRLNSKRVLVVLDDVRNALVGESFLEGFDWLGPGSLIIITSRDKQVFCLCGINQIYEVQGLNEKEARQLFLLSASIKED
MGEQNLQELSVRVINYANGNPLAINVYGRELKGKKKLSEMETAFLKLKRRPPFKIVDAFKSTYDTLSDNEKNIFLDIACF
FQGENVNYVIQLLEGCGFFPHVEIDVLVDKCLVTISENRVWLHKLTQDIGREIINGETVQIERRRRLWEPWSIKYLLEYN
EHKANGEPKTTFKRAQGSEEIEGLFLDTSNLRFDLQPSAFKNMLNLRLLKIYCSNPEVHPVINFPTGSLHSLPNELRLLH
WENYPLKSLPQNFDPRHLVEINMPYSQLQKLWGGTKNLEMLRTIRLCHSHHLVDIDDLLKAENLEVIDLQGCTRLQNFPA
AGRLLRLRDVNLSGCIKIKSVLEIPPNIEKLHLQGTGILALPVSTVKPNHRELVNFLTEIPGLSEASKLERLTSLLESNS
SCQDLGKLICLELKDCSCLQSLPNMANLDLNVLDLSGCSSLNSIQGFPRFLKQLYLGGTAIREVPQLPQSLEILNAHGSC
LRSLPNMANLEFLKVLDLSGCSELETIQGFPRNLKELYFAGTTLREVPQLPLSLEVLNAHGSDSEKLPMHYKFNNFFDLS
QQVVNDFFLKTLTYVKHIPRGYTQELINKAPTFSFSAPSHTNQNATFDLQPGSSVMTRLNHSWRNTLVGFGMLVEVAFPE
DYCDATDFGISCVCRWSNKEGRSCRIERNFHCWAPGKVVPKVRKDHTFVFSDVNMRPSTGEGNDPDIWAGLVVFEFFPIN
QQTKCLNDRFTVTRCGVRVINVATGNTSLENISLVLSLDPVEVSGYEVLRVSYDDLQEMDKVLFLYIASLFNDEDVDFVA
PLIAGIDLDVSSGLKVLADVSLISVSSNGEIVMHSLQRQMGKEILHGQSMLLSDCESSMTENLSDVPKKEKKHRESKVKK
VVSIPAIDEGDLWTWRKYGQKDILGSRFPRGYYRCAYKFTHGCKATKQVQRSETDSNMLAITYLSEHNHPRPTKRKALAD
STRSTSSSICSAITTSASSRVFQNKDEPNKPHLPSSSTPPGNAAVLFKMTDMEEFQDNMEVDNDVVDTRTLALFPEFQHQ
PEEEYPWSTFFDY
>C4B7M6|PF00931(163...372)|Disease resistance protein RRS1
MTNCEKDEEFVCISCVEEVRYSFVSHLSEALRRKGINNVVVDVDIDDLLFKESQAKIEKAGVSVMVLPGNCDPSEVWLDK
FAKVLECQRNNKDQAVVSVLYGDSLLRDQWLSELDFRGLSRIHQSRKECSDSILVEEIVRDVYETHFYVGRIGIYSKLLE
IENMVNKQPIGIRCVGIWGMPGIGKTTLAKAVFDQMSSAFDASCFIEDYDKSIHEKGLYCLLEEQLLPGNDATIMKLNSL
RDRLNSKRVLVVLDDVCNALVAESFLEGFDWLGPGSLIIITSRDKQVFRLCGINQIYEVQGLNEKEARQLFLLSASIKED
MGEQNLHELSVRVISYANGNPLAISVYGRELKGKKKLSEMETAFLKLKRRPPFKIVDAFKSSYDTLSDNEKNIFLDIACF
FQGENVNYVIQLLEGCGFFPHVEIDVLVDKCLVTISENRVWLHKLTQDIGREIINGETVQIERRRRLWEPWSIKYLLEYN
EHKANGEPKTTFKRAQGSEEIEGLFLDTSNLRFDLQPSAFKNMLNLRLLKIYCSNPEVHPVINFPTGSLHSLPNELRLLH
WENYPLKSLPQNFDPRHLVEINMPYSQLQKLWGGTKNLEMLRTIRLCHSQHLVDIDDLLKAENLEVIDLQGCTRLQNFPA
AGRLLRLRVVNLSGCIKIKSVLEIPPNIEKLHLQGTGILALPVSTVKPNHRELVNFLTEIPGLSEASKLERLTSLLESNS
SCQDLGKLICLELKDCSCLQSLPNMANLDLNVLDLSGCSSLNSIQGFPRFLKQLYLGGTAIREVPQLPQSLEILNAHGSC
LRSLPNMANLEFLKVLDLSGCSELETIQGFPRNLKELYFAGTTLREVPQLPLSLEVLNAHGSDSEKLPMHYKFNNFFDLS
QQVVNDFFLKALTYVKHIPRGYTQELINKAPTFSFSAPSHTNQNATFDLQPGSSVMTRLNHSWRNTLVGFGMLVEVAFPE
DYCDATDVGISCVCRWSNKEGRSCRIERNFHCWAPGKVVPKVRKDHTFVFSDVNMRPSTGEGNDPDIWAGLVVFEFFPIN
QQTKCLNDRFTVTRCGVRVINVATGNTSLENISLVLSLDPVEVSGYEVLRVSYDDLQEMDKVLFLYIASLFNDEDVDFVA
PLIAGIDLDVSSGLKVLADVSLISVSSNGEIVMHSLQRQMGKEILHGQSMLLSDCESSMTENLSDVPKKEKKHRESKVKK
VVSIPAIDEGDLWTWRKYGQKDILGSRFPRGYYRCAYKFTHGCKATKQVQRSETDSNMLAITYLSEHNHPRPTKRKALAD
STRSTSSSICSAITTSASSRVFQNKDEPNKPHLPSSSTPPGNAAVLFKMTDMEEFQDNMEVDNDVVDTRTLALFPEFQHQ
PEEEYPWSTFFDD
>C4B7M7|PF00931(211...449)|Disease resistance protein RPS4
METSSISTVEDKPPQHQVFINFRGADLRRRFVSHLVTALKLNNINVFIDDYEDRGQPLDVLLKRIEESKIVLAIFSGNYT
ESVWCVRELEKIKDCTDEGTLVAIPIFYKLEPSTVRDLKGKFGDRFRSMAKGDERKKKWKEAFNLIPNIMGITIDKKSVE
SEKVNEIVKAVKTALTGIPPEGSHNAVVGALGNSNAGTSSGDKKHETFGNEQRLKDLEEKLDRDKYKGTRIIGVVGMPGI
GKTTLLKELYKTWQGKFSRHALIDQIRVKSKHLELDRLPQMLLGELSKLNNPHVDNLKDPYSQLHERKVLVVLDDVSKRE
QIDALREILDWIKEGKEGSRVVIATSDMSLTNGLVDDTYMVQNLNHRDSLQLFHYHAFIDDQANPQKKDFMKLSEGFVHY
ARGHPLALKVLGGELNKKSMDHWNSKMKKLAQSPSPNIVSVFQVSYDELTTAQKDAFLDIACFRSQDKDYVESLLASSDL
GSAEAMSAVKSLTDKFLINTCDGRVEMHDLLYKFSREIDLKASNQDGSRQRRLWLHQHIIKGGIINVLQNKMKAANVRGI
FLDLSEVEDETSLDRDHFINMGNLRYLKFYNSHCPQECKTNNKINIPDKLKLPLKEVRCLHWLKFPLETLPNDFNPINLV
DLKLPYSEMEQLWEGDKDTPCLRWVDLNHSSKLCSLSGLSKAEKLQRLNLEGCTTLKAFPHDMKKMKMLAFLNLKGCTSL
ESLPEMNLISLKTLTLSGCSTFKEFPLISDNIETLYLDGTAISQLPMNMEKLQRLVVLNMKDCKMLEEIPGRVGELKALQ
ELILSDCLNLKIFPEIDISFLNILLLDGTAIEVMPQLPSVQYLCLSRNAKISCLPVGISQLSQLKWLDLKYCTSLTSVPE
FPPNLQCLDAHGCSSLKTVSKPLARIMPTEQNHSTFIFTNCENLEQAAKEEITSYAQRKCQLLSYARKRYNGGLVSESLF
STCFPGCEVPSWFCHETVGSELEVKLLPHWHDKKLAGIALCAVVSCLDPQDQVSRLSVTCTFKVKDEDKSWVPYTCPVGS
WTRHGGGKDKIELDHVFIGYTSCPHTIKCHEEGNSDECNPTEASLKFTVTGGTSENGKYKVLKCGLSLVYAKDKDKNSAL
ETKYDMLIGKSFQETSEGVDGRVKKTKGKYVMPVEKNFQETTEGVDGRVKKKKKTRMDNGRPKKKQRSGRDDNQTRMQVE
LQEGNINSVIMHTVKNF
>E1B328|PF00931(163...372)|Disease resistance protein RRS1
MTNCEKDEEFVCISCVEEVRYSFVSHLSEALRRKGINNVVVDVDIDDLLFKESQAKIEKAGVSVMVLPGNCDPSEVWLDK
FAKVLECQRNNKDQAVVSVLYGDSLLRDQWLSELDFRGLSRIHQSRKECSDSILVEEIVRDVYETHFYVGRIGIYSKLLE
IENMVNKQPIGIRCVGIWGMPGIGKTTLAKAVFDQMSSAFDASCFIEDYDKSIHEKGLYCLLEEQLLPGNDATIMKLSSL
RDRLNSKRVLVVLDDVCNALVAESFLEGFDWLGPGSLIIITSRDKQVFRLCGINQIYEVQGLNEKEARQLFLLSASIMED
MGEQNLHELSVRVISYANGNPLAISVYGRELKGKKKLSEMETAFLKLKRRPPFKIVDAFKSSYDTLSDNEKNIFLDIACF
FQGENVNYVIQLLEGCGFFPHVEIDVLVDKCLVTISENRVWLHKLTQDIGREIINGETVQIERRRRLWEPWSIKYLLEYN
EHKANGEPKTTFKRAQGSEEIEGLFLDTSNLRFDLQPSAFKNMLNLRLLKIYCSNPEVHPVINFPTGSLHSLPNELRLLH
WENYPLKSLPQNFDPRHLVEINMPYSQLQKLWGGTKNLEMLRTIRLCHSQHLVDIDDLLKAENLEVIDLQGCTRLQNFPA
AGRLLRLRVVNLSGCIKIKSVLEIPPNIEKLHLQGTGILALPVSTVKPNHRELVNFLTEIPGLSEASKLERLTSLLESNS
SCQDLGKLICLELKDCSCLQSLPNMANLDLNVLDLSGCSSLNSIQGFPRFLKQLYLGGTAIREVPQLPQSLEILNAHGSC
LRSLPNMANLEFLKVLDLSGCSELETIQGFPRNLKELYFAGTTLREVPQLPLSLEVLNAHGSDSEKLPMHYKFNNFFDLS
QQVVNDFFLKALTYVKHIPRGYTQELINKAPTFSFSAPSHTNQNATFDLQPGSSVMTRLNHSWRNTLVGFGMLVEVAFPE
DYCDATDVGISCVCRWSNKEGRSCRIERNFHCWAPGKVVPKVRKDHTFVFSDVNMRPSTGEGNDPDIWAGLVVFEFFPIN
QQTKCLNDRFTVTRCGVRVINVATGNTSLENISLVLSLDPVEVSGYEVLRVSYDDLQEMDKVLFLYIASLFNDEDVDFVA
PLIAGIDLDVSSGLKVLADVSLISVSSNGEIVMHSLQRQMGKEILHGQSMLLSDCESSMTENLSDVPKKEKKHRESKVKK
VVSIPAIDEGDLWTWRKYGQKDILGSRFPRGYYRCAYKFTHGCKATKQVQRSETDSNMLAITYLSEHNHPRPTKRKALAD
STRSTSSSICSAITTSASSRVFQNKDEPNQPHLPSSSTPPRNAAVLFKMTDMEEFQDNMEVDNDVVDTRTLALFPEFQHQ
PEEEDPWSTFFDDYNFYF
>F2VYU4|PF00931(282...487)|Disease resistance protein Pik-1
MEAAAMAVTAATGALAPVLVKLAALLDDGECNLLEGSRSDAEFIRSELEAVHSLLTPNILGRMGDDDAACKDGLIAEVRE
LSYDLDDAVDDFLELNFEQRRSASPFGELKARVEERVSNRFSDWKLPAASLPPSSVHRRAGLPPPDAGLVGMHKRKEELI
ELLEQGSSDASRWRKRKPHVPLRIMGGEMQKIVFKIPMVDDKSRTKAMSLVASTVGVHSVAIAGDLRDEVVVVGDGIDSI
NLVSALRKKVGHAELLQVSQVKEDVKEITAMLAPVKSICEFHEVKTICILGLPGGGKTTIARVLYHALGTQFQCRVFASI
SPSSSPSPNLTETLADIFAQAQLGVTDTLSTPYGGSGTGRALQQHLIDNISAFLLNKKYLIVIDDIWHWEEWEVIRKSIP
KNDLGGRIIMTTRLNSIAEKCHTDDNDVFVYEVGDLDNNDALSLSWGIATKSGAGNRIGTGEDNSCYDIVNMCYGMPLAL
IWLSSALVGEIEELGGAEVKKCRDLRHIEDGILDIPSLQPLAESLCLGYNHLPLYLRTLLLYCSAYHWSNRIERGRLVRR
WIAEGFVSEEKEAEGYFGELINRGWITQHGDNNSYNYYEIHPVMLAFLRCKSKEYNFLTCLGLGSDTSTSASSPRLIRRL
SLQGGYPVDCLSSMSMDVSHTCSLVVLGDVARPKGIPFYMFKRLRVLDLEDNKDIQDSHLQGICEQLSLRVRYLGLKGTR
IRKLPQEMRKLKHLEILYVGSTRISELPQEIGELKHLRILDVRNTDITELPLQIRELQHLHTLDVRNTPISELPPQVGKL
QNLKIMCVRSTGVRELPKEIGELNHLQTLDVRNTRVRELPWQAGQISQSLRVLAGDSGDGVRLPEGVCEALINGIPGATR
AKCREVLSIAIIDRFGPPLVGIFKVPGSHMRIPKMIKDHFRVLSCLDIRLCHKLEDDDQKFLAEMPNLQTLVLRFEALPR
QPITINGTGFQMLESFRVDSRLPRIAFHEDAMPNLKLLEFKFYAGPASNDAIGITNLKSLQKVVFRCSPWYKSDAPGISA
TIDVVKKEAEEHPNRPITLLINAGYKEISTESHGSSENIAGSSGIDTEPAQAQHDNLPAVRDDYKGKGILLDGRCPTCGR
ATKIEEETQDRVADIEIQTETTS
>F4I594|PF00931(191...426)|Disease resistance protein RML1A
MASSSSSASRTWRYRVFTSFHGSDVRTSFLSHFRKQFNNNGITMFDDQRILRGETISPALTQAIRESRISIVLLSKNYAS
SGWCLDELLEILKCKDDMGQIVMTVFYGVDPSDVRKQTGEFGIAFNETCACRTEEERQKWSQALNYVGNIAGEHLLNWDN
EAKMIEKIARDVSEKLNVTPCRDFDGMVGIEAHLRKIQSLLDLDNDEVKMVAISGPAGIGKSTIGRALHSLLSNRFHHTC
FVDNLRGSHPIGLDEYGLKLRLQEQLLSKILNQDGSRICHLGAIKERLCDMKVFIILDDVNDVKQLEALANESNWFGPGS
RIIVTTENKELLKQHGINNTYYVGFPSDEEAIKILCRYAFRQSSSRHGFKKLTRSVTELCGKLPLGLRVVGSSLHGKNEE
EWEYVIRRLETIIDRDIEQVLRVGYESLHENEQSLFLHIAIFFNYEDGDLVKAMLAENDLDIEHELNILVNKSLIYISTD
GRIRMHKLLQLVGRQANQREEPWKRRILIDAQEICHVLENDIGTGAVSGILFDTSGINEVSISNKALRRMCNLRFLSVYK
TKHDGYNRMDIPEDMEFPPRLRLLHWDAYPSKCLPLKFRAENLVELDMKDSRLEYLWPGTQLLTKLKKLNLEGSYNLKEL
PDLSNATNLEMLDLSVCLALAELPSSIKNLHKLDVIYMDLCESLHMIPTNINLASLETMYMTGCPQLKTFPAFSTKIKRL
YLVRTGVEEVPASITHCSRLLKIDLSGSRNLKSITHLPSSLQTLDLSSTDIEMIADSCIKDLQRLDHLRLCRCRKLKSLP
ELPASLRLLTAEDCESLERVTYPLNTPTGQLNFTNCLKLGEEAQRVIIQQSLVKHACFPGSVMPSEFNHRARGNSLKILV
KSSASFAFKACVLISPRQLQCERNQRRVKIRCRVTDGRGRFVGSKVVSLEHPNHSTGIRTKHLCFFNGVLTEVSCDALCF
VFKISAYNPLDNYEISECAVQILTNEPERRSCDGGSE
>F4I902|PF00931(183...400)|Disease resistance protein CHS1
MSTSYSFLLAGRELDVFLSFSGKIALDVDFGYDLSRNGIKAFKSESWKESSFKPIDLRTLEALTESKVAVVMTSDEEVSS
VGFLEELIVIIEFQEKRSLTVIPVFLTKHPLDVEKVSQIFPERAKIWRTAIAKLDNIAAQYSFSRNLAVMHGTHRIKQIA
DDIRLMFLSSASSDFKGLAGMDRHMKALYALLALESDEKVRTIGIWGSSGVGKTTLARYTYAEISVKFQAHVFLENVENM
KEMLLPSENFEGEDLRSVNHEMNEMAEAKQKHRKVLLIADGVNNIEQGKWIAENANWFAPGSRVILITQEKSLLVQSGVN
HVYEVGSLRYDEALQLFSRFAFKQPYPSPDFERLSVRAVQLAGFLPVTIRLFGSFLTGRDKEEWEATLLKLNAKQGKDIK
EVWKIMEALEDKDIVEASQR
>F4IBE4|PF00931(167...419)|Probable disease resistance protein RF45
MAGELISFGIQNLWNLLSQECELFQGVEDQVTELKRDLNMLSSFLKDANAKKHTSAVVKNCVEEIKEIIYDGEDTIETFV
LEQNLGKTSGIKKSIRRLACIIPDRRRYALGIGGLSNRISKVIRDMQSFGVQQAIVDGGYKQPQGDKQREMRQKFSKDDD
SDFVGLEANVKKLVGYLVDEANVQVVSITGMGGLGKTTLAKQVFNHEDVKHQFDGLSWVCVSQDFTRMNVWQKILRDLKP
KEEEKKIMEMTQDTLQGELIRLLETSKSLIVLDDIWEKEDWELIKPIFPPTKGWKVLLTSRNESVAMRRNTSYINFKPEC
LTTEDSWTLFQRIALPMKDAAEFKIDEEKEELGKLMIKHCGGLPLAIRVLGGMLAEKYTSHDWRRLSENIGSHLVGGRTN
FNDDNNNTCNNVLSLSFEELPSYLKHCFLYLAHFPEDYEIKVENLSYYWAAEGIFQPRHYDGETIRDVGDVYIEELVRRN
MVISERDVKTSRFETCHLHDMMREVCLLKAKEENFLQITSSRPSTANLQSTVTSRRFVYQYPTTLHVEKDINNPKLRALV
VVTLGSWNLAGSSFTRLELLRVLDLIEVKIKGGKLASCIGKLIHLRYLSLEYAEVTHIPYSLGNLKLLIYLNLASFGRST
FVPNVLMGMQELRYLALPSDMGRKTKLELSNLVKLETLENFSTENSSLEDLCGMVRLSTLNIKLIEETSLETLAASIGGL
KYLEKLEIYDHGSEMRTKEAGIVFDFVHLKRLWLKLYMPRLSTEQHFPSHLTTLYLESCRLEEDPMPILEKLLQLKELEL
GFESFSGKKMVCSSGGFPQLQRLSLLKLEEWEDWKVEESSMPLLRTLDIQVCRKLKQLPDEHLPSHLTSISLFFCCLEKD
PLPTLGRLVYLKELQLGFRTFSGRIMVCSGGGFPQLQKLSIYRLEEWEEWIVEQGSMPFLHTLYIDDCPKLKKLPDGLQF
IYSLKNLKISERWKERLSEGGEEYYKVQHIPSVEFYHRVLHIFRSVGGDITGRLLMR
>F4J339|PF00931(284...510)|Probable disease resistance protein RPP1
MGSVMSLGCSKRKATNQDVDSESRKRRKICSTNDAENCRFIQDESSWKHPWSLCANRVISVAAVALTNFRFQQDNQESNS
SSLSLPSPATSVSRNWKHDVFPSFHGADVRRTFLSHIMESFRRKGIDTFIDNNIERSKSIGPELKEAIKGSKIAIVLLSR
KYASSSWCLDELAEIMKCRQMVGQIVMTIFYEVDPTDIKKQTGEFGKAFTKTCRGKPKEQVERWRKALEDVATIAGYHSH
SWRNEADMIEKISTDVSNMLNSFTPSRDFDGLVGMRAHMDMLEQLLRLDLDEVRMIGIWGPPGIGKTTIARFLFNQVSDR
FQLSAIMVNIKGCYPRPCFDEYSAQLQLQNQMLSQMINHKDIMISHLGVAQERLRDKKVFLVLDEVDQLGQLDALAKETR
WFGPGSRIIITTEDLGVLKAHGINHVYKVEYPSNDEAFQIFCMNAFGQKQPHEGFDEIAWEVTCLAGELPLGLKVLGSAL
RGKSKREWERTLPRLKTSLDGKIGSIIQFSYDVLCDEDKYLFLYIACLFNGESTTKVKELLGKFLDVKQGLHLLAQKSLI
SFDGERIHMHTLLEQFGRETSRKQFVHHGFTKRQLLVGARGICEVLDDDTTDSRRFIGIHLELSNTEEELNISEKVLERV
HDFHFVRIDASFQPERLQLALQDLIYHSPKIRSLNWYGYESLCLPSTFNPEFLVELDMRSSNLRKLWEGTKQLRNLKWMD
LSYSSYLKELPNLSTATNLEELKLRNCSSLVELPSSIEKLTSLQILDLENCSSLEKLPAIENATKLRELKLQNCSSLIEL
PLSIGTATNLKQLNISGCSSLVKLPSSIGDITDLEVFDLSNCSSLVTLPSSIGNLQNLCKLIMRGCSKLEALPININLKS
LDTLNLTDCSQLKSFPEISTHISELRLKGTAIKEVPLSIMSWSPLADFQISYFESLMEFPHAFDIITKLHLSKDIQEVPP
WVKRMSRLRDLSLNNCNNLVSLPQLSDSLDYIYADNCKSLERLDCCFNNPEIRLYFPKCFKLNQEARDLIMHTCIDAMFP
GTQVPACFIHRATSGDSLKIKLKESPLPTTLRFKACIMLVKVNEELMSYDQTPMIVDIVIRDEHNDLKEKIYPSIYPSIY
PLLTEHIYTFELDVEEVTSTELVFEFPQLNKRNWKIGECGILQRETRSLRRSSSPDLSPESSRVSSYDHCLRGD
>F4JNA9|PF00931(189...418)|Disease resistance protein RPP4
MASSSSSPSSRRYDVFPSFSGVDVRKTFLSHLIEALDRRSINTFMDHGIVRSCIIADALITAIREARISIVIFSENYASS
TWCLNELVEIHKCYKKGEQMVIPVFYGVDPSHVRKQIGGFGDVFKKTCEDKPEDQKQRWVKALTDISNLAGEDLRNGPTE
AFMVKKIANDVSNKLFPLPKGFGDFVGIEDHIKAIKSILCLESKEARIMVGIWGQSGIGKSTIGRALFSQLSSQFHHRAF
ITYKSTSGSDVSGMKLSWEKELLSEILGQKDIKIDHFGVVEQRLKHKKVLILLDDVDNLEFLKTLVGKAEWFGSGSRIIV
ITQDKQLLKAHEIDLVYEVELPSQGLALKMISQYAFGKDSPPDDFKELAFEVAELVGSLPLGLSVLGSSLKGRDKDEWVK
MMPRLRNDSDDKIEETLRVGYDRLNKKNRELFKCIACFFNGFKVSNVKELLEDDVGLTMLADKSLIRITPDGDIEMHNLL
EKLGREIDRAKSKGNPAKRQFLTNFEDIQEVVTEKTGTETVLGIRVPPTVLFSTRPLLVINEESFKGMRNLQYLEIGHWS
EIGLWSEIGLWSKIDLPQGLVYLPLKLKLLKWNYCPLKSLPSTFKAEYLVNLIMKYSKLEKLWEGTLPLGSLKKMDLGCS
NNLKEIPDLSLAINLEELNLSKCESLVTLPSSIQNAIKLRTLYCSGVLLIDLKSLEGMCNLEYLSVDWSSMEGTQGLIYL
PRKLKRLWWDYCPVKRLPSNFKAEYLVELRMENSDLEKLWDGTQPLGSLKEMYLHGSKYLKEIPDLSLAINLERLYLFGC
ESLVTLPSSIQNATKLINLDMRDCKKLESFPTDLNLESLEYLNLTGCPNLRNFPAIKMGCSYFEILQDRNEIEVEDCFWN
KNLPAGLDYLDCLMRCMPCEFRPEYLTFLDVSGCKHEKLWEGIQSLGSLKRMDLSESENLTEIPDLSKATNLKRLYLNGC
KSLVTLPSTIGNLHRLVRLEMKECTGLELLPTDVNLSSLIILDLSGCSSLRTFPLISTRIECLYLENTAIEEVPCCIEDL
TRLSVLLMYCCQRLKNISPNIFRLTSLMVADFTDCRGVIKALSDATVVATMEDHVSCVPLSENIEYTCERFWDELYERNS
RSIFSYKDEDGDVYWVNWDLMMMLMLI
>F4JNB7|PF00931(192...425)|Disease resistance protein RPP5
MAASSSSGRRRYDVFPSFSGVDVRKTFLSHLIEALDGKSINTFIDHGIERSRTIAPELISAIREARISIVIFSKNYASST
WCLNELVEIHKCFNDLGQMVIPVFYDVDPSEVRKQTGEFGKVFEKTCEVSKDKQPGDQKQRWVQALTDIANIAGEDLLNG
PNEAHMVEKISNDVSNKLITRSKCFDDFVGIEAHIEAIKSVLCLESKEARMVGIWGQSGIGKSTIGRALFSQLSIQFPLR
AFLTYKSTSGSDVSGMKLSWEKELLSEILGQKDIKIEHFGVVEQRLKHKKVLILLDDVDNLEFLKTLVGKAEWFGSGSRI
IVITQDRQFLKAHDIDLVYEVKLPSQGLALTMLCRSAFGKDSPPDDFKELAFEVAKLAGHLPLGLNVLGSSLRRRGKKEW
MEMMPRLRNGLNGDIMKTLRVSYDRLHQKDQDMFLCIACLFNGFEVSYVKDLLEDNVGLTMLSEKSLIRITPDGHIEMHN
LLEKLGREIDRAKSKGNPGKRQFLTNFEDIHEVVTEKTGTETLLGIRLPFEEYFSTRPLLIDKESFKGMRNLQYLKIGDW
SDGGQPQSLVYLPLKLRLLDWDDCPLKSLPSTFKAEYLVNLIMKYSKLEKLWEGTLPLGSLKKMNLLCSKNLKEIPDLSN
ARNLEELDLEGCESLVTLPSSIQNAIKLRKLHCSGVILIDLKSLEGMCNLEYLSVDCSRVEGTQGIVYFPSKLRLLLWNN
CPLKRLHSNFKVEYLVKLRMENSDLEKLWDGTQPLGRLKQMFLRGSKYLKEIPDLSLAINLEEVDICKCESLVTFPSSMQ
NAIKLIYLDISDCKKLESFPTDLNLESLEYLNLTGCPNLRNFPAIKMGCSDVDFPEGRNEIVVEDCFWNKNLPAGLDYLD
CLMRCMPCEFRPEYLVFLNVRCYKHEKLWEGIQSLGSLEEMDLSESENLTEIPDLSKATNLKHLYLNNCKSLVTLPSTIG
NLQKLVRLEMKECTGLEVLPTDVNLSSLETLDLSGCSSLRTFPLISKSIKWLYLENTAIEEILDLSKATKLESLILNNCK
SLVTLPSTIGNLQNLRRLYMKRCTGLEVLPTDVNLSSLGILDLSGCSSLRTFPLISTNIVWLYLENTAIGEVPCCIEDFT
RLRVLLMYCCQRLKNISPNIFRLRSLMFADFTDCRGVIKALSDATVVATMEDSVSCVPLSENIEYTCERFWGELYGDGDW
DLGTEYFSFRNCFKLDRDARELILRSCFKPVALPGGEIPKYFTYRAYGDSLTVTLPRSSLSQSFLRFKACLVVDPLSEGK
GFYRYLEVNFGFNGKQYQKSFLEDEELEFCKTDHLFFCSFKFESEMTFNDVEFKFCCSNRIKECGVRLMYVSQETEYNQQ
TTRSKKRMRMTSGTSEEYINLAGDQIVADTGLAALNMELSLGEGEASSSTSLEGEALSVDYMITKEQDEDIPFLDPVSDG
TWRSFYSAE
>F4JT78|PF00931(187...412;752...958)|Disease resistance protein RPP2A
MAASFCGSRRYDVFPSFSKVDVRRSFLAHLLKELDRRLINTFTDHGMERNLPIDAELLSAIAESRISIVIFSKNYASSTW
CLDELVEIHTCYKELAQIVVPVFFNVHPSQVKKQTGEFGKVFGKTCKGKPENRKLRWMQALAAVANIAGYDLQNWPDEAV
MIEMVADDVSKKLFKSSNDFSDIVGIEAHLEAMSSILRLKSEKARMVGISGPSGIGKTTIAKALFSKLSPQFHLRAFVTY
KRTNQDDYDMKLCWIEKFLSEILGQKDLKVLDLGAVEQSLMHKKVLIILDDVDDLELLKTLVGQTGWFGFGSRIVVITQD
RQLLKAHDINLIYEVAFPSAHLALEIFCQSAFGKIYPPSDFRELSVEFAYLAGNLPLDLRVLGLAMKGKHREEWIEMLPR
LRNDLDGKFKKTLRNYLPVIRKRVSNEEGGREKLKKGNKKLDLDEEFPGGEIYSDEIPSPTSNWKDTDDFDSGDIIPIIA
DKSTTIIPNRRHSNDDWCSFCEFLRNRIPPLNPFKCSANDVIDFLRTRQVLGSTEALVDRLIFSSEAFGIKPEENPFRSQ
AVTSYLKAARDMTREKECILVFSCHDNLDVDETSFIEAISKELHKQGFIPLTYNLLGRENLDEEMLYGSRVGIMILSSSY
VSSRQSLDHLVAVMEHWKTTDLVIIPIYFKVRLSDICGLKGRFEAAFLQLHMSLQEDRVQKWKAAMSEIVSIGGHEWTKG
SQFILAEEVVRNASLRLYLKSSKNLLGILALLNHSQSTDVEIMGIWGIAGIGKTSIAREIFELHAPHYDFCYFLQDFHLM
CQMKRPRQLREDFISKLFGEEKGLGASDVKPSFMRDWFHKKTILLVLDDVSNARDAEAVIGGFGWFSHGHRIILTSRSKQ
VLVQCKVKKPYEIQKLSDFESFRLCKQYLDGENPVISELISCSSGIPLALKLLVSSVSKQYITNMKDHLQSLRKDPPTQI
QEAFRRSFDGLDENEKNIFLDLACFFRGQSKDYAVLLLDACGFFTYMGICELIDESLISLVDNKIEMPIPFQDMGRIIVH
EEDEDPCERSRLWDSKDIVDVLTNNSGTEAIEGIFLDASDLTCELSPTVFGKMYNLRLLKFYCSTSGNQCKLTLPHGLDT
LPDELSLLHWENYPLVYLPQKFNPVNLVELNMPYSNMEKLWEGKKNLEKLKNIKLSHSRELTDILMLSEALNLEHIDLEG
CTSLIDVSMSIPCCGKLVSLNMKDCSRLRSLPSMVDLTTLKLLNLSGCSEFEDIQDFAPNLEEIYLAGTSIRELPLSIRN
LTELVTLDLENCERLQEMPSLPVEIIRRT
>F4JT80|PF00931(201...428)|Disease resistance protein RPP2B
MAFASSSSSIVLSKCEFDVFVSFRGADTRHDFTSHLVKYLRGKGIDVFSDAKLRGGEYISLLFDRIEQSKMSIVVFSEDY
ANSWWCLEEVGKIMQRRKEFNHGVLPIFYKVSKSDVSNQTGSFEAVFQSPTKIFNGDEQKIEELKVALKTASNIRGFVYP
ENSSEPDFLDEIVKNTFRMLNELSPCVIPDDLPGIESRSKELEKLLMFDNDECVRVVGVLGMTGIGKTTVADIVYKQNFQ
RFDGYEFLEDIEDNSKRYGLPYLYQKLLHKLLDGENVDVRAQGRPENFLRNKKLFIVLDNVTEEKQIEYLIGKKNVYRQG
SRIVIITRDKKLLQKNADATYVVPRLNDREAMELFCLQVFGNHYPTEEFVDLSNDFVCYAKGLPLALKLLGKGLLTHDIN
YWKKKLEFLQVNPDKELQKELKSSYKALDDDQKSVFLDIACFFRSEKADFVSSILKSDDIDAKDVMRELEEKCLVTISYD
RIEMHDLLHAMGKEIGKEKSIRKAGERRRLWNHKDIRDILEHNTGTECVRGIFLNMSEVRRIKLFPAAFTMLSKLKFLKF
HSSHCSQWCDNDHIFQCSKVPDHFPDELVYLHWQGYPYDCLPSDFDPKELVDLSLRYSHIKQLWEDEKNTESLRWVDLGQ
SKDLLNLSGLSRAKNLERLDLEGCTSLDLLGSVKQMNELIYLNLRDCTSLESLPKGFKIKSLKTLILSGCLKLKDFHIIS
ESIESLHLEGTAIERVVEHIESLHSLILLNLKNCEKLKYLPNDLYKLKSLQELVLSGCSALESLPPIKEKMECLEILLMD
GTSIKQTPEMSCLSNLKICSFCRPVIDDSTGLVVLPFSGNSFLSDLYLTNCNIDKLPDKFSSLRSLRCLCLSRNNIETLP
ESIEKLYSLLLLDLKHCCRLKSLPLLPSNLQYLDAHGCGSLENVSKPLTIPLVTERMHTTFIFTDCFKLNQAEKEDIVAQ
AQLKSQLLARTSRHHNHKGLLLDPLVAVCFPGHDIPSWFSHQKMGSLIETDLLPHWCNSKFIGASLCVVVTFKDHEGHHA
NRLSVRCKSKFKSQNGQFISFSFCLGGWNESCGSSCHEPRKLGSDHVFISYNNCNVPVFKWSEETNEGNRCHPTSASFEF
YLTDETERKLECCEILRCGMNFLYARDENDRKFQGIRVTDTVERTSSEALVTIRGQSHSRIEERRYGRIRDEIMDMTGSS
MIGGPES
>F4JT82|PF00931(182...400)|Probable disease resistance protein At4g19520
MVDGKEVYISFNRWEDTIRHSFVSHLSAEFQRKGVSVFASEDSASDDRFAEESDAAIAKARVSVVIFSENFASSKGCLNE
FLKVSKCRRSKGLVVVPVFYGLTNSIVKKHCLELKKMYPDDKVDEWRNALWDIADLRGGHVSSHKRSDSELVEKIVADVR
QKLDRRGRIGVYSRLTKIEYLLCKQPGCIIRSLGIWGMAGIGKTTLARAAYDQLSRDFEASCFIEDFDREFQEKGFFGLL
EKQLGVNPQVTRLSILLKTLRSKRILLVLDDVRKPLGATSFLCEFDWLGPGSLIIVTSQDKQVLVQCQVNEIYKVQGLNK
HESLQLFSRCAFGKDVPDQNLLELSMKFVDYANGNPLALSICGKNLKGKTPLDMKSVVLELKRHLSDKIFVKLKSSYDAL
SVSEKEIFLDIVFTFRGANVDNVMQSLAGCGFFPRVGIEALVDKSFVTVSENRVQVNNLIYDVGLKIINDQSDEIGMCYR
FVDASNSQSLIEHKEIRESEQGYEDVKAINLDTSNLPFKGHIAFQHMYNLRYLTIYSSINPTKDPDLFLPGDPQFLPPEL
RLLHWTCYPLHSFPQNFGFQYLVELNMPCSKLKKLWGGTKNLEVLKRITLSCSVQLLNVDELQYSPNIEKIDLKGCLELQ
SFPDTGQLQHLRIVDLSTCKKIKSFPKVPPSIRKLHLQGTGIRDLSSLNHSSESQRLTRKLENVSSSNQDHRKQVLKLKD
SSHLGSLPDIVIFESLEVLDFSGCSELEDIQGFPQNLKRLYLAKTAIKEVPSSLCHHISKLVKLDMENCERLRDLPMGMS
NMKYLAVLKLSGCSNLENIKELPRNLKELYLAGTAVKEFPSTLLETLSEVVLLDLENCKKLQGLPTGMSKLEFLVMLKLS
GCSKLEIIVDLPLNLIELYLAGTAIRELPPSIGDLALLDTLDLKNCNRLRHLPMEMHNLNPLKVLDLSNCSELEVFTSSL
PKVRELRPAPTVMLLRSKLPFCFFIFYEHRVTLSLYKARLQYIPEEIRWMPSLKTLDLSRNGFTEVPVSIKDFSKLLSLR
LRYCENLRSLPQLPRSLQLLNAHGCSSLQLITPDFKQLPRYYTFSNCFGLPSHMVSEVLANAPAIVECRKPQQGLENALA
CSFCLPSPTSRDSKLYLQPGSSTMIILNPKTRSTLVGFAILVEVSFSKDFHDTAGLGFRCVCRWNDKKGHAHKRDNIFHC
WAPGEVVPKINDDHMFVFFDLKMHPSILFEGDVFGILADLVVFEIFPVNKQEMHVGDSCTITKCGVYVINDAAGSSSGNT
MTPQCSSMDSLKLLDGKGKKRLRVNYAGLKQREKALFLYIACLLGGEKADLLAQFLASTDFVIESTLEDLAGRYLIDISS
NGEVMMPPLQRNFSREIIHMLPASTKELVSMASGSPCNRNNDVFVSFHGKDFRKQFISDFLKKLVYKGIRICIGDKILSR
SLINKVIKESSIAVVVFSENYASSSLCLLQLMEIMKCWEELGQVVMPIFYKVNPSDIRNQSGHFGKGFKKTCKKTINDER
QRWSRALTDAASIAGECSLNWASDADMIEKVANDIRKKLISSKKLGKQIQRVDCDHDNPWETEFNKCIERFFQLPYDGNH
DESLVSLTTEKVIDMKQTLKEIYQITKVKLKNNLVGRRHINNICFMHILYEKCEERSSFNPTSLHTLYDNGIPYQVYTKR
KKHMSGEEKAPIGGCVGCFYMGQNQGITKAGGGRTMPTAYPAAPQANQGYNAGAQPYPPTAYAV
>F4JWM0|PF00931(243...488)|Disease resistance-like protein DSC2
MAIAEVIGFFTLVCVIWYWVYKKHKNLQLKICRSSIESSSSSSSLSSPPSLSSPISRTWTHQVFPSFRGEDVRKGFLSHI
QKEFKSKGIVPFIDDEMKRGESIGPGLFQAIRESKIAIVLLSKNYASSSWCLNELVEIMNCREEIGQTVMTVFYQVDPSD
VRKQTGDFGKAFKKTCVGKTQEVKQRWSRALMDVANILGQDSRKWDKEADMIVKVAKDVSDVLSYTPSRDFDDYVGIRPH
ITRINSLLCLESSDVRMIGILGPPGIGKTTIARVLYDQISEKFQFSAFIENIRLSYWKGWHDEGNLDFPVEIMTGDRQRK
LNLQRRLLSELFNQKDIQVRHLGAVQERLRDHKVLVILDGVDQLEQLTALAKETQWFGYGSRIIITTQDQRLLRAHEINH
VYKVDLPATDEALQIFCLYAFGQKFPYDGFKKLAREFTALAGELPLGLRVLGSYLRGMSLEEWKNALPRLRTSLDGEIEK
TLRFAYNVLSDKDKSLFLHIACLFNGCQVNHVKQWLANSSLDVNHGFEVLSNKSLISTDMGLVRMHSLLQQLGVDIVRKQ
SIGEPEKRQFLVDVNEISDVITDNTGTGTILGIMLHVSKIEDVLVIEETVFDRMTNLQFLILDECLRDKLNLPLGLNCLP
RKIRLLRWDYCPLSIWPSKFSAKFLVELIMRANKFEKLWEGIQPLKNLKRMELGDARNLKEIPDLSNATNLESLLLSFCT
SLLEIPSSIRGTTNLKELDLGGCASLVKLSSCICNATSLEELNLSACSNLVELPCALPGDSNMRSLSKLLLNGSSRLKTF
PEISTNIQELNLSGTAIEEVPSSIRLWSRLDKLDMSRCKNLKMFPPVPDGISVLNLSETEIEDIPPWVENLSQLRHFVMI
RCKKLDNISLSRISKMEGVHCLQITRGDEDVSGDSIVNIRWYSNFPNQWTLQSDMLQICLPELVYTSPVSLHFISNEFKT
IPDCIKNLSQLHQLSFYRCHKLVSLPQLSDCLSSLDAENCVSLETIDGSFHNPDIRLNFLNCNNLNQEARELIQKSVCKH
ALLPSGEVPAYFIHRAIGDSVTIHLKERHLPLYLIFKASLVLFNDDEINYDYDDDDDDDYDEEVIVYGDYDSYPHSDDYT
KQETMRLSCRVEGKQNGLTIQYGSSVHLLPTPHRYTEHVYIFEASFSLGECNSPEAESELVFDFKVHDYFWAIKECGLRL
LELPHAHGDD
>F4KHH8|PF00931(192...400)|Disease resistance protein RPS6
MASSSSSSSRNWSYHVFPSFSGEDVRNTFLSHFLKELDRKLIISFKDNEIERSQSLDPELKHGIRNSRIAVVVFSKTYAS
SSWCLNELLEIVKCKKEFGQLVIPIFYNLDPSHVRKQTGDFGKIFEKTCRNKTVDEKIRWKEALTDVANILGYHIVTWDN
EASMIEEIANDILGKMNISPSNDFEDLVGIEDHITKMSSLLHLESEEVRMVGIWGPSGIGKTTIARALFSRLSCQFQSSV
FIDKVFISKSMEVYSGANLVDYNMKLHLQRAFLAEIFDKKDIKIHVGAMEKMVKHRKALIVIDDLDDQDVLDALADQTQW
FGSGSRIIVVTENKHFLRANRIDHIYKVCLPSNALALEMFCRSAFKKNSPPDDFLELSSEVALRAGNLPLGLNVLGSNLR
GINKGYWIDMLPRLQGLDGKIGKTLRVSYDGLNNRKDEAIFRHIACIFNGEKVSDIKLLLANSNLDVNIGLKNLVDRSLI
CERFNTLEMHSLLQELGKEIVRTQSNQPGEREFLVDLKDICDVLEHNTGTKKVLGITLDIDETDELHIHESSFKGMHNLL
FLKIYTKKLDQKKKVRWHLPERFDYLPSRLRLLRFDRYPSKCLPSNFHPENLVKLQMQQSKLEKLWDGVHSLAGLRNMDL
RGSRNLKEIPDLSMATNLETLKLSSCSSLVELPSSIQYLNKLNDLDMSYCDHLETIPSGVNLKSLDRLNLSGCSRLKSFL
DIPTNISWLDIGQTADIPSNLRLQNLDELILCERVQLRTPLMTMLSPTLTRLTFSNNPSFVEVPSSIQNLYQLEHLEIMN
CRNLVTLPTGINLDSLISLDLSHCSQLKTFPDISTNISDLNLSYTAIEEVPLSIEKLSLLCYLDMNGCSNLLCVSPNISK
LKHLERADFSDCVELTEASWNGSSSEMVKLLPADNFSTVKLNFINCFKLDLTALIQNQTFFMQLILTGEEVPSYFTHRTS
GDSISLPHISVCQSFFSFRGCTVIDVDSFSTISVSFDIEVCCRFIDRFGNHFDSTDFPGYFITTKLGGHLVVFDCYFPFN
EEFTTFLDGQFNYDHVDIQFRLTNDNSQLKLKGCGILLSEDVPSLDNRPCSPNILPGVCEDSALERRSFRTKMRMMRMRL
LKKLLNR
>F4KHI3|PF00931(198...430)|Protein VARIATION IN COMPOUND TRIGGERED ROOT growth response
MASSSSSRNWVYDVFLSFSGKDVRVTFRSHFLKELDRKLISAFRDNEIERSHSLWPDLEQAIKDSRIAVVVFSKNYASSS
WCLNELLEIVNCNDKIIIPVFYGVDPSQVRYQIGEFGSIFEKTCKRQTEEVKNQWKKALTDVANMLGFDSAKWDDEAKMI
EEIANDVLAKLLLTSSTDSAENSIGIEDHIANMSVLLKLEAEEVRMVGIWGSSGIGKTTIARALFNQLSRHFPVSKFIDR
AFVYKSRETYKGANPDDPNMKLHLQGCFLSEILGKKDIKIDHLGALGERLKHQKTLIIIDDLDDLVVLDSLVGKTNWFGC
GSRIIVITNNKQFLRAHGIDHIYEVSLPSKERAQEMFCQSAFGENSPPEGFEELVVEIAWLAGSLPLGLTVFGSALRGRK
KEYWVKMLPRLQNDLDGNIEETLKVSYDAIGNVKDQALFRLIACLFNHVKVRDIELLLADSGLDVNIALENLVDKSLIHV
RNDHVEMHRLLQETGRNIVRSQSTDNPGEREFLVDSNDSRTVLSEGIGTRKVLGISLDTSKVSEFCVHENAFKGMGNLLF
LDISSKTFIEEEVKVHLPEKINYYSVQPKQLIWDRFPLKCMPYTFLRNLVKLEMHDSKLEKLWEGAMSFTCLKELDMWAS
KYLKEIPDLSKATNIEKLDFGHCWSLVELPSSIRNLNKLLELNMEYCGELETLPTGFNLKSLDYLNFNECWKLRTFPEFA
TNISNLILAETSIEEYPSNLYFKNVRELSMGKADSDENKCQGVKPFMPMLSPTLTLLELWNIPNLVELSSSFQNLNNLER
LDICYCRNLESLPTGINLESLVSLNLFGCSRLKRFPDISTNIKYLDLDQTGIEEVPWQIENFFNLTKLTMKGCRELKCVS
LNIFKLKHLGEVSFSNCGALTRVDLSCYPSGVEMMKADNADIVSEETTSSLPDSCVLNVNFMDCVNLDREPVLHQQSIIF
NSMILPGEEVPSYFTYRTSDSQPFGTSSSLPIPLLPTQLSQPFFRFRVCAVVSASNGVYIGVYSRFKGRIGNKFDSFGEV
HNFMEIEKGIHLCIFDCRIRLYKDNVPLSQLNYDHVDINIHITSGDWRSTVVLKEWGIRLLETGSSAENRLGNPNSTLPH
VSQAEEGNMGYYTHVQGLVNEIENSEDSGDNNVETERSKKRMRLHHFI
>F4KIF3|PF00931(211...432)|Disease resistance-like protein CSA1
MTSSSSWVKTDGETPQDQVFINFRGVELRKNFVSHLEKGLKRKGINAFIDTDEEMGQELSVLLERIEGSRIALAIFSPRY
TESKWCLKELAKMKERTEQKELVVIPIFYKVQPVTVKELKGDFGDKFRELVKSTDKKTKKEWKEALQYVPFLTGIVLDEK
SDEDEVINIIIRKVKEILNRRSEGPPSKCSALPPQRHQKRHETFWGIELRIKQLEEKLRFGSDETTRTIGVVGMPGIGKT
TLATMLYEKWNDRFLRHVLIRDIHEASEEDGLNYLATKFLQGLLKVENANIESVQAAHEAYKDQLLETKVLVILDNVSNK
DQVDALLGERNWIKKGSKILITTSDKSLMIQSLVNDTYEVPPLSDKDAIKHFIRYAFDGNEGAAPGPGQGNFPKLSKDFV
HYTKGNPLALQMLGKELLGKDESHWGLKLNALDQHHNSPPGQSICKMLQRVWEGSYKALSQKEKDALLDIACFRSQDENY
VASLLDSDGPSNILEDLVNKFMINIYAGKVDMHDTLYMLSKELGREATATDRKGRHRLWHHHTIIAVLDKNKGGSNIRSI
FLDLSDITRKWCFYRHAFAMMRDLRYLKIYSTHCPQECESDIKLNFPEGLLLPLNEVRYLHWLKFPLKEVPQDFNPGNLV
DLKLPYSEIERVWEDNKDAPKLKWVNLNHSKKLNTLAGLGKAQNLQELNLEGCTALKEMHVDMENMKFLVFLNLRGCTSL
KSLPEIQLISLKTLILSGCSKFKTFQVISDKLEALYLDGTAIKELPCDIGRLQRLVMLNMKGCKKLKRLPDSLGQLKALE
ELILSGCSKLNEFPETWGNMSRLEILLLDETAIKDMPKILSVRRLCLNKNEKISRLPDLLNKFSQLQWLHLKYCKNLTHV
PQLPPNLQYLNVHGCSSLKTVAKPLVCSIPMKHVNSSFIFTNCNELEQAAKEEIVVYAERKCHLLASALKRCDESCVPEI
LFCTSFPGCEMPSWFSHDAIGSMVEFELPPHWNHNRLSGIALCVVVSFKNCKSHANLIVKFSCEQNNGEGSSSSITWKVG
SLIEQDNQEETVESDHVFIGYTNCLDFIKLVKGQGGPKCAPTKASLEFSVRTGTGGEATLEVLKSGFSFVFEPEENRVPS
PRNDDVKGKVKINKTPSANGCFKDQAKGNESPKGQWQTYIENSSTNIPSEAHSSQKTGFNGFNGMYSVCVLYEMYSH
>F7J0M4|PF00931(180...401)|Disease resistance protein RGA4
MEAALLSGFIKAILPRLFSLVDDKHKLHKGVKGDIDFLIKELRMIVGAIDDDLSLDHPAAAAVQTLCMEDLRELAHGIED
CIDGVLYRAARDQQQSPVRRAVQAPKKLQRNLQLAQQLQRLKRMAAEANQRKQRYTAAAPGQHGQVYSSAAAQVDEPWPS
CSSASDPRIHEADLVGVDADREELLEQLAERQPEQLKVIAIVGFCGLGKTALAAEAYNRETGGGRFERHAWVCAGHRSAR
EVLGELLRRLDADGRSFHGDSDAGQLCVDIRQQLEKNRYFIVIDDIQTEDQWKSIKSAFPTDKDIGSRIVVTTTIQSVAN
ACCSANGYLHKMSRLDKNCSKQLLSKKACPERYSHYKQPDSAAILKKCDGQPLALVTIGEFLQANGWPTGPNCEDLCNRL
HYHLENDKTLERMWRVLVRNYTSLPGHALKACLLYFGMFPSDHPIRRKSLLRRWLAEGFVEPLSSSSNIDSTAAFNVLMD
RNIIEPINVSNNDKVKTCQTYGMMREFISHMSISQNFVTFFCDDKFVPKYVRRLSLHGDTVVNGDNFNGIDLSLVRSLAV
FGEAGTTVLDFSKYQLLRVLDLEKCDDLKDDHLKEICNLVLLKYLSLGGNISKLPKDIAKLKDLEALDVRRSKVKIMPVE
VFGLPCLIHLLGKFKLSDKVKQKTEVQEFLLKGKSNLQTLAGFASNGSEGFLHLMRYMNKLRKLKIWCTSSAGSTDWTDL
REAIQQFILDEKEANIGTRSLSLHFSGCSEDAINSLKEPCYLSSLKLHGNFPQLPQFVTSLRGLKELCLSSTKFTTGLLE
ALSNLSYLQYLKLVADELEKFIIKVQGFPRLLRLCIVLQYPTFPVIEEGALPFLVTLQLLCKDLHGLSDIQIECFKHLQE
VTLHSGVTPATRQEWVKAAKEHPNRPKVLLLKSVDTAESEHTDVDSVMEAVKSETTEYSIAPEGPEQVNNKMQLDHGLES
SSVLNKQNNFADQSSSKDQLHYSFNNMGLSDVSCCE
>F7J0M6|PF00931(189...421)|Disease resistance protein RGA4
MEAALLSGFIKAILPRLFSLVNDKLNLHKGVKGDIDFLIKELRMIVGAIDDDLSVEHGAAAAAAAVQTLCMEDLRELAHG
IEDCIDGVLYRAAREQRRSSSLLPRTVRATKKLLQTNQHLAQELQRLKRMVEEANQRKQRYTAAAPGQHGQVYSSAAAQV
DEPWPSCSSASDPRIHEADLVGVDADRAELLEQLAERQPEQLKVIAIVGFCGLGKTALAAEAYNRETRGGRFERHAWVCA
AHRSAREVLGELLRRIDAACHGDSDAGQLCVDIRQQLEKKRYFIVIDDIQTEDQWKSIKSAFPTDKDIGSRIVVTTTIQS
VANACCSANGYLHKMSRLDKNCSKQLLSKKACPERYSHYKQPDSAAILKKCDGQPLALVTIGEFLQANGWPTGPNCEDLC
NRLHYHLENDKTLERMRRVLVRNYTSLPGHALKACLLYFGMFPSDHPIRRKSLLRRWLAEGFVEPVSSSSNLDSTAAFDV
LMDRNIIEPINVSNNDKVKTCQTYGMMREFISHMSISQNFVTFFCDDKFLPKYVRRLSLHGDTVVNGDNFNGIDLSLVRS
LVVFGEAGTTVLDFSKYQLLRVLDLEKCDDLNDDHLKEICNLVLLKYLSLGGNISKLPKDIAKLKDLEALDVRRSKVKIM
PVEVFGLPCLIHLLGKFKLSDKVKQKTEVQEFLSKGKSNLQTLAGFASNGSEGFLHLMRYMNKLRKLKIWCTSSAGSTDW
TDLREAIQQFILDEKEANIGTRSLSLHFTGCSEDAINSLKEPCYLSSLKLHGNFPQLPQFVTSLRGLKELCLSSTKFTTG
LLEALSNLSYLQYLKLVADELEKFIIKVQGFPRLLCLCIVLQCPTFPVIEEGALPFLVTLQLLCKDLHGLSDIKIECFKH
LQEVTLHSGVTPATRQEWVKAAKEHPNRPKVLLLKSVDTAESEHTDVDSVMEAVKSETTEYSIAPEGPEQVIDMNNKMQL
DHGLESSSVLNKQNNFADQSSSKDQLHYSFNNMGLSDVSPAVSELPNGMVPSCT
>F7J0N2|PF00931(182...426)|Disease resistance protein RGA5
MDAPASFSLGAMGPLLRKLDSLLVAPEIRLPKPLKEGIELLKEDLEEIGVSLVEHSVVDSPTHKARFWMDEVRDLSYHIE
DCIDTMFSMRSGGDDGKPRSERRHKVGRAKIDGFSKKPKPCTRMARIAELRALVREASERLERYQLGDVCGSSSPVVFTA
DGRARPLHHGVSANLVGVDEFKTKLNRWLSDEEGPHLKVAAIVGPAGIGKTALATELYRDHRWQFECRAFVRASRKPDMQ
RLLGGILSQVQRRQRSSDAYADSTVQSLIDNLREHLQDRRYLIIIDGLWETAVWNIANSAFPDVNSFSRILITADIEQVA
LECCGYKYDYIMRMEPLGSLDSKKVFFNKVFGSEDQCPPELKEVSNTILEKCGGLPLAIISIAGLLGSQPENPVLWDYVT
KYLCSSLGTNPTLKDVVKETLNLSYNSLPHPFKTCLLYLGMYPDGHIMLKADLMKQWSAEGFVSANEAKDTEEIVDKYFD
ELVNRGILEPVEINKNGKVLSCTLHHAVHDLVMPKFNDDKFTMSVDYSQTITGPSTMVRRLSLHFSSTRYATKPAGIILS
RVRSLAFFGLLNCMPCIGEFKLLRVLILEFWGSHGEQRSLNLIPVCRLFQLRYLKTSGDVVVQLPAQISGLQYLETLEID
ARVSAVPFDLVHLPNLLHLQLQDETKLPDGIGCMRSLRTLQYFDLGNNSVDNLRGLGELTNLQDLHLSYSAPSSNEGLMI
NLNAITSSLSRLSNLKSLILSPGAISMVIFFDISSIISVVPVFLQRLELLPPICIFCRLPKSIGQLHKLCILKVSVRELL
TTDIDNLTGLPSLTVLSLYAQTAPEGRFIFKDGTLPVLKYFKFGCGELCLAFMAGAMPNLQRLKLVFNIRKSEKYRHTLF
GIEHLVSLQDIATRIGVDTSTGESDRRAAESAFKETVNKHPRCLRSSLQWVVSTEEESHPLEKQHHKREKGSSAGHGVLE
KESVEDSEKNTDRVQTLLSPQLSNMESVVESALTGQRTKIVVKVHMPCGKSRAKAMALAASVNGVDSVEITGEDKDRLVV
VGRGIDPVRLVALLREKCGLAELLMVELVEKEKTQLAGGKKGAYKKHPTYNLSPFDYVEYPPSAPIMQDINPCSTM
>O04093|PF00931(44...296)|Putative inactive disease susceptibility protein LOV1
MKSLGIQEIIDGASSMSLQERQREQKEIRQTFANSSESDLVGVEQSVEALAGHLVENDNIQVVSISGMGGIGKTTLARQV
FHHDMVQRHFDGFAWVFVSQQFTQKHVWQRIWQELQPQNGDISHMDEHILQGKLFKLLETGRYLVVLDDVWKEEDWDRIK
AVFPRKRGWKMLLTSRNEGVGIHADPKSFGFKTRILTPEESWKLCEKIVFHRRDETGTLSEVRVDEDMEAMGKEMVTCCG
GLPLAVKVLGGLLATKHTVPEWKRVYDNIGPHLAGRSSLDDNLNSIYRVLSLSYENLPMCLKHCFLYLAHFPEYYEIHVK
RLFNYLAAEGIITSSDDGTTIQDKGEDYLEELARRNMITIDKNYMFLRKKHCQMHDMMREVCLSKAKEENFLEIFKVSTA
TSAINARSLSKSRRLSVHGGNALPSLGQTINKKVRSLLYFAFEDEFCILESTTPCFRSLPLLRVLDLSRVKFEGGKLPSS
IGDLIHLRFLSLHRAWISHLPSSLRNLKLLLYLNLGFNGMVHVPNVLKEMQELRYLQLPMSMHDKTKLELSDLVNLESLM
NFSTKYASVMDLLHMTKLRELSLFITDGSSDTLSSSLGQLRSLEVLHLYDRQEPRVAYHGGEIVLNCIHLKELELAIHMP
RFPDQYLFHPHLSHIYLWCCSMEEDPIPILERLLHLKSVILTFGAFVGRRMVCSKGGFPQLCFLKLEELEELEEWIVEEG
RCHFFVL
>O14727|PF00931(130...374)|Apoptotic protease-activating factor 1
MDAKARNCLLQHREALEKDIKTSYIMDHMISDGFLTISEEEKVRNEPTQQQRAAMLIKMILKKDNDSYVSFYNALLHEGY
KDLAALLHDGIPVVSSSSGKDSVSGITSYVRTVLCEGGVPQRPVVFVTRKKLVNAIQQKLSKLKGEPGWVTIHGMAGCGK
SVLAAEAVRDHSLLEGCFPGGVHWVSVGKQDKSGLLMKLQNLCTRLDQDESFSQRLPLNIEEAKDRLRILMLRKHPRSLL
ILDDVWDSWVLKAFDSQCQILLTTRDKSVTDSVMGPKYVVPVESSLGKEKGLEILSLFVNMKKADLPEQAHSIIKECKGS
PLVVSLIGALLRDFPNRWEYYLKQLQNKQFKRIRKSSSYDYEALDEAMSISVEMLREDIKDYYTDLSILQKDVKVPTKVL
CILWDMETEEVEDILQEFVNKSLLFCDRNGKSFRYYLHDLQVDFLTEKNCSQLQDLHKKIITQFQRYHQPHTLSPDQEDC
MYWYNFLAYHMASAKMHKELCALMFSLDWIKAKTELVGPAHLIHEFVEYRHILDEKDCAVSENFQEFLSLNGHLLGRQPF
PNIVQLGLCEPETSEVYQQAKLQAKQEVDNGMLYLEWINKKNITNLSRLVVRPHTDAVYHACFSEDGQRIASCGADKTLQ
VFKAETGEKLLEIKAHEDEVLCCAFSTDDRFIATCSVDKKVKIWNSMTGELVHTYDEHSEQVNCCHFTNSSHHLLLATGS
SDCFLKLWDLNQKECRNTMFGHTNSVNHCRFSPDDKLLASCSADGTLKLWDATSANERKSINVKQFFLNLEDPQEDMEVI
VKCCSWSADGARIMVAAKNKIFLFDIHTSGLLGEIHTGHHSTIQYCDFSPQNHLAVVALSQYCVELWNTDSRSKVADCRG
HLSWVHGVMFSPDGSSFLTSSDDQTIRLWETKKVCKNSAVMLKQEVDVVFQENEVMVLAVDHIRRLQLINGRTGQIDYLT
EAQVSCCCLSPHLQYIAFGDENGAIEILELVNNRIFQSRFQHKKTVWHIQFTADEKTLISSSDDAEIQVWNWQLDKCIFL
RGHQETVKDFRLLKNSRLLSWSFDGTVKVWNIITGNKEKDFVCHQGTVLSCDISHDATKFSSTSADKTAKIWSFDLLLPL
HELRGHNGCVRCSAFSVDSTLLATGDDNGEIRIWNVSNGELLHLCAPLSEEGAATHGGWVTDLCFSPDGKMLISAGGYIK
WWNVVTGESSQTFYTNGTNLKKIHVSPDFKTYVTVDNLGILYILQTLE
>O22727|PF00931(157...398)|Probable disease resistance protein At1g61190
MGNFVCIEISGDQMLDRIIRCLCGKGYIRNLEKNLRALQREMEDLRATQHEVQNKVAREESRHQQRLEAVQVWLDRVNSI
DIECKDLLSVSPVELQKLCLCGLCSKYVCSSYKYGKRVFLLLEEVTKLKSEGNFDEVSQPPPRSEVEERPTQPTIGQEEM
LKKAWNRLMEDGVGIMGLHGMGGVGKTTLFKKIHNKFAETGGTFDIVIWIVVSQGAKLSKLQEDIAEKLHLCDDLWKNKN
ESDKATDIHRVLKGKRFVLMLDDIWEKVDLEAIGIPYPSEVNKCKVAFTTRDQKVCGQMGDHKPMQVKCLEPEDAWELFK
NKVGDNTLRSDPVIVGLAREVAQKCRGLPLALSCIGETMASKTMVQEWEHAIDVLTRSAAEFSDMQNKILPILKYSYDSL
EDEHIKSCFLYCALFPEDDKIDTKTLINKWICEGFIGEDQVIKRARNKGYEMLGTLIRANLLTNDRGFVKWHVVMHDVVR
EMALWIASDFGKQKENYVVRARVGLHEIPKVKDWGAVRRMSLMMNEIEEITCESKCSELTTLFLQSNQLKNLSGEFIRYM
QKLVVLDLSHNPDFNELPEQISGLVSLQYLDLSWTRIEQLPVGLKELKKLIFLNLCFTERLCSISGISRLLSLRWLSLRE
SNVHGDASVLKELQQLENLQDLRITESAELISLDQRLAKLISVLRIEGFLQKPFDLSFLASMENLYGLLVENSYFSEINI
KCRESETESSYLHINPKIPCFTNLTGLIIMKCHSMKDLTWILFAPNLVNLDIRDSREVGEIINKEKAINLTSIITPFQKL
ERLFLYGLPKLESIYWSPLPFPLLSNIVVKYCPKLRKLPLNATSVPLVEEFEIRMDPPEQENELEWEDEDTKNRFLPSIK
PLVRRLKIHYSGMGFLNVKNQNPRFFFYCFIYLLVVHLDCIIDLHSDTSGMCCVVHLDYVFHFPFVFPKTFCILFRLHFY
TIKSLCV
>O23317|PF00931(133...371)|Probable disease resistance protein At4g14610
MALTKLRFVNQFSQWLCVRKGYIHSLPENLAALQKAIEVLKTKHDDVKRRVDKEEFLGRRHRLSQVQVEIERLCFCGFCS
KSFGKSYHYGKMVSVMLKEVENLSSRGVFDVVTEENLVAQVEEMPIQSTVVGQETMLERVWNTLMKDGFKIMGLYGMGGV
GKTTLLTQINKKFSETDGGFDIVMWVVVSKTSEIYRIQEDIAKRLGLTGEEWDKKNENKRAVDIHNVLRRHKFVLLLDDI
WEKVNLELVGVPYPSRENGSIVAFTTRSRDVCGRMGVDDPMQVSCLEPEDAWDLFQNKVGENTLKSHPDIPELAKQVAEK
CRGLPLALNVIGETMACKSTVQEWRHAIDEEWKKTEVKMHDVVREMALWISSDLGKHKDQCIVRAGVGLHAVPEVKNWRA
VRRMSLMKNELEKILGCPTCPQLTTLLLQKNHKLVNISGEFFRFMPNLVVLDLSWNSSLTGLPKKISEVETTNTSEFGVH
EEFGEYAGVSKLLSLKTLRLQKSKKALDVNSAKELQLLEHIEVLTIDIFSKVEEESFKILTFPSMCNIRRIGIWKCGMKE
IKVEMRTSSCFSSLSKVVIGQCDGLKELTWLLFAPNLTYLDARFAEQLEDIISEEKAASVTDENASIIIPFQKLECLSLS
DLPKLKSIYWSPLSFPRLSELAVQEHCPKLKKLPLNSKSGTAGVELVVKYGENKWLEGVEWEDKATELRFLATCKSLYR
>O23530|PF00931(196...430)|Protein SUPPRESSOR OF npr1-1, CONSTITUTIVE 1
MMDTSKDDDMEIASSSGSRRYDVFPSFRGEDVRDSFLSHLLKELRGKAITFIDDEIERSRSIGPELLSAIKESRIAIVIF
SKNYASSTWCLNELVEIHKCYTNLNQMVIPIFFHVDASEVKKQTGEFGKVFEETCKAKSEDEKQSWKQALAAVAVMAGYD
LRKWPSEAAMIEELAEDVLRKTMTPSDDFGDLVGIENHIEAIKSVLCLESKEARIMVGIWGQSGIGKSTIGRALYSKLSI
QFHHRAFITYKSTSGSDVSGMKLRWEKELLSEILGQKDIKIEHFGVVEQRLKQQKVLILLDDVDSLEFLKTLVGKAEWFG
SGSRIIVITQDRQLLKAHEIDLIYEVEFPSEHLALTMLCRSAFGKDSPPDDFKELAFEVAKLAGNLPLGLSVLGSSLKGR
TKEWWMEMMPRLRNGLNGDIMKTLRVSYDRLHQKDQDMFLYIACLFNGFEVSYVKDLLKDNVGFTMLTEKSLIRITPDGY
IEMHNLLEKLGREIDRAKSKGNPGKRRFLTNFEDIHEVVTEKTGTETLLGIRLPFEEYFSTRPLLIDKESFKGMRNLQYL
EIGYYGDLPQSLVYLPLKLRLLDWDDCPLKSLPSTFKAEYLVNLIMKYSKLEKLWEGTLPLGSLKEMNLRYSNNLKEIPD
LSLAINLEELDLVGCKSLVTLPSSIQNATKLIYLDMSDCKKLESFPTDLNLESLEYLNLTGCPNLRNFPAIKMGCSDVDF
PEGRNEIVVEDCFWNKNLPAGLDYLDCLTRCMPCEFRPEQLAFLNVRGYKHEKLWEGIQSLGSLEGMDLSESENLTEIPD
LSKATKLESLILNNCKSLVTLPSTIGNLHRLVRLEMKECTGLEVLPTDVNLSSLETLDLSGCSSLRSFPLISTNIVWLYL
ENTAIEEIPSTIGNLHRLVRLEMKKCTGLEVLPTDVNLSSLETLDLSGCSSLRSFPLISESIKWLYLENTAIEEIPDLSK
ATNLKNLKLNNCKSLVTLPTTIGNLQKLVSFEMKECTGLEVLPIDVNLSSLMILDLSGCSSLRTFPLISTNIVWLYLENT
AIEEIPSTIGNLHRLVKLEMKECTGLEVLPTDVNLSSLMILDLSGCSSLRTFPLISTRIECLYLQNTAIEEVPCCIEDFT
RLTVLMMYCCQRLKTISPNIFRLTRLELADFTDCRGVIKALSDATVVATMEDHVSCVPLSENIEYIWDKLYRVAYLQEHF
SFRNCFKLDRDARELILRSCFKPVALPGEEIPKYFTYRAYGDSLTVIVPQSSLSQNFLRFKACVVVEPLSKGKGFYPFLK
VNVGFNGKQYQKSFSKDAELELCKTDHLFFCSFKFRSEDLPSKLNFNDVEFKFCCSNRIKECGVRLMYVSQEENNQQTTR
SEKRMRMTSGTSEEDINLPYGLIVADTGLAALNMELSLGQGEPSSSTSLEGEALCVDYMITEEQDKGIPILFPVSGN
>O48573|PF00931(262...491)|Disease resistance protein LAZ5
MAASSEILPESWQVFINFRGADLRNGFISHLAGALTSAGITYYIDTEEVPSEDLTVLFKRIEESEIALSIFSSNYAESKW
CLDELVKIMEQVKKGKLRIMPVFFNVKPEEVREQNGEFGLKLYGEGKSKRPNIPNWENALRSVPSKIGLNLANFRNEKEL
LDKIIDSIKKVLARITRASRVAESLNGISKDSEAKNVDTFSPNSSDFPSTSIDDDLSINSPQYQATIPPASREGERLNTI
STVSSTGSIEHPPPNYGIEPRLKEMEEKLDFDSLETKTVGIVGMPGIGKTTLAETLYRKWEHKFERSMFFPDASKMANEH
GMCWLQKRLLEELLKDTNLNIGYTTNEHEFCKDVLLLKKVFLVIDNVSSEEQIETLFGKWNWIKNGSKIVITSSDESMLK
GFVKDTYVVPSLNSRDSLLWFTNHAFGLDDAQGNLVKLSKHFLNYAKGNPLALGAFGVELCGKDKADWEKRIKTLTLISN
KMIQDVLRRRYDELTERQKDIFLDVACFFKSENESYVRHVVNSCDSESTKSWDEITDLKGKFLVNISGGRVEMHDILCTF
AKELASQALTEDTRVHLRLWNYQDIMWFLNNELEMENVRGIFLDMSKVPEEMTFDGNIFSNMCNLRYLKIYSSVCHKEGE
GIFKFDTVREIQLPLDKVRYLHWMKYPWEKLPSDFNPENLVDLELPYSSIKKVWEGVKDTPILKWANLSYSSKLTNLLGL
SNAKNLERLNLEGCTSLLKLPQEMENMKSLVFLNMRRCTSLTCLQSIKVSSLKILILSDCSKLEEFEVISENLEELYLDG
TAIKGLPPAAGDLTRLVVLNMEGCTELESLPKRLGKQKALQELVLSGCSKLESVPTDVKDMKHLRLLLLDGTRIRKIPKI
KSLKCLCLSRNIAMVNLQDNLKDFSNLKCLVMKNCENLRYLPSLPKCLEYLNVYGCERLESVENPLVADRLTLFLDRSEE
LRSTFLFTNCHNLFQDAKDSISTYAKWKCHRLAVECYEQDIVSGAFFNTCYPGYIVPSWFDHQAVGSVLEPRLEPHWYNT
MLSGIALCAVVSFHENQDPIIGSFSVKCTLQFENEDGSLRFDCDIGCLNEPGMIEADHVFIGYVTCSRLKDHHSIPIHHP
TTVKMQFHLTDACKSKVVDCGFRLMYTQSRGCLLEEEVNANFTKLYLGLL
>O49471|PF00931(222...441)|Probable disease resistance protein At4g19530
MATSSSVVSSVPQQHQVFLNFRGDELRNNFVSHLDKALRGKQINVFIDEAVEKGENLDNLFKEIEKSRIALAIISQKYTE
SKWCLNELVKMKELEGKLVTIPIFYNVEPATVRYQKEAFGAALTKTQENDSDGQMKKWKEALTYVSLLVGFPFNSKSKEK
ETTLIDKIVDAVLQKLSKISSEESTSGSVDQGRGEEVEEAKADKISGLNQRLKELEEKVAITGDKRDETRIVEVVGMPGI
GKSTLLKAFYETWKTRFLSSALLQNISELVKAMGLGRLTGMLLKELLPDENIDEETYEPYKEKLLKNTVFIVLDGISDET
HIQKLLKDHRKWAKKGSKIVIARRAVTRDLLHEDSMVRYTYFVPLLSHRDGLNHFCHYAFRHFAAHQNNKEAFMKESKEF
VRYARGHPLILKLLGEELREKSLSYWEEKLKSLPKSLSQNIRDRVLQVTYDELSQVQKDAFLDIACFRSHDLVYVKSLLD
SSGPAFSKATVTIDALKDMFMIYISDSRVEMHDLLYTFAMELGPEARDDDGRGRHRIWHHHNQDNKGRLNRLLKRPGGST
SVRSFFLDMYVMKTDVTLGTDYLKNMRNLRYLKFYSSHCPQECTPKENIHIPGELELPLEEVRCLHWLNFPKDELPQDFI
PKNLVDLKLPYSKIRQIWREEKDAPKLRWVDLNHSSKLENLSGLSQALNLERLNLEGCTALKTLLLGPENMASLVFLNLK
GCTGLESLPKINLRSLKTLILSNCSNLEEFWVISETLYTLYLDGTAIKTLPQDMVKLTSLVKLYMKDCEMLVKLPEEFDK
LKVLQELVCSGCKRLSSLPDVMKNMQCLQILLLDGTAITKIPHISSLERLCLSRNEKISCLSNDIRLLSQLKWLDLKYCT
KLVSIPELPTNLQCLDANGCESLTTVANPLATHLPTEQIHSTFIFTNCDKLDRTAKEVITTYAQRKCQMLSDALKRWNEG
FVPEALFSTCFPGCEVPSWFCHEAVGSVLKLNLLPHWNENRFVGIALCAVVGSLPNCQEQTNSCSVTCTFNIASKDSKKG
DPYKISFDRLVGRWNKHGNKLDKKGNKLKKTESDHVFICYTRCSNSIKCLQDQHSGTCTPTEAFLEFGVTDKESRLEVLK
CGLRLVYASDEPQKTNSDMDLSLSSSDSTPTRNGSSNTTTSSGSVSTNTIREEDSNILHEAQSQNGRGL
>O64789|PF00931(158...399)|Probable disease resistance protein At1g61310
MGSCFSFQIAVGDQTMNRIFDCLIGKSYIRTLEKNLRALQREMEDLRATQHEVQNKVAREESRHQQRLEAVQVWLDRVNS
IDIECKDLLSVSPVELQKLCLCGLCTKYVCSSYKYGKKVFLLLEEVKILKSEGNFDEVSQPPPRSEVEERPTQPTIGQEE
MLEKAWNRLMEDGVGIMGLHGMGGVGKTTLFKKIHNKFAEIGGTFDIVIWIVVSQGAKLSKLQEDIAEKLHLCDDLWKNK
NESDKATDIHRVLKGKRFVLMLDDIWEKVDLEAIGIPYPSEVNKCKVAFTTRSREVCGEMGDHKPMQVNCLEPEDAWELF
KNKVGDNTLSSDPVIVGLAREVAQKCRGLPLALNVIGETMASKTMVQEWEYAIDVLTRSAAEFSGMENKILPILKYSYDS
LGDEHIKSCFLYCALFPEDGQIYTETLIDKLICEGFIGEDQVIKRARNKGYAMLGTLTRANLLTKVGTELANLLTKVSIY
HCVMHDVVREMALWIASDFGKQKENFVVQASAGLHEIPEVKDWGAVRRMSLMRNEIEEITCESKCSELTTLFLQSNQLKN
LSGEFIRYMQKLVVLDLSDNRDFNELPEQISGLVSLQYLDLSFTRIEQLPVGLKELKKLTFLDLAYTARLCSISGISRLL
SLRVLSLLGSKVHGDASVLKELQQLENLQDLAITLSAELISLDQRLAKVISILGIEGFLQKPFDLSFLASMENLSSLWVK
NSYFSEIKCRESETDSSYLHINPKIPCFTNLSRLDIVKCHSMKDLTWILFAPNLVVLFIEDSREVGEIINKEKATNLTSI
TPFLKLERLILCYLPKLESIYWSPLPFPLLLNIDVEECPKLRKLPLNATSAPKVEEFRILMYPPELEWEDEDTKNRFLPE
MVSTSTSSKDPLLRNGIPRCLKSESTLLLLILLYLSSCRAFGLYN
>O64790|PF00931(45...286)|Probable disease resistance protein At1g61300
MGCCFSVQFSFDDQTLVRIFNFLCGNINRNSFGVEERPTQPTIGQEEMLEKAWNRLMEDRVGIMGLHGMGGVGKTTLFKK
IHNKFAKMSSRFDIVIWIVVSKGAKLSKLQEDIAEKLHLCDDLWKNKNESDKATDIHRVLKGKRFVLMLDDIWEKVDLEA
IGVPYPSEVNKCKVAFTTRDQKVCGEMGDHKPMQVKCLEPEDAWELFKNKVGDNTLRSDPVIVELAREVAQKCRGLPLAL
SVIGETMASKTMVQEWEHAIDVLTRSAAEFSNMGNKILPILKYSYDSLGDEHIKSCFLYCALFPEDDEIYNEKLIDYWIC
EGFIGEDQVIKRARNKGYEMLGTLTLANLLTKVGTEHVVMHDVVREMALWIASDFGKQKENFVVRARVGLHERPEAKDWG
AVRRMSLMDNHIEEITCESKCSELTTLFLQSNQLKNLSGEFIRYMQKLVVLDLSYNRDFNKLPEQISGLVSLQFLDLSNT
SIKQLPVGLKKLKKLTFLNLAYTVRLCSISGISRLLSLRLLRLLGSKVHGDASVLKELQKLQNLQHLAITLSAELSLNQR
LANLISILGIEGFLQKPFDLSFLASMENLSSLWVKNSYFSEIKCRESETASSYLRINPKIPCFTNLSRLGLSKCHSIKDL
TWILFAPNLVYLYIEDSREVGEIINKEKATNLTSITPFLKLERLILYNLPKLESIYWSPLHFPRLLIIHVLDCPKLRKLP
LNATSVPLVEEFQIRMYPPGLGNELEWEDEDTKNRFVLSIKK
>O64973|PF00931(161...402)|Disease resistance protein RPS5
MGGCFSVSLPCDQVVSQFSQLLCVRGSYIHNLSKNLASLQKAMRMLKARQYDVIRRLETEEFTGRQQRLSQVQVWLTSVL
IIQNQFNDLLRSNEVELQRLCLCGFCSKDLKLSYRYGKRVIMMLKEVESLSSQGFFDVVSEATPFADVDEIPFQPTIVGQ
EIMLEKAWNRLMEDGSGILGLYGMGGVGKTTLLTKINNKFSKIDDRFDVVIWVVVSRSSTVRKIQRDIAEKVGLGGMEWS
EKNDNQIAVDIHNVLRRRKFVLLLDDIWEKVNLKAVGVPYPSKDNGCKVAFTTRSRDVCGRMGVDDPMEVSCLQPEESWD
LFQMKVGKNTLGSHPDIPGLARKVARKCRGLPLALNVIGEAMACKRTVHEWCHAIDVLTSSAIDFSGMEDEILHVLKYSY
DNLNGELMKSCFLYCSLFPEDYLIDKEGLVDYWISEGFINEKEGRERNINQGYEIIGTLVRACLLLEEERNKSNVKMHDV
VREMALWISSDLGKQKEKCIVRAGVGLREVPKVKDWNTVRKISLMNNEIEEIFDSHECAALTTLFLQKNDVVKISAEFFR
CMPHLVVLDLSENQSLNELPEEISELASLRYFNLSYTCIHQLPVGLWTLKKLIHLNLEHMSSLGSILGISNLWNLRTLGL
RDSRLLLDMSLVKELQLLEHLEVITLDISSSLVAEPLLCSQRLVECIKEVDFKYLKEESVRVLTLPTMGNLRKLGIKRCG
MREIKIERTTSSSSRNKSPTTPCFSNLSRVFIAKCHGLKDLTWLLFAPNLTFLEVGFSKEVEDIISEEKAEEHSATIVPF
RKLETLHLFELRGLKRIYAKALHFPCLKVIHVEKCEKLRKLPLDSKSGIAGEELVIYYGEREWIERVEWEDQATQLRFLP
SSRWRWRET
>O81825|PF00931(120...357)|Probable disease resistance protein At4g27220
MFRSNARALNRALERLKNVQTKVNEALKRSGIQEKSLERKLRIWLRKVEENVPLGELILEKRSSCAIWLSDKDVEILEKV
KRLEEQGQDLIKKISVNKSSREIVERVLGPSFHPQKTALEMLDKLKDCLKKKNVQKIGVWGMGGVGKTTLVRTLNNDLLK
YAATQQFALVIWVTVSKDFDLKRVQMDIAKRLGKRFTREQMNQLGLTICERLIDLKNFLLILDDVWHPIDLDQLGIPLAL
ERSKDSKVVLTSRRLEVCQQMMTNENIKVACLQEKEAWELFCHNVGEVANSDNVKPIAKDVSHECCGLPLAIITIGRTLR
GKPQVEVWKHTLNLLKRSAPSIDTEEKIFGTLKLSYDFLQDNMKSCFLFCALFPEDYSIKVSELIMYWVAEGLLDGQHHY
EDMMNEGVTLVERLKDSCLLEDGDSCDTVKMHDVVRDFAIWFMSSQGEGFHSLVMAGRGLIEFPQDKFVSSVQRVSLMAN
KLERLPNNVIEGVETLVLLLQGNSHVKEVPNGFLQAFPNLRILDLSGVRIRTLPDSFSNLHSLRSLVLRNCKKLRNLPSL
ESLVKLQFLDLHESAIRELPRGLEALSSLRYICVSNTYQLQSIPAGTILQLSSLEVLDMAGSAYSWGIKGEEREGQATLD
EVTCLPHLQFLAIKLLDVLSFSYEFDSLTKRLTKFQFLFSPIRSVSPPGTGEGCLAISDVNVSNASIGWLLQHVTSLDLN
YCEGLNGMFENLVTKSKSSFVAMKALSIHYFPSLSLASGCESQLDLFPNLEELSLDNVNLESIGELNGFLGMRLQKLKLL
QVSGCRQLKRLFSDQILAGTLPNLQEIKVVSCLRLEELFNFSSVPVDFCAESLLPKLTVIKLKYLPQLRSLCNDRVVLES
LEHLEVESCESLKNLPFVPGNTGMINEQMAWEYMSRTLG
>O82484|PF00931(158...399)|Putative disease resistance protein At4g10780
MGSCISLQISCDQVLTRAYSCFFSLGNYIHKLKDNIVALEKAIEDLTATRDDVLRRVQMEEGKGLERLQQVQVWLKRVEI
IRNQFYDLLSARNIEIQRLCFYSNCSTNLSSSYTYGQRVFLMIKEVENLNSNGFFEIVAAPAPKLEMRPIQPTIMGRETI
FQRAWNRLMDDGVGTMGLYGMGGVGKTTLLTQIHNTLHDTKNGVDIVIWVVVSSDLQIHKIQEDIGEKLGFIGKEWNKKQ
ESQKAVDILNCLSKKRFVLLLDDIWKKVDLTKIGIPSQTRENKCKVVFTTRSLDVCARMGVHDPMEVQCLSTNDAWELFQ
EKVGQISLGSHPDILELAKKVAGKCRGLPLALNVIGETMAGKRAVQEWHHAVDVLTSYAAEFSGMDDHILLILKYSYDNL
NDKHVRSCFQYCALYPEDYSIKKYRLIDYWICEGFIDGNIGKERAVNQGYEILGTLVRACLLSEEGKNKLEVKMHDVVRE
MALWTLSDLGKNKERCIVQAGSGLRKVPKVEDWGAVRRLSLMNNGIEEISGSPECPELTTLFLQENKSLVHISGEFFRHM
RKLVVLDLSENHQLDGLPEQISELVALRYLDLSHTNIEGLPACLQDLKTLIHLNLECMRRLGSIAGISKLSSLRTLGLRN
SNIMLDVMSVKELHLLEHLEILTIDIVSTMVLEQMIDAGTLMNCMQEVSIRCLIYDQEQDTKLRLPTMDSLRSLTMWNCE
ISEIEIERLTWNTNPTSPCFFNLSQVIIHVCSSLKDLTWLLFAPNITYLMIEQLEQLQELISHAKATGVTEEEQQQLHKI
IPFQKLQILHLSSLPELKSIYWISLSFPCLSGIYVERCPKLRKLPLDSKTGTVGKKFVLQYKETEWIESVEWKDEATKLH
FLPSTKLVYILS
>O82500|PF00931(190...423)|Putative disease resistance protein At4g11170
MASSSSNSWRYDVFPSFRGEDVRNNFLSHLLKEFESKGIVTFRDDHIKRSHTIGHELRAAIRESKISVVLFSENYASSSW
CLDELIEIMKCKEEQGLKVMPVFYKVDPSDIRKQTGKFGMSFLETCCGKTEERQHNWRRALTDAANILGDHPQNWDNEAY
KITTISKDVLEKLNATPSRDFNDLVGMEAHIAKMESLLCLESQGVRIVGIWGPAGVGKTTIARALYNQYHENFNLSIFME
NVRESYGEAGLDDYGLKLHLQQRFLSKLLDQKDLRVRHLGAIEERLKSQKVLIILDDVDNIEQLKALAKENQWFGNKSRI
VVTTQNKQLLVSHDINHMYQVAYPSKQEALTIFCQHAFKQSSPSDDLKHLAIEFTTLAGHLPLALRVLGSFMRGKGKEEW
EFSLPTLKSRLDGEVEKVLKVGYDGLHDHEKDLFLHIACIFSGQHENYLKQMIIANNDTYVSFGLQVLADKSLIQKFENG
RIEMHSLLRQLGKEVVRKQSIYEPGKRQFLMNAKETCGVLSNNTGTGTVLGISLDMCEIKEELYISEKTFEEMRNLVYLK
FYMSSPIDDKMKVKLQLPEEGLSYLPQLRLLHWDAYPLEFFPSSFRPECLVELNMSHSKLKKLWSGVQPLRNLRTMNLNS
SRNLEILPNLMEATKLNRLDLGWCESLVELPSSIKNLQHLILLEMSCCKKLEIIPTNINLPSLEVLHFRYCTRLQTFPEI
STNIRLLNLIGTAITEVPPSVKYWSKIDEICMERAKVKRLVHVPYVLEKLCLRENKELETIPRYLKYLPRLQMIDISYCI
NIISLPKLPGSVSALTAVNCESLQILHGHFRNKSIHLNFINCLKLGQRAQEKIHRSVYIHQSSYIADVLPGEHVPAYFSY
RSTGSSIMIHSNKVDLSKFNRFKVCLVLGAGKRFEGCDIKFYKQFFCKPREYYVPKHLDSPLLKSDHLCMCEFELMPPHP
PTEWELLHPNEFLEVSFESRGGLYKCEVKECGLQFLEPHETSEFRYLSPHLYLGGSWIGNSSSSIEEIIHVDQEESSSDS
EEIIYADQEESSSGIEEIIHAEREGTNRRKSVMRWIKVGARKMGLSLECLKPWTR
>O88879|PF00931(130...374)|Apoptotic protease-activating factor 1
MDAKARNCLLQHREALEKDIKTSYIMDHMISNGVLSVIEEEKVKSQATQYQRAAALIKMILNKDNCAYISFYNALLHEGY
KDLAALLQSGLPLVSSSSGKDTDGGITSFVRTVLCEGGVPQRPVIFVTRKKLVHAIQQKLWKLNGEPGWVTIYGMAGCGK
SVLAAEAVRDHSLLEGCFSGGVHWVSIGKQDKSGLLMKLQNLCMRLDQEESFSQRLPLNIEEAKDRLRVLMLRKHPRSLL
ILDDVWDPWVLKAFDNQCQILLTTRDKSVTDSVMGPKHVVPVESGLGREKGLEILSLFVNMKKEDLPAEAHSIIKECKGS
PLVVSLIGALLRDFPNRWAYYLRQLQNKQFKRIRKSSSYDYEALDEAMSISVEMLREDIKDYYTDLSILQKDVKVPTKVL
CVLWDLETEEVEDILQEFVNKSLLFCNRNGKSFCYYLHDLQVDFLTEKNRSQLQDLHRKMVTQFQRYYQPHTLSPDQEDC
MYWYNFLAYHMASANMHKELCALMFSLDWIKAKTELVGPAHLIHEFVAYRHILDEKDCAVCENFQEFLSLNGHLLGRQPF
PNIVQLGLCEPETSEVYRQAKLQAKQEGDTGRLYLEWINKKTIKNLSRLVVRPHTDAVYHACFSQDGQRIASCGADKTLQ
VFKAETGEKLLDIKAHEDEVLCCAFSSDDSYIATCSADKKVKIWDSATGKLVHTYDEHSEQVNCCHFTNKSNHLLLATGS
NDFFLKLWDLNQKECRNTMFGHTNSVNHCRFSPDDELLASCSADGTLRLWDVRSANERKSINVKRFFLSSEDPPEDVEVI
VKCCSWSADGDKIIVAAKNKVLLFDIHTSGLLAEIHTGHHSTIQYCDFSPYDHLAVIALSQYCVELWNIDSRLKVADCRG
HLSWVHGVMFSPDGSSFLTASDDQTIRVWETKKVCKNSAIVLKQEIDVVFQENETMVLAVDNIRGLQLIAGKTGQIDYLP
EAQVSCCCLSPHLEYVAFGDEDGAIKIIELPNNRVFSSGVGHKKAVRHIQFTADGKTLISSSEDSVIQVWNWQTGDYVFL
QAHQETVKDFRLLQDSRLLSWSFDGTVKVWNVITGRIERDFTCHQGTVLSCAISSDATKFSSTSADKTAKIWSFDLLSPL
HELKGHNGCVRCSAFSLDGILLATGDDNGEIRIWNVSDGQLLHSCAPISVEEGTATHGGWVTDVCFSPDSKTLVSAGGYL
KWWNVATGDSSQTFYTNGTNLKKIHVSPDFRTYVTVDNLGILYILQVLE
>P0C8S1|PF00931(167...413)|Probable disease resistance RPP8-like protein 2
MAEAVVSFGVEKLWELLSRESARLNGIDEQVDGLKRQLGRLQSLLKDADAKKNETERVRNFLEDVKDIVYDADDIIESFL
LNELRGKEKGIKKQVRTLACFLVDRRKFASDIEGITKRISEVIVGMQSLGIQHIADGGGRSLSLQERQREIRQTFSRNSE
SDLVGLDQSVEELVDHLVENDSVQVVSVSGMGGIGKTTLARQVFHHDIVRRHFDGFSWVCVSQQFTRKDVWQRILQDLRP
YDEGIIQMDEYTLQGELFELLESGRYLLVLDDVWKEEDWDRIKAVFPHKRGWKMLLTSRNEGLGLHADPTCFAFRPRILT
PEQSWKLFERIVSSRRDKTEFKVDEAMGKEMVTYCGGLPLAVKVLGGLLAKKHTVLEWKRVHSNIVTHIVGKSGLSDDNS
NSVYRVLSLSYEDLPMQLKHCFFYLAHFPEDYKIDVKILFNYWVAEGIITPFHDGSTIQDTGESYLEELVRRNMVVVEES
YLTSRIEYCQMHDMMREVCLSKAKEENFIRVVKVPTTTSTTINAQSPCRSRRLVLHSGNALHMLGHKDNKKARSVLIFGV
EEKFWKPRGFQCLPLLRVLDLSYVQFEGGKLPSSIGDLIHLRFLSLYEAGVSHLPSSLGNLKLLLCLNLGVADRLLVHVP
NVLKEMQELRYLRLPRSMPAKTKLELGDLVNLESLTNFSTKHGSVTDLLRMTKLSVLNVIFSGECTFETLLLSLRELRNL
ETLSFHDFQKVSVANHGGELLVLDFIHLKDLTLSMHLPRFPDQYRFPPHLAHIWLIGCRMEEDPMPILEKLLHLKSVYLS
SGAFLGRRMVCSKGGFPQLLALKMSYKKELVEWRVEEGSMPCLRTLTIDNCKKLKQLPDGLKYVTCLKELKIERMKREWT
ERLVIGGEDYYKVQHIPSVQFINCDH
>P0CB16|PF00931(10...284)|Putative disease resistance protein At4g19050
MEKQDQTSREEILKKIMDSLGQDGVPSKTVLVGEAGIGKTWLAKEVSQRVTQEKYNVLWLHLNKKIEDEKSLYEILAAQL
SIIYEFEEGEEPDELDYPLESLKEKIKEEMIKHKKDNLLLILDDEGSMTTEEDVMQELNLQDFLKEYSAVKILVTRRDER
EEKESTTIKVGPLTEKESLDLLHDAEDLLTSFTSEDWPVLLKRLCDNKEIKEPTLMSCILSKSKGLPAAIVVLIKSLNSI
KSMSAKQRKIFKELILSSKSLDEAAASKNAIDRSRYNPVLQLSYELLKPDETVKRPVIACFWHILDFYKYSGCAYYRDLI
VHWMLEGYFDPVKSVDKAYQEGHSILMDFMNRGILKIQEDNMVVPEFSMSNLLDLQDCGFFGRSSLGFDRVYGGDKRKGL
GKIILIDDMIQTIQSKKKNITTIIASGNRLRREVHGKFFEKPEMQDLEVVVLFEPTFHELVLSLSKLKKLRVLVIRDCDL
IDNIDKLSGLQGLHVLEVSGASSLVNIPDDFFKNMTQLQSLNLSGLAIKSSPSTIEKLSMLRCFILRHCSELQDLPNFIV
ETRKLEVIDIHGARKLESYFDRVKDWKDYKGKNKNFAQLQLLEHLDFSETKIIRLPIFHLKDSTNDFSTMPILTRLLLRN
CTRLKRLPQLRPLTNLQILDACGATDLVEMLEVCLEEKKELRILDMSKTSLPELADTIADVVNLNKLLLRNCSLIEELPS
IEKLTHLEVFDVSGCIKLKNINGSFGEMSYLHEVNLSETNLSELPDKISELSNLKELIIRKCSKLKTLPNLEKLTNLEIF
DVSGCTELETIEGSFENLSCLHKVNLSETNLGELPNKISELSNLKELILRNCSKLKALPNLEKLTHLVIFDVSGCTNLDK
IEESFESMSYLCEVNLSGTNLKTFPELPKQSILCSSKRIVLADSSCIERDQWSQIKECLTSKSEGSSFSNVGEKTREKLL
YHGNRYRVIDPEVPLNIDIVDIKRSTDLKTEYIAKAEYVSIAENGSKSVSSLFDELQMASVKGCWVERCKNMDVLFESDE
QLEKEKSSSPSLQTLWISNLPLLTSLYSSKGGFIFKNLKKLSVDCCPSIKWLFPEIPDNLEILRVKFCDKLERLFEVKAG
ELSKLRKLHLLDLPVLSVLGANFPNLEKCTIEKCPKLKAREDEPRIGARITDEISEDQPHKNTIGPETQTPTQPTKATDT
V
>P0DI16|PF00931(167...419)|Probable disease resistance protein RDL5
MAGELISFGIQNLWNLLSQECELFQGVEDQVTELKRDLNMLSSFLKDANAKKHTSAVVKNCVEEIKEIIYDGEDTIETFV
LEQNLGKTSGIKKSIRRLACIIPDRRRYALGIGGLSNRISKVIRDMQSFGVQQAIVDGGYKQPQGDKQREMRQKFSKDDD
SDFVGLEANVKKLVGYLVDEANVQVVSITGMGGLGKTTLAKQVFNHEDVKHQFDGLSWVCVSQDFTRMNVWQKILRDLKP
KEEEKKIMEMTQDTLQGELIRLLETSKSLIVLDDIWEKEDWELIKPIFPPTKGWKVLLTSRNESVAMRRNTSYINFKPEC
LTTEDSWTLFQRIALPMKDAAEFKIDEEKEELGKLMIKHCGGLPLAIRVLGGMLAEKYTSHDWRRLSENIGSHLVGGRTN
FNDDNNNTCNNVLSLSFEELPSYLKHCFLYLAHFPEDYEIKVENLSYYWAAEGIFQPRHYDGETIRDVGDVYIEELVRRN
MVISERDVKTSRFETCHLHDMMREVCLLKAKEENFLQITSSRPSTANLQSTVTSRRFVYQYPTTLHVEKDINNPKLRALV
VVTLGSWNLAGSSFTRLELLRVLDLIEVKIKGGKLASCIGKLIHLRYLSLEYAEVTHIPYSLGNLKLLIYLNLASFGRST
FVPNVLMGMQELRYLALPSDMGRKTKLELSNLVKLETLENFSTENSSLEDLCGMVRLSTLNIKLIEETSLETLAASIGGL
KYLEKLEIYDHGSEMRTKEAGIVFDFVHLKRLWLKLYMPRLSTEQHFPSHLTTLYLESCRLEEDPMPILEKLLQLKELEL
GFESFSGKKMVCSSGGFPQLQRLSLLKLEEWEDWKVEESSMPLLRTLDIQVCRKLKQLPDEHLPSHLTSISLFFCCLEKD
PLPTLGRLVYLKELQLGFRTFSGRIMVCSGGGFPQLQKLSIYRLEEWEEWIVEQGSMPFLHTLYIDDCPKLKKLPDGLQF
IYSLKNLKISERWKERLSEGGEEYYKVQHIPSVEFYHRVLHIFRSVGGDITGRLLMR
>P0DI17|PF00931(167...418)|Probable disease resistance protein RF9
MAGELISFGIQNLWNLLSQECELFQGVEDQVTELKRDLNLLSSFLKDADAKKHTSAVVKNCVEEIKEIIYDGEDTIETFV
LEQNLGKTSGIKKSIRRLACIIPDRRRYALGIGGLSNRISKVIRDMQSFGVQQAIVDGGYKQPQGDKQREMRPRFSKDDD
SDFVGLEANVKKLVGYLVDEANVQVVSITGMGGLGKTTLAKQVFNHEDVKHQFDGLSWVCVSQDFTRMNVWQKILRDLKP
KEEEKKIMEMTQDTLQGELIRLLETSKSLIVLDDIWEKEDWELIKPIFPPTKGWKVLLTSRNESVAMRRNTSYINFKPEC
LTTEDSWTLFQRIALPMKDAAEFKIDEEKEELGKLMIKHCGGLPLAIRVLGGMLAEKYTSHDWRRLSENIGSHLVGGRTN
FNDDNNNTCNYVLSLSFEELPSYLKHCFLYLAHFPDDYEINVKNLSYYWAAEGIFQPRHYDGEIIRDVGDVYIEELVRRN
MVISERDVKTSRFETCHLHDMMREVCLLKAKEENFLQITSSRTSTGNSLSIVTSRRLVYQYPITLDVEKDINDPKLRSLV
VVANTYMFWGGWSWMLLGSSFIRLELLRVLDIHRAKLKGGKLASSIGQLIHLRYLNLKHAEVTHIPYSLGNLKLLIYLNL
VILVSGSTLVPNVLKEMQQLRYLALPKDMGRKTKLELSNLVKLETLKNFSTKNCSLEDLRGMVRLRTLTIELRKETSLET
LAASIGGLKYLESLTITDLGSEMRTKEAGIVFDFVYLKTLTLKLYMPRLSKEQHFPSHLTTLYLQHCRLEEDPMPILEKL
HQLKELELRRKSFSGKEMVCSSGGFPQLQKLSIKGLEEWEDWKVEESSMPVLHTLDIRDCRKLKQLPDEHLPSHLTSISL
FFCCLEEDPMPTLERLVHLKELQLLFRSFSGRIMVCAGSGFPQLHKLKLSELDGLEEWIVEDGSMPQLHTLEIRRCPKLK
KLPNGFPQLQNLELNELEEWEEWIVEDGSMPLLHTLRIWNCPKLKQLPDGLRFIYSLKNLTVPKRWKKRLSKGGEDYYKV
QHIPSVEFY
>P0DI18|PF00931(167...418)|Probable disease resistance protein RDL6
MAGELISFGIQNLWNLLSQECELFQGVEDQVTELKRDLNLLSSFLKDADAKKHTSAVVKNCVEEIKEIIYDGEDTIETFV
LEQNLGKTSGIKKSIRRLACIIPDRRRYALGIGGLSNRISKVIRDMQSFGVQQAIVDGGYKQPQGDKQREMRPRFSKDDD
SDFVGLEANVKKLVGYLVDEANVQVVSITGMGGLGKTTLAKQVFNHEDVKHQFDGLSWVCVSQDFTRMNVWQKILRDLKP
KEEEKKIMEMTQDTLQGELIRLLETSKSLIVLDDIWEKEDWELIKPIFPPTKGWKVLLTSRNESVAMRRNTSYINFKPEC
LTTEDSWTLFQRIALPMKDAAEFKIDEEKEELGKLMIKHCGGLPLAIRVLGGMLAEKYTSHDWRRLSENIGSHLVGGRTN
FNDDNNNTCNYVLSLSFEELPSYLKHCFLYLAHFPDDYEINVKNLSYYWAAEGIFQPRHYDGEIIRDVGDVYIEELVRRN
MVISERDVKTSRFETCHLHDMMREVCLLKAKEENFLQITSSRTSTGNSLSIVTSRRLVYQYPITLDVEKDINDPKLRSLV
VVANTYMFWGGWSWMLLGSSFIRLELLRVLDIHRAKLKGGKLASSIGQLIHLRYLNLKHAEVTHIPYSLGNLKLLIYLNL
VILVSGSTLVPNVLKEMQQLRYLALPKDMGRKTKLELSNLVKLETLKNFSTKNCSLEDLRGMVRLRTLTIELRKETSLET
LAASIGGLKYLESLTITDLGSEMRTKEAGIVFDFVYLKTLTLKLYMPRLSKEQHFPSHLTTLYLQHCRLEEDPMPILEKL
HQLKELELRRKSFSGKEMVCSSGGFPQLQKLSIKGLEEWEDWKVEESSMPVLHTLDIRDCRKLKQLPDEHLPSHLTSISL
FFCCLEEDPMPTLERLVHLKELQLLFRSFSGRIMVCAGSGFPQLHKLKLSELDGLEEWIVEDGSMPQLHTLEIRRCPKLK
KLPNGFPQLQNLELNELEEWEEWIVEDGSMPLLHTLRIWNCPKLKQLPDGLRFIYSLKNLTVPKRWKKRLSKGGEDYYKV
QHIPSVEFY
>P0DKH5|PF00931(163...371)|Disease resistance protein RRS1
MTNCEKDEEFVCISCVEEVRYSFVSHLSEALRRKGINNVVVDVDIDDLLFKESQAKIEKAGVSVMVLPGNCDPSEVWLDK
FAKVLECQRNNKDQAVVSVLYGDSLLRDQWLSELDFRGLSRIHQSRKECSDSILVEEIVRDVYETHFYVGRIGIYSKLLE
IENMVNKQPIGIRCVGIWGMPGIGKTTLAKAVFDQMSSAFDASCFIEDYDKSIHEKGLYCLLEEQLLPGNDATIMKLSSL
RDRLNSKRVLVVLDDVRNALVGESFLEGFDWLGPGSLIIITSRDKQVFCLCGINQIYEVQGLNEKEARQLFLLSASIKED
MGEQNLQELSVRVINYANGNPLAISVYGRELKGKKKLSEMETAFLKLKRRPPFKIVDAFKSTYDTLSDNEKNIFLDIACF
FQGENVNYVIQLLEGCGFFPHVEIDVLVDKCLVTISENRVWLHKLTQDIGREIINGETVQIERRRRLWEPWSIKYLLEYN
EHKANGEPKTTFKRAQGSEEIEGLFLDTSNLRFDLQPSAFKNMLNLRLLKIYCSNPEVHPVINFPTGSLHSLPNELRLLH
WENYPLKSLPQNFDPRHLVEINMPYSQLQKLWGGTKNLEMLRTIRLCHSHHLVDIDDLLKAENLEVIDLQGCTRLQNFPA
AGRLLRLRVVNLSGCIKIKSVLEIPPNIEKLHLQGTGILALPVSTVKPNHRELVNFLTEIPGLSEELERLTSLLESNSSC
QDLGKLICLELKDCSCLQSLPNMANLDLNVLDLSGCSSLNSIQGFPRFLKQLYLGGTAIREVPQLPQSLEILNAHGSCLR
SLPNMANLEFLKVLDLSGCSELETIQGFPRNLKELYFAGTTLREVPQLPLSLEVLNAHGSDSEKLPMHYKFNNFFDLSQQ
VVNDFLLKTLTYVKHIPRGYTQELINKAPTFSFSAPSHTNQNATFDLQSGSSVMTRLNHSWRNTLVGFGMLVEVAFPEDY
CDATDVGISCVCRWSNKEGRSCRIERKFHCWAPWQVVPKVRKDHTFVFSDVNMRPSTGEGNDPDIWAGLVVFEFFPINQQ
TKCLNDRFTVRRCGVRVINVATGNTSLENIALVLSLDPVEVSGYEVLRVSYDDLQEMDKVLFLYIASLFNDEDVDFVAPL
IAGIDLDVSSGLKVLADVSLISVSSNGEIVMHSLQRQMGKEILHGQSMLLSDCESSMTENLSDVPKKKKKHSESRVKKVV
SIPAIDEGDLWTWRKYGQKDILGSRFPRGYYRCAYKFTHGCKATKQVQRSETDSNMLAITYLSEHNHPRPTKRKALADST
RSTSSSIC
>P0DKH6|PF00931(192...400)|Disease resistance protein RPS6
MASSSSSSSRNWSYHVFPSFSGEDVRNTFLSHFLKELDRKLIISFKDNEIERSQSLDPELKHGIRNSRIAVVVFSKTYAS
SSWCLNELLEIVKCKKEFGQLVIPIFYNLDPSHVRKQTGDFGKIFEKTCRNKTVDEKIRWKEALTDVANILGYHIVTWDN
EASMIEEIANDILGKMNISPSNDFEDLVGIEDHITKMSSLLHLESEEVRMVGIWGPSGIGKTTISRALFSRLSCQFQSSV
FIDKVFISKSMEVYSGANLVDYNMKLHLQRAFLAEIFDKKDIKIHVGAMEKMVKHRKALIVIDDLDDQDVLDALAGQTQW
FGSGSRIIVVTENKHFLRANRIDHIYKVCLPSNALALEMFCRSAFKKNSPPDDFLELSSEVALRAGNLPLGLNVLGSNLR
GINKGYWIDMLPRLQGLDGKIGKTLRVSYDGLNNRKDEAIFRHIACIFNGEKVSDIKLLLANSNLDVNIGLKNLVDRSLI
CERFNTLEMHSLLQELGKEIVRTESNQPGEREFLVDLKDICDVLEHNTGTKKVLGITLDIDETDELHIHESSFKGMHNLL
FLKIYTKKLDQKKKVRWHLPERFDYLPSRLRLLRFDRYPSKCLPSNFHPENLVKLQMQQSKLEKLWDGVHSLAGLRNMDL
RGSRNLKEIPDLSMATNLETLKLSSCSSLVELPSSIQYLNKLNDLDMSYCDHLETIPSGVNLKSLDRLNLSGCSRLKSFL
DIPTNISWLDIGQTADIPSNLRLQNLDELILCERVQLRTPLMTMLSPTLTRLTFSNNPSFVEVPSSIQNLYQLEHLEIMN
CRNLVTLPTGINLDSLISLDLSHCSQLKTFPDISTNISDLNLSYTAIEEVPLSIEKLSLLCYLDMNGCSNLLCVSPNISK
LKHLERADFSDCVELTEASWNGSSSEMVKLLPADNFSTVKLNFINCFKLDLTALIQNQTFFMQLILTGEEVPSYFTHRTS
GDSISLPHISVCQSFFSFRGCTVIDVDSFSTISVSFDIEVCCRFIDRFGNHFDSTDFPGYFITTKLGGHLVVFDCYFPFN
EEFTTFLDGQFNYDHVDIQFRLTNDNSQLKLKGCGILLSEDVPSLDNRPCSPNILPGVCEDSALERRSFRTKMRMMRMRL
LKKLLNR
>P0DO07|PF00931(186...286;312...479)|Disease resistance protein Pik-2
MELVVGASEATMKSLLGKLGNLLAQEYALISGIRGDIQYINDELASMQAFLRDLSNVPEGHSHGHRMKDWMKQIRDIAYD
VEDCIDDFAHRLPQDSISDAKWSFLLTKIYELWTWWPRRVIASNIAQLKVRAQQIADRRSRYGVNNPEHLDSSSSARTRA
VNYEIAEYQVTSPQIIGIKEPVGMKTVMEELEVWLTNPQAENGQAVLSIVGFGGVGKTTIATALYRKVSEKFQCRASVAV
SQNYDQGKVLNSILSQVSNQEQGSSTTISEKKNLTSGAKSMLKTALSLLRGNCICQPENDGNPDNTPIRLQETTDDDQNP
RKLEQLLAEKSYILLIDDIWSAETWESIRSILPKNNKGGRIIVTTRFQAVGSTCSPLETDRLHTVDFLTDDESQNLFNTS
ICESKIRKDSNKVDEQVPEEIWKICGGLPLAIVSMAGLVACNPRKACCDWSKLCKSLFPEQETPLTLDGVTRILDCCYND
LPADLKTCLLYLSIFPKGWKISRKRLSRRWIAEGFANEKQGLTQERVAEAYFNQLTRRNLVRPMEHGSNGKVKTFQVHDM
VLEYIMSKSIEENFITVVGGHWQMTAPSNKVRRLSMQSSGSNRGSSTKGLNLAQVRSLTVFGNLNHVPFHSFNYGIIQVL
DLEDWKGLKERHMTEICQMLLLKYLSIRRTEISKIPSKIQKLEYLETLDIRETYVRDLPKSIVQLKRIISILGGNKNTRK
GLRLPQEKSKKPIKNPSPQGKTKEPAKKGFLSQEKGKGAMKALRVLSGIEIVEESSEVAAGLHQLTGLRKLAIYKLNITK
GGDTFKQLQSSIEYLGSCGLQTLAINDENSEFINSLGDMPAPPRYLVALELSGKLEKLPKWITSITTLNKLTISVTVLRT
ETLEILHILPSLFSLTFAFSLSAAKQDQDIIKDILENNKLDSDGEIVIPAEGFKSLKLLRFFAPLVPKLSFLDKNAMPAL
EIIEMRFKDFEGLFGIEILENLREVHLKVSDGAEAITKFLVNDLKVNTEKPKVFVDGIVTA
>P0DO08|PF00931(186...286;312...479)|Disease resistance protein Pikm2-TS
MELVVGASEATMKSLLGKLGNLLAQEYALISGIRGDIQYINDELASMQAFLRDLSNVPEGHSHGHRMKDWMKQIRDIAYD
VEDCIDDFAHRLPQDSISDAKWSFLLTKIYELWTWWPRRVIASNIAQLKVRAQQIADRRSRYGVNNPEHLDSSSSARTRA
VNYEIAEYQVTSPQIIGIKEPVGMKTVMEELEVWLTNPQAENGQAVLSIVGFGGVGKTTIATALYRKVSEKFQCRASVAV
SQNYDQGKVLNSILSQVSNQEQGSSTTISEKKNLTSGAKSMLKTALSLLRGNCICQPENDGNPDNTPIRLQETTDDDQNP
RKLEQLLAEKSYILLIDDIWSAETWESIRSILPKNNKGGRIIVTTRFQAVGSTCSPLETDRLHTVDFLTDDESQNLFNTS
ICESKIRKDSNKVDEQVPEEIWKICGGLPLAIVSMAGLVACNPRKACCDWSKLCKSLFPEQETPLTLDGVTRILDCCYND
LPADLKTCLLYLSIFPKGWKISRKRLSRRWIAEGFANEKQGLTQERVAEAYFNQLTRRNLVRPMEHGSNGKVKTFQVHDM
VLEYIMSKSIEENFITVVGGHWQMTAPSNKVRRLSMQSSGSNRGSSTKGLNLAQVRSLTVFGNLNHVPFHSFNYGIIQVL
DLEDWKGLKERHMTEICQMLLLKYLSIRRTEISKIPSKIQKLEYLETLDIRETYVRDLPKSIVQLKRIISILGGNKNTRK
GLRLPQEKSKKPIKNPSPQGKTKEPAKKGFLSQEKGKGAMKALRVLSGIEIVEESSEVAAGLHQLTGLRKLAIYKLNITK
GGDTFKQLQSSIEYLGSCGLQTLAINDENSEFINSLGDMPAPPRYLVALELSGKLEKLPKWITSITTLNKLTISVTVLRT
ETLEILHILPSLFSLTFAFSLSAAKQDQDIIKDILENNKLDSDGEIVIPAEGFKSLKLLRFFAPLVPKLSFLDKNAMPAL
EIIEMRFKDFEGLFGIEILENLREVHLKVSDGAEAITKFLVNDLKVNTEKPKVFVDGIVTA
>P0DO09|PF00931(282...487)|Disease resistance protein Piks-1
MEAAAMAVTAATGALAPVLVKLAALLDDGECNLLEGSRSDAEFIRSELEAVHSLLTPNILGRMGDDDAACKDGLIAEVRE
LSYDLDDAVDDFLELNFEQRRSASPFGELKARVEERVSNRFSDWKLPAASLPPSSVHRRAGLPPPDAGLVGMHKRKEELI
ELLEQGSSDASRWRKRKPHVPLRIMGGEMQKIVFKIPMVDDKSRTKAMSLVASTVGVHSVAIAGDLRDEVVVVGDGIDSI
NLVSALRKKVGPAMFLEVSQAKEDVKEITAMLAPVKSICEFHEVKTICILGLPGGGKTTIARVLYHALGTQFQCRVFASI
SPSSSPSPNLTETLADIFAQAQLGVTDTLSTPYGGSGTGRALQQHLIDNISAFLLNKKYLIVIDDIWHWEEWEVIRKSIP
KNDLGGRIIMTTRLNSIAEKCHTDDNDVFVYEVGDLDNNDAWSLSWGIATKSGAGNRIGTGEDNSCYDIVNMCYGMPLAL
IWLSSALVGEIEELGGAEVKKCRDLRHIEDGILDIPSLQPLAESLCLGYNHLPLYLRTLLLYCSAYHWSNRIERGRLVRR
WIAEGFVSEEKEAEGYFGELINRGWITQHGDNNSYNYYEIHPVMLAFLRCKSKEYNFLTCLGLGSDTSTSASSPRLIRRL
SLQGGYPVDCLSSMSMDVSHTCSLVVLGDVARPKGIPFYMFKRLRVLDLEDNKDIQDSHLQGICEQLSLRVRYLGLKGTR
IRKLPQEMRKLKHLEILYVGSTRISELPQEIGELKHLRILDVRNTDITELPLQIRELQHLHTLDVRNTPISELPPQVGKL
QNLKIMCVRSTGVRELPKEIGELNHLQTLDVRNTRVRELPWQAGQISQSLRVLAGDSGDGVRLPEGVCEALINGIPGATR
AKCREVLSIAIIDRFGPPLVGIFKVPGSHMRIPKMIKDHFRVLSCLDIRLCHKLEDDDQKFLAEMPNLQTLVLRFEALPR
QPITINGTGFQMLESFRVDSRVPRIAFHEDAMPNLKLLEFKFYAGPASNDAIGITNLKSLQKVVFRCSPWYKSDAPGISA
TIDVVKKEAEEHPNRPITLLINAGYKEISTESHGSSENIAGSSGIDTEPAQAQHDNLPAVRDDYKGKGILLDGRCPTCGR
ATKIEEETQDRVADIEIQTETTS
>P0DO10|PF00931(186...286;312...479)|Disease resistance protein Piks-2
MELVVGASEATMKSLLGKLGNLLAQEYALISGIRGDIQYINDELASMQAFLRDLSNVPEGHSHGHRMKDWMKQIRDIAYD
VEDCIDDFAHRLPQDSISDAKWSFLLTKIYELWTWWPRRVIASNIAQLKVRAQQIADRRSRYGVNNPEHLDSSSSARTRA
VNYEIAEYQVTSPQIIGIKEPVGMKTVMEELEVWLTNPQAENGQAVLSIVGFGGVGKTTIATALYRKVSEKFQCRASVAV
SQNYDQGKVLNSILSQVSNQEQGSSTTISEKKNLTSGAKSMLKTALSLLRGNCICQPENDGNPDNTPIRLQETTDDDQNP
RKLEQLLAEKSYILLIDDIWSAETWESIRSILPKNNKGGRIIVTTRFQAVGSTCSPLETDRLHTVDFLTDDESQNLFNTS
ICESKIRKDSNKVDEQVPEEIWKICGGLPLAIVSMAGLVACNPRKACCDWSKLCKSLFPEQETPLTLDGVTRILDCCYND
LPADLKTCLLYLSIFPKGWKISRKRLSRRWIAEGFANEKQGLTQERVAEAYFNQLTRRNLVRPMEHGSNGKVKTFQVHDM
VLEYIMSKSIEENFITVVGGHWQMTAPSNKVRRLSMQSSGSNRGSSTKGLNLAQVRSLTVFGNLNHVPFHSFNYGIIQVL
DLEDWKGLKERHMTEICQMLLLKYLSIRRTEISKIPSKIQKLEYLETLDIRETYVRDLPKSIVQLKRIISILGGNKNTRK
GLRLPQEKSKKPIKNPSPQGKTKEPAKKGFLSQEKGKGAMKALRVLSGIEIVEESSEVAAGLHQLTGLRKLAIYKLNITK
GGDTFKQLQSSIEYLGSCGLQTLAINDENSEFINSLGDMPAPPRYLVALELSGKLEKLPKWITSITTLNKLTISVTVLRT
ETLEILHILPSLFSLTFAFSLSAAKQDQDIIKDILENNKLDSDGEIVIPAEGFKSLKLLRFFAPLVPKLSFLDKNAMPAL
EIIEMRFKDFEGLFGIEILENLREVHLKVSDGAEAITKFLVNDLKVNTEKPKVFVDGIVTA
>P25941|PF00931(325...506)|Regulatory protein AfsR
MDGGPRVPEQRRPGFPAEEEESGALRFGVLGPVRAWRDGETLATGSPQQRALLAALLLREGRTATAGELIDALWGEEPPS
QALAAVRTYASRLRKVLDPGVLVSESGGYAVRGLAEGALDLARAQDLASAAEKARSAGDLCHARDLLRRALDLWDGEVLA
GVPGPYAQTQRVRLGEWRLQLLETRLDMDLDQGCHAEAVSELTALTAAHPLRERLRELLMLALYRSGRQAEALAVYADTR
RLLADELGVDPRPGLQELQQRILQADPALAELSAATAETATATLRPAQLPATVSDFTGRAAFVRELSDVLSAASGESASG
RVMAVSALAGIGGVGKTTLAVHVAHRARAAFPDGQLYVDLQGAGARPAEPETVLGSFLRALGTADSAIPDSLEERAALYR
SVLDGRRVLVLLDNARDAAQVRPLLPGTDGCAALVTARVRMVDLAGAHLVDLDVMAPEEALALFTKIVGEERVASERQAA
LDVVGACGFLPLAIRIAASRLAARRTWTVSVLAAKLADERRRLDELQAGDQAVEATFELGYGQLEPAQARAFRLLGLADG
PDISLAAAAAVLDLPAQDTEDLLESLVDTSLLESAAPGRYRFHDLVRLYARACAERTERDGNAPSERGAALSRLLDFYLA
TAAGVYAIERPGDRLVDGLEPTEYPGLTFTEGSAALDWLYTEAAPLLACVRQSAGTARLRRAVDLLWAAKDLTESGANSH
QYEATARAMCDATGSAADTRAEGRARTVLSDVLLVSGRIEHAEEEARLAMRLAGSAEDSAAVSWVANNRGLVCLHQRRYA
EGKGLFHQAIAGFRATDNRAGEASALSNLSRAQLGMGNVAEAVDIARQGLAVYAELGRTMRLANGHFALGVALTRAGRHE
EALGEFAEALDLFGDHRQRLWEGATNFRLAEVHLAAGRPSSAAQHAEQALALGCIGGDRMRGNVLALLGRALSALGQADR
ARACWREALSLYEQHDAQEVGEVRALLARSVAR
>P30429|PF00931(133...405)|Cell death protein 4
MLCEIECRALSTAHTRLIHDFEPRDALTYLEGKNIFTEDHSELISKMSTRLERIANFLRIYRRQASELGPLIDFFNYNNQ
SHLADFLEDYIDFAINEPDLLRPVVIAPQFSRQMLDRKLLLGNVPKQMTCYIREYHVDRVIKKLDEMCDLDSFFLFLHGR
AGSGKSVIASQALSKSDQLIGINYDSIVWLKDSGTAPKSTFDLFTDILLMLARVVSDTDDSHSITDFINRVLSRSEDDLL
NFPSVEHVTSVVLKRMICNALIDRPNTLFVFDDVVQEETIRWAQELRLRCLVTTRDVEISNAASQTCEFIEVTSLEIDEC
YDFLEAYGMPMPVGEKEEDVLNKTIELSSGNPATLMMFFKSCEPKTFEKMAQLNNKLESRGLVGVECITPYSYKSLAMAL
QRCVEVLSDEDRSALAFAVVMPPGVDIPVKLWSCVIPVDICSNEEEQLDDEVADRLKRLSKRGALLSGKRMPVLTFKIDH
IIHMFLKHVVDAQTIANGISILEQRLLEIGNNNVSVPERHIPSHFQKFRRSSASEMYPKTTEETVIRPEDFPKFMQLHQK
FYDSLKNFACC
>P39143|PF00931(182...399)|Transcription activator GutR
MAELENRKQFAQMLAPGVKTLKLHPDYKVRRKKNEKTGQSYIDKIALQLGVSPNTIKSWIGQMGANYIPGRIDDGKLFGM
IWIILEKTDLDIEWLTDLLEATTIPVIKPALPVWAASCLKKAKILRKDGLFGAPSEGEIENVVKRLFHDRPGQETNALTE
QPITHNLPSRWSGRFIGRSFDMEAIRQWMLSPSPVCLITGWAGMGKTTIALEAAYSCVDDTSVWPAFNSIIWVSADWKGL
SFSDFLNTIAYQLGRKEQIDKSINVKRFVVRNALANYTREKPILLIVDSIDTAERDIHEFITSLPQGVKVLLTARENVKQ
TYRESFGEMTAIQLSGLDQTDAHEFFQQEVHHCLQTCNLPRKREKLEQLLHLSSDLKNEFISATAGNPKAMALSIAYMSD
DDIPAQQLIHELGKAGYSLLELFEFLFGRTWDRCNEDTRKLWQTLCFFSKPPDEKSLAAAAGLDARRFHYAMEQMRSYAL
IQPERSQGRTQYLAHQTVVAYGEQHLSEQHEYEKEARNRWAHYYIDYAETHLKREQPNSIYWSYLLGRNLDQMKQEWPNI
LKVIQWASETEQKEILIELITRISHFLSRINLPLRIEYGRKAADAAHHLGQHTREAYFRIDTSGWALMEVNDLDGALQQI
EAGLKILEQSDAHDAYDLKVWGHALKARLFLKDGQQEKAETILNEIENQPISPTIQHRVLLVRGDLSFARGYHVEAIQLY
EAANEISSTYGGEKTIEAYFNLGVAYVKCDQFEKAEEAFEQMLYDKHNANQVELIYYHYGMAQLLYRKGEKTKAVESNQK
AIRLIDSWEPAIGIRGEVERLARATKENE
>P59584|PF00931(169...418)|Disease resistance protein RPH8A
MAEGFVSFGLEKLWDLLSRESERLQGIDEQLDGLKRQLRSLQSLLKDADAKKHGSDRVRNFLEDVKDLVFDAEDIIESYV
LNKLRGEGKGVKKHVRRLARFLTDRHKVASDIEGITKRISEVIGEMQSFGIQQIIDGGRSLSLQERQRVQREIRQTYPDS
SESDLVGVEQSVTELVCHLVENDVHQVVSIAGMGGIGKTTLARQVFHHDLVRRHFDGFAWVCVSQQFTQKHVWQRILQEL
QPHDGEILQMDEYTIQGKLFQLLETGRYLVVLDDVWKKEDWDRIKAVFPRKRGWKMLLTSRNEGVGIHADPTCLTFRASI
LNPEESWKLCERIVFPRRDETEVRLDEEMEAMGKEMVTHCGGLPLAVKALGGLLANKHTVPEWKRVSDNIGSQIVGGSCL
DDNSLNSVYRILSLSYEDLPTHLKHCFLHLAHYPEDSKIYTQDLFNYWAAEGIYDGSTIQDSGEYYLEELVRRNLVIADN
RYLISEFKIKNCQMHDMMREVCLSKAKEENFLQIIKDPTCTSTINAQSPSRSRRLSIHSGKAFHILGHKRNAKVRSLIVS
RFEEDFWIRSASVFHNLTLLRVLDLSWVKFEGGKLPCSIGGLIHLRYLRLYGAVVSHLPSTMRNLKLLLYLNLSVHNEDL
IHVPNVLKEMIELRYLSIPVKMDDKTKLELGDLVNLEYLYGFSTQHTSVTDLLRMTKLRNLTVSLSERYNFKTLSSSLRE
LRNLETLYVLFSRKTYMVDHMGEFVLDHFIHLKELGLVVRMSKIPDQHQFPPHLVHIFLFYCGMEEDPMPILEKLHHLKS
VQLRYKAFVGRRMVCSKDGFTQLCALDISKQSELEDWIVEEGSMPCLRTLTIHDCEKLKELPDGLKYITSLKELKIEGMK
REWKEKLVPGGEDYYKVQHIPDVQFINCDQ
>P60838|PF00931(160...401)|Disease resistance protein SUMM2
MGACLTLSFSCDEVVNQISQGLCINVGYICELSKNVVAMKKDMEVLKKKRDDVKRRVDIEEFTRRRERLSQVQGWLTNVS
TVENKFNELLTTNDAELQRLCLFGFCSKNVKMSYLYGKRVVLMLKEIESLSSQGDFDTVTLATPIARIEEMPIQPTIVGQ
ETMLERVWTRLTEDGDEIVGLYGMGGVGKTTLLTRINNKFSEKCSGFGVVIWVVVSKSPDIHRIQGDIGKRLDLGGEEWD
NVNENQRALDIYNVLGKQKFVLLLDDIWEKVNLEVLGVPYPSRQNGCKVVFTTRSRDVCGRMRVDDPMEVSCLEPNEAWE
LFQMKVGENTLKGHPDIPELARKVAGKCCGLPLALNVIGETMACKRMVQEWRNAIDVLSSYAAEFPGMEQILPILKYSYD
NLNKEQVKPCFLYCSLFPEDYRMEKERLIDYWICEGFIDENESRERALSQGYEIIGILVRACLLLEEAINKEQVKMHDVV
REMALWIASDLGEHKERCIVQVGVGLREVPKVKNWSSVRRMSLMENEIEILSGSPECLELTTLFLQKNDSLLHISDEFFR
CIPMLVVLDLSGNSSLRKLPNQISKLVSLRYLDLSWTYIKRLPVGLQELKKLRYLRLDYMKRLKSISGISNISSLRKLQL
LQSKMSLDMSLVEELQLLEHLEVLNISIKSSLVVEKLLNAPRLVKCLQILVLRGVQEESSGVLTLPDMDNLNKVIIRKCG
MCEIKIERKTLSLSSNRSPKTQFLHNLSTVHISSCDGLKDLTWLLFAPNLTSLEVLDSELVEGIINQEKAMTMSGIIPFQ
KLESLRLHNLAMLRSIYWQPLSFPCLKTIHITKCPELRKLPLDSEIAIRDEELVIKYQEEEWLERVEWDNEATRLRFLPF
FKFFGPEWQVSYVR
>P60839|PF00931(159...401)|Probable disease resistance protein At1g12290
MGGCVSVQVSCDQLLNHLGRCFCRKLYYIQNIKENLTSLEEAMEDLKALRDDLLRKVQTAEEGGLQRLHQIKVWLKRVKT
IESQFNDLDSSRTVELQRLCCCGVGSRNLRLSYDYGRRVFLMLNIVEDLKSKGIFEEVAHPATRAVGEERPLQPTIVGQE
TILEKAWDHLMDDGTKIMGLYGMGGVGKTTLLTQINNRFCDTDDGVEIVIWVVVSGDLQIHKIQKEIGEKIGFIGVEWNQ
KSENQKAVDILNFLSKKRFVLLLDDIWKRVELTEIGIPNPTSENGCKIAFTTRCQSVCASMGVHDPMEVRCLGADDAWDL
FKKKVGDITLSSHPDIPEIARKVAQACCGLPLALNVIGETMACKKTTQEWDRAVDVSTTYAANFGAVKERILPILKYSYD
NLESESVKTCFLYCSLFPEDDLIEKERLIDYWICEGFIDGDENKKGAVGEGYEILGTLVCASLLVEGGKFNNKSYVKMHD
VVREMALWIASDLRKHKDNCIVRAGFRLNEIPKVKDWKVVSRMSLVNNRIKEIHGSPECPKLTTLFLQDNRHLVNISGEF
FRSMPRLVVLDLSWNVNLSGLPDQISELVSLRYLDLSYSSIGRLPVGLLKLKKLMHLNLESMLCLESVSGIDHLSNLKTV
RLLNLRMWLTISLLEELERLENLEVLTIEIISSSALEQLLCSHRLVRCLQKVSVKYLDEESVRILTLPSIGDLREVFIGG
CGMRDIIIERNTSLTSPCFPNLSKVLITGCNGLKDLTWLLFAPNLTHLNVWNSRQIEEIISQEKASTADIVPFRKLEYLH
LWDLPELKSIYWNPLPFPCLNQINVQNKCRKLTKLPLDSQSCIVAGEELVIQYGDEEWKERVEWEDKATRLRFLPSCKLV
LCNR
>Q2QZF1|PF00931(188...270;319...502)|Disease resistance protein PIK6-NP
MELAVGASEATMRSLLGKLGNLLAQEYSLVSGVRGDIQYINDELASMQAFLRDLSVVTEGHNHDNRRKDWMKQIRDVAYD
VEDCIDDFAHRLPQDSISDAKCSFILTKMYELLTWWPRRDIASRIAELKVRAQQIADRRNRYGVNNPEHCDSSNSPRPRA
HAAAQDIAEYQDTKPQIVSIKEPVGMKTVMENLEKWLTEPQPDKGRAVLSIVGFGGVGKTTIAMALYRKVSGKFDCQASV
AVSQNYDEDEVLRSILNQVSKQEEAGGSTESSSRDENTREPQGSSSTSSREENTAESGTKRMLNKLKKALPLSLLGGNDD
KTSVRQQETMGSLQLREELKRRLAEKRYILLIDDIWSAKTWNSIIIPFLPSENDKDSRIIVTTRFHAVGSTCSPRHKNDE
ATSSPGHGKDLLHKVDFLTGDKPLDLFNASIPDPMKRTDRDKKLSKICGGLPLAIVTMAGLVACNPNKANSDWSKLCESL
FPYPVTTLNLDGVTRILDCCYNDLPADLKTCLLYLSIFPKGWKISRKRLARRWIAEGFATEKQGLTEEEVAEAYFNQLAR
RNLIRPVEHGSNGKVKAFQVHDMVLEYIMSKSIEENFITVVGGHWQMTAPSNKVRRLSLQSSGSKHGNSTKGLNLAQVRS
LTVFGNLNHVPFHSFNYGIIQVLDLEGWKGLKERHVTEICQMLVLKYLSIRRTEIAKIPSKIEKLEYLETLDIRETYVEE
LPKSVGQLKRISSILGGNKNTRKGLRLPQEKRNKAMKNPSPQGKTKEPAEKGFLSQEKAKGTMKSLRVLSGIEIVDESAA
VAASLHQLTGLRKLAIYKLKISEENDTFKELLSSIEYLGSCGLQTLAINDENSKFINSLYNMSAPPRYLVSLELSGKLKW
LPEWITSITTLNKLTISITVLTTETLEILRNLPSLFSLTFAFSLSAAKQDQDTVKGILEDNKLATDGEIVIPAKEFKSLK
LLRFFAPFVPKLSFPDKSAMPALEIIEMRFQEFEGLFGIEILENLREVHLKVSDGAEAITKFLVSDLKDNTEKPKVFVDG
IVTA
>Q2QZF2|PF00931(285...484)|Disease resistance protein PIK5-NP
MAVYSVATGALAPVLSKLSALLGDEHLDLAERTRSDAMFIRSQLEAVHSLLLPRISWGMTGEEVDALCKDELMAEVRELS
YDMDDAIDEFFLEEPMAGGDGGPFDELKTRVEDVSKRFSDSRRWRPPVEQHQPSLTAATVDCPPPHARFVHNMMDVSELV
EMDKQHEKELIKLLEQGADTSIYASRWRIATPWHDKEQSTVVKVPEREWGFPDNRNSPFIWASDSFERLRSGSLCGDTLR
LDGEGANIRKLLSTLRNKVGRAQLVQVEDKRKRVEEATKPCEFHEVKTICILGLPGAGKTTLAKLLYSHHSTTEQQFQHR
AFVSLSPGANLTDTLTDILLQVGAYNDDATPYCGTGTPHQQYLIDNISAYLIGKKYLIIIDDVWHWEEWEVIRKSIPKND
LGSRIIMTTRLNSIAEKCRNDDMDAFVYETEALDYVDAWLLCDKVARKSVTCMNINPCYDIVDMCYGMPLALIRVSSALA
EEIQALDSDERQIWRALRRVEDGILDIPSLKPLAESLCLGYDHLPLYLRTLLLCCSVYHWLDGGIVQRGRLVTRWIAEGF
VSEEKAAEGYFDELVGRGWMKHRGLNEYEIHPMMLAILRYKSKEYNFVTCLGTGSDTCTSASLSYSSPTMAIRRLCLQRG
YPMKCFSSMDVSHTRSLVILGDVIGVPLDMFKRLRVLDLEDNIGIEDSHLKKICEQLESLRLLKYLGLKGTRITKLPQEI
QKLKQLEILYVRSTGIEELPWEIGELKQLRTLDVRNTRISELPSQIGELKHLRTLDVSNMWNISELPSQIGELKHLQTLD
VRNTSVRELPSQIGELKHLRTLDVRNTGVRELPWQAGQISGSLHVHTDDSDEGMRLPEGVCEDLIKGIPKAELAKCSEVL
SINIVDRLGSPPIGIFKVIGLHKSIPKLIKDHFNVLSSLDIRRYNKLEEDDHEFLANNMPNLQMLVLRFEAPQREPIIIN
RTGFQMLERFLVESRVPRITFQEGAMPKLKHLEFKFYAGPPSKDPIGITHLKSLQKVVFRCSKWYKSDNPGIKAAIDVVK
KEARQHPNRPISLLITEGDKEVPNIEAHGSSENIVVVHAAPDDAISCSSCGRTSTSIQEGTVRDRIPAMDLFWPEFNSYE
KAKRN
>Q2R8L1|PF00931(180...395)|Disease resistance protein RGA5
MDAPVSFSLGAMGPLLRKLDSLPVAPEIRLPEPLKDGIELLKEDLEEIGAALVEQSMVDSPSHRARYWMDEVRDLSYHIE
DCIDTMFSMRCGGDDGKPRSVRRHKVGRVKVDGFSKTQKPCTRLARIAELRALVREASERHERYQLGDGRASSSSSSSHR
VFTAHGQVPAPCRNLVGMDEPKTKLTNMLTDEAELHMKVVCILGSAGIGKTTLAEQVYRKLRWQFDCHAFVRASRKPDMR
RLLGAILSQVQLRIRISDTSTVQSLIDNLWEYLQKKRYFIVIDELYETATWDIITSAFPEDNNCSRIMTTAGIEGVALEC
CSYHSVNIFKMIPLGLDDSAKLFFNRVFGSEQQCPYELNEVSYRITAKCGGLPLAVIIIAGLLASLPCKTELWYNIDGCL
CSSVTTDIDLDEILKEIISLGYDNLPHYLKTCLLYLSLYSEGFIIWTADLLKQWISEGFIAVIDGEDIEEVAESYFYNLV
NRGMIQSVKTKYNNQVLCTVHHTVFDLIIHKSKEEKFISAIDYSQTMPGNSLEARRLSFHFSNTRYATEVAGITLSQVRS
FAFLGLLKCMPSIMEFKLLRVLILEFWGDNHGCMSFNVARICRLFQLRYLKISSQIIIELPAQIRGLKYLETLEIDARVT
AIPSDIIHLRSLLHLYFQDGIVLPDGIGCIRSLRTLKYFDLGSNSEENIRSLGQLTNLRDLHLTCSAPKSNQQAKRNLVI
LASYTGKLGNLKSVKFSPGDSGMDISFLFYGIGISVDRSRTASSLPFSVRTLELPSICIFARLPDWIGQLRKLHTLNLAV
RELIENDIDSLAGLPDLIVLSMHIMKAPMERIVFNRKAFPVLKYFKFICGTLRMAFQAGAMANLHRLKLGFNAHKGEKYD
NILVGIEHLLNLKKIAVRIGGAAEAKESDRMAAEAALKEAIRKHLMFLDDLDIARVECVKEEYKCIKKKHKIKIEDSISE
KNGDSKKQHSVEKKAVWGKTMKNIADSGVFPEDYTMSREQRVAEGFVVGIEKCRAEDAAERIIRNVPVDYDGLGQVSTSK
IQDHLPELAPRAVQNEKFGSSNDLSIMIQINKYARLPSYEWRDTDISKLNFRLLRAPMLLEAVTARCHLLDLILIGSNNI
TVLDLGRPTITKLPASIECLPNLRYLRLQGTQLKSLSEVIVKMPTIRGLDIKNTKTEELPQGILRMKKLSHLSMGEKQKN
IQVFMEKMQTLAETVQDSDDLSDETEGIADDEGEFSTRANASTPKVDEDEVDRRANNFIARFRKQITIRNSGFAKKESSI
DERLWIRDLDECQLSKRGGRF
>Q38834|PF00931(164...410)|Disease resistance RPP13-like protein 4
MVDAVVTVFLEKTLNILEEKGRTVSDYRKQLEDLQSELKYMQSFLKDAERQKRTNETLRTLVADLRELVYEAEDILVDCQ
LADGDDGNEQRSSNAWLSRLHPARVPLQYKKSKRLQEINERITKIKSQVEPYFEFITPSNVGRDNGTDRWSSPVYDHTQV
VGLEGDKRKIKEWLFRSNDSQLLIMAFVGMGGLGKTTIAQEVFNDKEIEHRFERRIWVSVSQTFTEEQIMRSILRNLGDA
SVGDDIGTLLRKIQQYLLGKRYLIVMDDVWDKNLSWWDKIYQGLPRGQGGSVIVTTRSESVAKRVQARDDKTHRPELLSP
DNSWLLFCNVAFAANDGTCERPELEDVGKEIVTKCKGLPLTIKAVGGLLLCKDHVYHEWRRIAEHFQDELRGNTSETDNV
MSSLQLSYDELPSHLKSCILTLSLYPEDCVIPKQQLVHGWIGEGFVMWRNGRSATESGEDCFSGLTNRCLIEVVDKTYSG
TIITCKIHDMVRDLVIDIAKKDSFSNPEGLNCRHLGISGNFDEKQIKVNHKLRGVVSTTKTGEVNKLNSDLAKKFTDCKY
LRVLDISKSIFDAPLSEILDEIASLQHLACLSLSNTHPLIQFPRSMEDLHNLQILDASYCQNLKQLQPCIVLFKKLLVLD
MTNCGSLECFPKGIGSLVKLEVLLGFKPARSNNGCKLSEVKNLTNLRKLGLSLTRGDQIEEEELDSLINLSKLMSISINC
YDSYGDDLITKIDALTPPHQLHELSLQFYPGKSSPSWLSPHKLPMLRYMSICSGNLVKMQEPFWGNENTHWRIEGLMLSS
LSDLDMDWEVLQQSMPYLRTVTANWCPELESFAIEDVGFRGGVWMKTPLHRT
>Q39214|PF00931(177...425)|Disease resistance protein RPM1
MASATVDFGIGRILSVLENETLLLSGVHGEIDKMKKELLIMKSFLEDTHKHGGNGSTTTTTQLFQTFVANTRDLAYQIED
ILDEFGYHIHGYRSCAKIWRAFHFPRYMWARHSIAQKLGMVNVMIQSISDSMKRYYHSENYQAALLPPIDDGDAKWVNNI
SESSLFFSENSLVGIDAPKGKLIGRLLSPEPQRIVVAVVGMGGSGKTTLSANIFKSQSVRRHFESYAWVTISKSYVIEDV
FRTMIKEFYKEADTQIPAELYSLGYRELVEKLVEYLQSKRYIVVLDDVWTTGLWREISIALPDGIYGSRVMMTTRDMNVA
SFPYGIGSTKHEIELLKEDEAWVLFSNKAFPASLEQCRTQNLEPIARKLVERCQGLPLAIASLGSMMSTKKFESEWKKVY
STLNWELNNNHELKIVRSIMFLSFNDLPYPLKRCFLYCSLFPVNYRMKRKRLIRMWMAQRFVEPIRGVKAEEVADSYLNE
LVYRNMLQVILWNPFGRPKAFKMHDVIWEIALSVSKLERFCDVYNDDSDGDDAAETMENYGSRHLCIQKEMTPDSIRATN
LHSLLVCSSAKHKMELLPSLNLLRALDLEDSSISKLPDCLVTMFNLKYLNLSKTQVKELPKNFHKLVNLETLNTKHSKIE
ELPLGMWKLKKLRYLITFRRNEGHDSNWNYVLGTRVVPKIWQLKDLQVMDCFNAEDELIKNLGCMTQLTRISLVMVRREH
GRDLCDSLNKIKRIRFLSLTSIDEEEPLEIDDLIATASIEKLFLAGKLERVPSWFNTLQNLTYLGLRGSQLQENAILSIQ
TLPRLVWLSFYNAYMGPRLRFAQGFQNLKILEIVQMKHLTEVVIEDGAMFELQKLYVRACRGLEYVPRGIENLINLQELH
LIHVSNQLVERIRGEGSVDRSRVKHIPAIKHYFRTDNGSFYVSLSS
>Q40253|PF00931(241...480)|Disease resistance protein L6
MSYLREVATAVALLLPFILLNKFWRPNSKDSIVNDDDDSTSEVDAISDSTNPSGSFPSVEYEVFLSFRGPDTREQFTDFL
YQSLRRYKIHTFRDDDELLKGKEIGPNLLRAIDQSKIYVPIISSGYADSKWCLMELAEIVRRQEEDPRRIILPIFYMVDP
SDVRHQTGCYKKAFRKHANKFDGQTIQNWKDALKKVGDLKGWHIGKNDKQGAIADKVSADIWSHISKENLILETDELVGI
DDHITAVLEKLSLDSENVTMVGLYGMGGIGKTTTAKAVYNKISSCFDCCCFIDNIRETQEKDGVVVLQKKLVSEILRIDS
GSVGFNNDSGGRKTIKERVSRFKILVVLDDVDEKFKFEDMLGSPKDFISQSRFIITSRSMRVLGTLNENQCKLYEVGSMS
KPRSLELFSKHAFKKNTPPSYYETLANDVVDTTAGLPLTLKVIGSLLFKQEIAVWEDTLEQLRRTLNLDEVYDRLKISYD
ALNPEAKEIFLDIACFFIGQNKEEPYYMWTDCNFYPASNIIFLIQRCMIQVGDDDEFKMHDQLRDMGREIVRREDVLPWK
RSRIWSAEEGIDLLLNKKGSSKVKAISIPWGVKYEFKSECFLNLSELRYLHAREAMLTGDFNNLLPNLKWLELPFYKHGE
DDPPLTNYTMKNLIIVILEHSHITADDWGGWRHMMKMAERLKVVRLASNYSLYGRRVRLSDCWRFPKSIEVLSMTAIEMD
EVDIGELKKLKTLVLKFCPIQKISGGTFGMLKGLRELCLEFNWGTNLREVVADIGQLSSLKVLKTTGAKEVEINEFPLGL
KELSTSSRIPNLSQLLDLEVLKVYDCKDGFDMPPASPSEDESSVWWKVSKLKSLQLEKTRINVNVVDDASSGGHLPRYLL
PTSLTYLKIYQCTEPTWLPGIENLENLTSLEVNDIFQTLGGDLDGLQGLRSLEILRIRKVNGLARIKGLKDLLCSSTCKL
RKFYITECPDLIELLPCELGGQTVVVPSMAELTIRDCPRLEVGPMIRSLPKFPMLKKLDLAVANITKEEDLDAIGSLEEL
VSLELELDDTSSGIERIVSSSKLQKLTTLVVKVPSLREIEGLEELKSLQDLYLEGCTSLGRLPLEKLKELDIGGCPDLTE
LVQTVVAVPSLRGLTIRDCPRLEVGPMIQSLPKFPMLNELTLSMVNITKEDELEVLGSLEELDSLELTLDDTCSSIERIS
FLSKLQKLTTLIVEVPSLREIEGLAELKSLRILYLEGCTSLERLWPDQQQLGSLKNLNVLDIQGCKSLSVDHLSALKTTL
PPRARITWPDQPYR
>Q40392|PF00931(193...417)|TMV resistance protein N
MASSSSSSRWSYDVFLSFRGEDTRKTFTSHLYEVLNDKGIKTFQDDKRLEYGATIPGELCKAIEESQFAIVVFSENYATS
RWCLNELVKIMECKTRFKQTVIPIFYDVDPSHVRNQKESFAKAFEEHETKYKDDVEGIQRWRIALNEAANLKGSCDNRDK
TDADCIRQIVDQISSKLCKISLSYLQNIVGIDTHLEKIESLLEIGINGVRIMGIWGMGGVGKTTIARAIFDTLLGRMDSS
YQFDGACFLKDIKENKRGMHSLQNALLSELLREKANYNNEEDGKHQMASRLRSKKVLIVLDDIDNKDHYLEYLAGDLDWF
GNGSRIIITTRDKHLIEKNDIIYEVTALPDHESIQLFKQHAFGKEVPNENFEKLSLEVVNYAKGLPLALKVWGSLLHNLR
LTEWKSAIEHMKNNSYSGIIDKLKISYDGLEPKQQEMFLDIACFLRGEEKDYILQILESCHIGAEYGLRILIDKSLVFIS
EYNQVQMHDLIQDMGKYIVNFQKDPGERSRLWLAKEVEEVMSNNTGTMAMEAIWVSSYSSTLRFSNQAVKNMKRLRVFNM
GRSSTHYAIDYLPNNLRCFVCTNYPWESFPSTFELKMLVHLQLRHNSLRHLWTETKHLPSLRRIDLSWSKRLTRTPDFTG
MPNLEYVNLYQCSNLEEVHHSLGCCSKVIGLYLNDCKSLKRFPCVNVESLEYLGLRSCDSLEKLPEIYGRMKPEIQIHMQ
GSGIRELPSSIFQYKTHVTKLLLWNMKNLVALPSSICRLKSLVSLSVSGCSKLESLPEEIGDLDNLRVFDASDTLILRPP
SSIIRLNKLIILMFRGFKDGVHFEFPPVAEGLHSLEYLNLSYCNLIDGGLPEEIGSLSSLKKLDLSRNNFEHLPSSIAQL
GALQSLDLKDCQRLTQLPELPPELNELHVDCHMALKFIHYLVTKRKKLHRVKLDDAHNDTMYNLFAYTMFQNISSMRHDI
SASDSLSLTVFTGQPYPEKIPSWFHHQGWDSSVSVNLPENWYIPDKFLGFAVCYSRSLIDTTAHLIPVCDDKMSRMTQKL
ALSECDTESSNYSEWDIHFFFVPFAGLWDTSKANGKTPNDYGIIRLSFSGEEKMYGLRLLYKEGPEVNALLQMRENSNEP
TEHSTGIRRTQYNNRTSFYELING
>Q42484|PF00931(159...398)|Disease resistance protein RPS2
MDFISSLIVGCAQVLCESMNMAERRGHKTDLRQAITDLETAIGDLKAIRDDLTLRIQQDGLEGRSCSNRAREWLSAVQVT
ETKTALLLVRFRRREQRTRMRRRYLSCFGCADYKLCKKVSAILKSIGELRERSEAIKTDGGSIQVTCREIPIKSVVGNTT
MMEQVLEFLSEEEERGIIGVYGPGGVGKTTLMQSINNELITKGHQYDVLIWVQMSREFGECTIQQAVGARLGLSWDEKET
GENRALKIYRALRQKRFLLLLDDVWEEIDLEKTGVPRPDRENKCKVMFTTRSIALCNNMGAEYKLRVEFLEKKHAWELFC
SKVWRKDLLESSSIRRLAEIIVSKCGGLPLALITLGGAMAHRETEEEWIHASEVLTRFPAEMKGMNYVFALLKFSYDNLE
SDLLRSCFLYCALFPEEHSIEIEQLVEYWVGEGFLTSSHGVNTIYKGYFLIGDLKAACLLETGDEKTQVKMHNVVRSFAL
WMASEQGTYKELILVEPSMGHTEAPKAENWRQALVISLLDNRIQTLPEKLICPKLTTLMLQQNSSLKKIPTGFFMHMPVL
RVLDLSFTSITEIPLSIKYLVELYHLSMSGTKISVLPQELGNLRKLKHLDLQRTQFLQTIPRDAICWLSKLEVLNLYYSY
AGWELQSFGEDEAEELGFADLEYLENLTTLGITVLSLETLKTLFEFGALHKHIQHLHVEECNELLYFNLPSLTNHGRNLR
RLSIKSCHDLEYLVTPADFENDWLPSLEVLTLHSLHNLTRVWGNSVSQDCLRNIRCINISHCNKLKNVSWVQKLPKLEVI
ELFDCREIEELISEHESPSVEDPTLFPSLKTLRTRDLPELNSILPSRFSFQKVETLVITNCPRVKKLPFQERRTQMNLPT
VYCEEKWWKALEKDQPNEELCYLPRFVPN
>Q5MLE9|PF00931(162...388)|ToMV resistant protein Tm-2 netted virescent
MAEILLTSVINKSVEIAGNLLIQEGKRLYWLKEDIDWLQREMRHIRSYVDNAKAKEAGGDSRVKNLLKDIQELAGDVEDL
LDDFLPKIQQSNKFNYCLKRSSFADEFAMEIEKIKRRVVDIDRIRKTYNIIDTDNNNDDCVLLDRRRLFLHADETEIIGL
DDDFNMLQAKLLNQDLHYGVVSIVGMPGLGKTTLAKKLYRLIRDQFECSGLVYVSQQPRASEILLDIAKQIGLTEQKMKE
NLEDNLRSLLKIKRYVFLLDDVWDVEIWDDLKLVLPECDSKVGSRIIITSRNSNVGRYIGGESSLHALQPLESEKSFELF
TKKIFNFDDNNSWANASPDLVNIGRNIVGRCGGIPLAIVVTAGMLRARERTEHAWNRVLESMGHKVQDGCAKVLALSYND
LPIASRPCFLYFGLYPEDHEIRAFDLINMWIAEKFIVVNSGNRREAEDLAEDVLNDLVSRNLIQLAKRTYNGRISSCRIH
DLLHSLCVDLAKESNFFHTAHDAFGDPGNVARLRRITFYSDNVMIEFFRSNPKLEKLRVLFCFAKDPSIFSHMAYFDFKL
LHTLVVVMSQSFQAYVTIPSKFGNMTCLRYLRLEGNICGKLPNSIVKLTRLETIDIDRRSLIQPPSGVWESKHLRHLCYR
DYGQACNSCFSISSFYPNIYSLHPNNLQTLMWIPDKFFEPRLLHRLINLRKLGILGVSNSTVKMLSIFSPVLKALEVLKL
SFSSDPSEQIKLSSYPHIAKLHLNVNRTMALNSQSFPPNLIKLTLANFTVDRYILAVLKTFPKLRKLKMFICKYNEEKMA
LSGEANGYSFPQLEVLHIHSPNGLSEVTCTDDVSMPKLKKLLLTGFHCGISLSERLKKLSK
>Q60CZ8|PF00931(530...775)|Putative late blight resistance protein homolog R1A-10
MYFNNELSDLKDHLLRKLQYYTYSDVVRDRINFILWEFKFLDCFLYLKSFPFASECGMLHVSQKMIEIWKSQWNKLIYIC
MYDEEGSPWDAVVYWKELISQTKQEFRAQYSFPKSPLAANEVIDDDDDDNTHSPEFVMEVIGFFVGNINVLVKINDPCSC
FFVPGLKEQIEQILKELKLLRFLVCFVSNKCIVPQYRCTTFYTRALIEASYIAMVAWLYLPIYGNGNQDLAPSEVSRLLS
DFMEMKIKSIEPGISRNSIYIDVLQALKSTIPQAQKKHVEIPTHSLTVGLSDQMANLQEMLCLLRDNLIHLPILDLEFHL
QDMDSVIVDAGLLIYSLYDIKGQMEDTSLDVINWALGFDLPRNIEPIKVMAYLVMQKAFHCNLPRIHGLGYVDFLLKNLN
DFQDCYSDSLAFLKNQLQVIQTEFESLQPFLKVVAEEPHNKLKTLNEDCATQIIRKAYEVEYVVDACINKEALHWCLERW
LLDIIEEITCIKAKIQEKNTVEDTMKTVIARTSSKLARTPRMKEEIVGFEDVIENLRKKLLSRTKGQDVISIHGMPGLGK
TTLANRLYSDRSVVSQFDFCAQCCVSQVYSCKDLLLSLLRDAIGEESERRELPDNELADMLRKTLLPRRYLILVDDVWDN
SAWDDLRGCFPDVNNRSRIILTTRHHEVAKYASVRSDPLHLRMFDEVESWKLLEKKVFGEQSCPPLLKNIGLRIAKMCGQ
LPLSIVLVAGILSEMEKDVECWEQVANNLGSHIHNDSRAIVDQSYHVLPCHLKSCFLYFGAFLEDRVIDISRLIRLWISE
AFIKSSEGRSLEDIAEGYLENLIGRNLVMVTQRAISDGKVKACRLHDVLLDFCKERAAEENFLLWINRDQITKPSSCVYS
HKQHAHLAFTEMHNLVEWSASCSFVGSVVLSNKYEPYFHDLSSLHDFSISRILPNFKFLKVLDLEHRVFIDFIPTELPYL
RYFSALIDQNSIPSSISNLWNLETLILNRRSADSHNRVLLPSTVWDMVKLRHLHIPNFSPENKKALLKNSPNLDDLETLS
YPYFARVKDAELMLRKTPNLRKLTCKVKCLEYLHQYHALNFPIRLEILKLYRSNAFKAIPFCISAPNLKYLKLSGFYLDS
QYLSKTADHLKNLEVLKLYYVEFGDHREWKVSNGMFPQLKILKLEDVSLMKWIVADDAFPNLEQLVLRGCQDLMEIPSCF
MDILSLQYIEVEDCNESVVKSAMNIQETQVEDYQNTNFKLVLIEKWPKFYKLFSQLSLPRGLVLHLGIESVSSDEKEKKL
TVTGDVDADEVQLVVEKLRKCGMPGL
>Q60Z52|PF00931(134...407)|Cell death protein 4
MLCEIECRALNAAHTMLIQDFEPRDALTYLEGEKIFTEDHSDLISNMPTRLERIANFLRAYRRQASELAPLIDFFEYNNQ
NHLKDFLDEYLWFATHQPDKLRPVVLVPKFSRQMLDRKLLLGNVPKQMNCFSREFHVDRVIEKLDEMCDLESFFLFLHGR
SGSGKSVIASQALSKSDQLIGINYDSVVWLKDSGTTPKATFDLFTDLLLMLKRARVVSDTDDSHNMPDFINRVLSRSEDD
LLNFPSVEHVTSVVLKRMIANALIDRPNTLFVLDDVVQEDTIRWAQELRLRCLITTRDVEISNAASPECEFIEVTPLESY
ECFELLESYGMPVPAIERDEDILHKTIDLTSGNPAALMMIFKSCEPKTFEKMAQLNSKLETRGLSAIECITPYCYKSLSS
SLQRCVEVLSDEDRSALAFAVIMPPGIDIPVKIWSCVIPVDICSNEEDQLDDEVADRLKRLSKRGALLSGKRSPVLTYKI
DHVIHLFLKHVVDVQTIANGISILEQRLHELGNNNTPTPERHMPSKFRRTSAGDMFPKVEDSVIRPEDYSKFMQIHRTFY
DSLKKFTSQ
>Q6L3L0|PF00931(484...729)|Putative late blight resistance protein homolog R1B-23
MIEFWKSEYTRILSICHDSGTQYRNKNVRMRSLYLEKVWVAFKSFAYWKEVIWKTKQEFRAQYSFPKTSLEANKVDDANT
HSPKFVMEVIDVFVENLNDLMKINDPSSWLFVPGHMKEQIEKVLKELKLLRFFVCFVSNKCIQPQYQHTTFYTHALIEAS
HNAMVVWLHLPVYGIGNQDLAPSEVSRLLSDFMEMKIKSIQPGISRNSIYIDVLQALKSTIPQAQQKHVAESGIVEIPTH
SLTVGLSDQMANLQEMLCLLRDNLIHLPILDLEFHLQDMDSVIVDAGLLIYSLYDIKGEKEDTILEDIKRELGFDLPRNI
EPIKVMVYLVMQKAFQCNLPRIHGLGYVDFLLKNLKDFQGRYSDSLAFLKNQLQVIQTKFESMQPFLKVVVEEPHNKLKT
LNEDCATQIIRKAYEVEYVVDACINKEVPQWCIERWLLDIIEEITCIKEKIQEKNTVEDTMKSVIASSQLARTPRMNEEI
VGFEDVIETLRKKLLNGTKGQDVISMHGMPGLGKTTLANRLYSDRSVVSQFDICAQCCVSQVYSYKDLLLALLRDAIGEG
SVRTELHANELADMLRKTLLPRRYLILVDDVWENSVWDDLSGCFPDVNNRSRIILTTRHHEVAKYASVHSDPLHLRMFDE
VESWKLLEKKVFGEESCSPLLRDIGQRIAKMCGQLPLSIVLVAGILSEMEKEVECWEQVANNLGTHIHNDSRAVVDQSYH
VLPCHLKSCFLYFGAFLEDRVIDIPRLIRLWISESFIKSCEGRSLEDIAEGYLENLIGRNLVMVTQRDDSDGKVKACRLH
DVLLDFCKERAAEENFLLWINRDQITKPSSCVYSHNQHAHLAFTDMKNLVEWSASCSCVGSVLFKNYDPYFAGRPLSSHA
FSISRILLNFKFLKVLDLEHQVVIDSIPTELFYLRYISAHIEQNSIPSSISNLWNLETLILNRTSAATGKTLLLPSTVWD
MVKLRHLHIPKFSPENKKALLENSARLDDLETLFNPYFTRVEDAELMLRKTPNLRKLICEVQCLEYPHQYHVLNFPIRLE
MLKLHQSNIFKPISFCISAPNLKYLELSGFYLDSQYLSETADHLKHLEVLKLYYVEFGDHREWKVSNGMFPQLKILKLKC
VSLLKWIVADDAFPNLEQLVLRRCRHLMEIPSCFMDILSLQYIEVENCNESVVKSAMNIQETQVEDNQNTNFKLVLIEIH
LFCLFDMKGIESISTDMKEKKLTVTRDVDADEVQLVVEKLRNVAYADEVQLVVEKLRKRGML
>Q6L3N7|PF00931(514...759)|Putative late blight resistance protein homolog R1C-3
MYFNNELSNLKDHLLVTLQNNSDVERDRINFILWDLKFLDCFLHLKRLPFASECGMLEFSQKMIEIWKIQSHREPYDCPY
WKEVIWKTKQEFRAEYSFPNTSLAANKVDDVSPKFVMEVIDVFVENLNVVVKINDPYSWLFVPEHKEQIEQVLKELKLLR
FFVCFVSNKCIEPQYRHTTFYIHALIEASHIAMVVWLHLPVLNGIVNQYLAPSEVSRLRSDFMEMKIKSIQPDISRNNIY
IDVLQALKSTIPQAQNKHAVESGIVETPTQNLTVGLSDQMVNLQEMLCFLRDNLIHLPILDLEFHLQDMDSVIVDAGLLI
YSLYDIKGEKEDTVLDNMNRALGFDLPRNIEPIKAMVYLVMQKAFQSNLPRVHGLGYVDFLLKNLKDFQGRYSDSLAFLK
NQLQVIQTKFESMQPFLKVVVEEPHNKLKTLNEDYATQIIRKAYEVEYVVDACINKEVPQWCIERWLLDIIEEITCIKAK
IQEKNTVEDTMKSVIASSQLARTPRMNEEIVGFEDVIETLRKKLLNGTKGQDVISMHGMPGLGKTTLANRLYSDRSVVSQ
FDICAQCCVSQVYSYKDLLLALLRDAIGEGSVRTELHANELADMLRKTLLPRRYLILVDDVWENSVWDDLSGCFPDVNNR
SRIILTTRHHEVAKYASVHSDPLHLRMFDEVESWKLLEKKVFGEESCSPLLRDIGQRIAKMCGQLPLSIVLVAGILSEME
KEVEYWEQVANNLGTHIHNDSRAVVDQSYHVLPCHLKSCFLYFGAFLEDRVIDISRLIRLWISESFVKSCEGRSLEDIAE
GYLENLIGRNLVMVTQRDDSDGKVKACRLHDVLLDFCKERAAEENFLLWINRDQITKPSSCVYSHNQHAHLAFTDMKNLV
EWSASCSRVGSVLFKNYDPYFAGRPLSSHAFSISRILLNFKFLKVLDLEHQVVIDSIPTELFYLRYISAHIEQNSIPSSI
SNLWNLETLILNRTSAATGKTLLLPSTVWDMVKLRHLHIPKFSPENKKALLKKSARLDDLETLFNPYFTRVEDAELMLRK
TPNLRKLICEVQCLEYPHQYHVLNFPIRLEMLKLHQSNIFNPISFCISAPNLKYLELSGFYLDSQYLSETADHLKHLEVL
KLYYVEFGDHREWKVSNGMFPQLKILKLKCVSLLKWIVADDAFPNLEQLVLRGCRHLMEIPSCFMDILSLQYIEVENCNE
SVVKSAMNIQETQVEDNQNTNFKLILIEIHLFYLFDMKGIESISTDMKEKKLTVTRDVDADEVQLVVEKLRNVAYADEVQ
LVVEKLRKRGML
>Q6L3X3|PF00931(447...709)|Putative late blight resistance protein homolog R1B-8
MIEFWRSEYTRILSICPDPGKKYRNKNVRMWSLYLERVREVIWKTKQEFKAEYSFPKTSLAANKVDDVSPKFVMEVMDVF
VENLNVLMKINDPCLWLFVPGHMKEQIEQVLKELKLLRFFVCFVSSKCIEPQYRRTTFYTHALIEASHNAMVVWLHLPVY
GNKNQDLAPTEVSRLLSDFMEMKIKSIQPGNSIYIDVLQALKSTIPQAQQKHAAESGIVEIPIHSLTVGLSDQMANLQEM
ICLLRDNLIHLPILDLEFHLQDMDSVILDAGLLIYSFYDIKGEKEDTMLEDINRALGFDLPRNIEPIKAMVYLVMQKAFQ
CNLPRVHGLGYVDFLLKNLKDFQGRYSDSLAFLKNQLQVIQTEFESLQPFLKVVAEEPHNKLKTLNEDCATQIIRKSYED
IIEEITCIKAKIQEKNTVEDTMKTVIARTSSQLARTLRMNEEIVGFEDVIEKLRNRLLNRTKGQDVISIHGMPGLGKTTL
ANRLYSDMSVVSQFDICARCCVSQVYSYKDLLLSLIRDAIGENSDQHRELIRDAIGENSDQHRELCANELADKLRKTLLR
RRYLILVDDVWENSVWDDLRGWFPDANNRSRIILMTRHHEVAKYASVHGDPLHLRMLDEDESWKLLEKKVFGEQSCSSPL
LKNVGLRIAKMCGQLPLSIVLVAGILSEMEKEVECWEQVANNLGSHIHNDSRAIVDQSYHVLPCHLKSCFLYFGAFLEDR
VIDISRLIGLWISESFIKSCEGRRLEYIAEGYLENLIGRNLVMVTQRAISDGKVKACRLHDVLLDFCKKRAAEENFLLWI
NRDQSTKAVYSHKQHAHLAFTEMDNLVEWSASCSLVGSVLFKSYDPYFRPLSSHAFAISHILLNFKFLKVLDLEHQVIID
FIPTELFYLRYLSAHIDQNSIPSSISNLWNLETLILKSRSASKHNRVLLPSTVWDMVKLRHLHIPYFSTEDEEALLENSA
KLYDLETLSSPYFSRVEDAELMLRRTPNLRKLICEVQCLESPHQYHVLNFPIRLEILKLYNRSKAFKTIPFCISAPNLKY
LKLSRFYLDSQYLSETADHLKHLEVLKLSCVEFGDHGEWEVSNGMFPQLKILKLEYVSLMKWIVADDVFPNLEQLVLRGC
RHLMEIPSCFMDILSLKYIKVDEYSESVVQSARKIQETQIEEYQNNNFKLVIIKVHYREKLNELFSLLSLTVLGLVLHPI
FL
>Q6L3Y2|PF00931(689...736)|Putative late blight resistance protein homolog R1B-11
MIEIWKSQCTRILSISPDSGIQYWKKTESMKSQYLEEVGVALDSFVYWKEVIWKTKQEFRAEYSFPKTSLAANKVIDDDD
INIDSLKFVKEVINVFVGNINVLVKINDPRSWFFVPGLKEQIEQVLKEFKLLRFFVCFVSNKCIEPQYRCSTFYSHVLIE
ASHIAMVVCLHLPIYGNGNQDLAPSEKMIDIWKSHCPDSFPYMKVISKTNVIIKTLYVDELRSCPSCNSYDSFDNWKEVI
WKTKQEFRAEYSFPKTSLAVNKVDDVNTHSPKFVMEVIDVFVGNLNVLVEINDPSSWLFVPGHMKEQIEQVLKELKLLRF
FVCFVSSKCIEPQYRCTTFYTLVLIEASHNAMVVWLHLPVYGNGNQDLAPSEVSRLFSDFMEMKIKSIEPGISRNSIYID
VLQALKSTIPQAQKKQLDIPTHSLTVGFSGQMANLQEMLCLLRDNLIHLPILDLEFHLQDMDSVIVDAGLLIYSLYDIKG
EKEDTVLDDMNQALGFDLPRNIEPIKAMVYLVMQKAFHCNLPRIHGLGYVDFLLKNLNDFQGRYSDSLAFLKNQLQVIQT
EFESLQPFLKVVAEEPHNKLKTLNEDCATQIIRKAYEVEYVVDACINKETPHWCLKCWLLDIIEENTCIKAKIQEKNTVE
DTMKSVIARTSSQLARTPRMNEEIVGFEDDLLLALLRDAIGEGSVRRELHANELSDMLRKTLLPRRYLILVDDVWENSVW
DDLRGCFPDANNRSRIFGPSHPMLGPPKSKLPTHQMLSTGREVGEQVANNLGTHIHNDSRAIVDQSYHVLPCHLKSCFLY
FGAFLEDRVIDISRLIRLWISEAFIKSSEGRSLEDIAEGYLENLIGRNLVMVTQRAISDGKVKACRLHDVLLDFCKERAA
EENFLLWIKRDQTTKAVYSHKQHAHLAFTEMDNLVEWSASCSLVGSVLFKSYDPYFACRPLSSHAFAVSHILLNFKFLKV
LDLEHQIVIDFIPTELPYLRYFSALIDQNSIPSSKSNLWNLETLILKRRSAATYKTLLLPSTVWDMVKLIYLYIPNFSPE
NKKALFKNSPKLDDLETLSNPYFARVEDYLSETVDHLKHLEVLELYRVEFGDHGEWKVSSGKFPKLKILKLDYVSLMKWI
VADDAFPNLEQLVSLGCQNLMEIPSCFTDILSLKYIEVDICNKSVVKSAKYIQETQVEYNQNTNFKLVIIKKLVLKFDRF
HGDEEIRKRLSSLPGIKSISINRGEKKLTVGGDVDADEVRLVVGKLNKRDML
>Q6L3Z0|PF00931(540...743)|Putative late blight resistance protein homolog R1B-13
MTKRVITDRLRSTLQDSNYSDVGRDLINFILWELKFLDCFLHLKSLPFASECCMLDVSQKMIEILKSRILSICPDSGIQL
WKGNLSMKTLYLEDVRVTLDSFGYWKEVIWKTKQEFSAEYSFPNTSLAANKVDDVSPKFVMEVIDVFVENLNVVVKINDP
ISWLFVPEHKEQIEQVLKELKLLRFFVWFVSNKYIEPQYQHTTFYIHALIEASHISMAVWLHLPVCSKGNQNLAPSEVSR
LLSDFVEMKIKATEPGISRNNIYIDVLQDLKLTIPQAQKKHAAESGIVEILTHSMMVGLSDQMANLQEMLCLLRDNLIHL
PILDLEFHLQDMDSIIVDAGLLIYSLYDIKGEKEDTTLEDINRELGFDLPRNIEPIKVIVYLVMQKAFQCNLPRIHGLGY
VDFLLKNLKDFQGRYSDSLAFLKNQIQVIQMEFEILQPFLKVVVEEPHNKFKRLNEDCAIQIIRKAHEVEYVVDACINKG
IPHWCLERWLQDIIEETTCIKAKIQEKNTVEDTMKTVITHTSSQLARTPRMNEEIVWFKDVIENLRNRLLNGTKGQDVIS
IHSMPGLGKTTLANRLYSDRSIVSQFDICAQCCVSQVYSYKELLLALLCDAIGEGSDQHREIHANELADMLRKTLLPRRY
LILVDDVWENSAWDDLRGCFPDVNNRSRIILTTRHHEVAKYASVHSEPLHLRMFEEDESWKLLEKRVFGEESCSPLLKDV
GLRIAKMCRQLPLSIVLVADVLLDFCKERAAEENFLLWIKRDQITKAAYSHKQHTHLALTEMDTLLEWSTSGSLVGSVLF
KNYDPYFVRSLLSSHAFEISHILPHFKFLKVLDLEHQVVIDFIPTELPYLRYFSALIHQNSIPSSISNLWNLETLILKGT
SAKTLLLPSTVWDMVKLGYLYIPNFSPENKKALLENSPKLDDLETLSNPYFARVEDAELMLRKTPNLRKLICEVECLEYP
HQYHVLNFPVQLEILKFYRSKASKTIPFCISAPNLKYLKLSGYYLDSQYLSETVDHLKHLEVLKLYNVEFGDYREWEVSN
GKFPQLKILKLENLSLMKWIVADDAFPILEQLVLHDCRDLMEIPSCFMDILSLKYIEVDMSNKSVVKSAKNIEETQVEDN
QNTNFKLVIIKVHYWEKLYSA
>Q6L3Z4|PF00931(571...816)|Putative late blight resistance protein homolog R1B-12
MAQHGDGKQYMELDQSKGTEMRNKALMDNNMLLETFIQMSEKGRLSSNYMTVTAIVRDVEQESFAFASECGILDVSQKML
KNFKSLCAILRSIRPDASSNNAFAYWKEVICKWLCATLLSTRPDAGSDDGFAYWKEVIWKTKQEFRAKYPFPETPFAANK
VDDVNTHSPKFVMEFIDAVVGNLNVLVKINDPSSLLFVPGPNEQTEQVLKELKLLRFFVCFVSNKCIEPQYRRTTFYTHA
LIEASHITMVVWLHFPIYGNGNQDLNPGDVSRLLSDFMEMKIKSIQLGISRNNIYIDVLKALKSTIPQAQNKHAAESGIE
ETPTHNLMVGLSDQMANLREMICLLRDNLIHLPILDLEFHVQDMDSVIVDAGLLFYSLYDIKGEKEDKTLEDINQALGFD
IPRNIEPIKAMVYLVMQKAFQSNLPRIHGLGYVDFLLKNLKDFQGRYSDSLAFLKNQLQVIQTEFESLQPFLKVVVEEPH
NRLKTLNEDCATQIIRKAYEVEYVVDACINKEVPQWCIERWLLDIIEEITCIKANIQEKNTVEDTMKTVIGRTSSQLTRT
PRMNEEIVGFEDVIENLRKKLLNGTKGQDVISIHGMPGLGKTTLANRLYSDRSVVSQFDICAQCCVSQVYSYKELLLALL
CDAVGEDSARRELPDNELADMFRKTLLPRRYLILVDDVWENSAWDDLRGCFPDVNNRSRIILTTRHHEVAKYASVHSDPL
HLRMFGEDESWKLLEKKVFGEERCSPLLKNVGLRIAKMCGRLPLSIVLVAGILSEMEKEVECWEQVANNLGSHIHNDSRA
IVDQSYHVLPFHLKSCFLYFGAFLEDRVINVSRLIRLWISESFIKSCEGRRLEDIAEGYLENLIGRNLVMVTQRANSDGK
VKACRLHDVLLDFCKERAAEENFLLRIKWDQSTKPSSCVYSHKQHAHLAFTGMDNLLEWSTSGSLVGSVLFKNYDPNFAY
NSCSSHAFAISRILPNFKFLKVLDLEHQFFIDFIPTELLYLRYLSARIGQNSIPSSISNLWNLETLILKDVRYMRRCRLL
QPNTVWDMVKLRHLHIPYFSTEKEEALLENSAKLYDLETLSTPYFFRVENAELMLRKTPNLRKLICAIECLEYPPQYHVL
NFPITLEILKLYRSSDFKVIPFCISAQNLKYLKLSGFYLNSQYLSETADHLKHLEVLKLHNIEFGGHSEWEVSNAKFPQL
KILKLEYVSLMKLIVADDAFPNLEQLVLHDCEDLMEIPSCFMDILSLKYIEVDNCSESVVKSARNIQETQVEDSQNNNFK
LVIVKKMVLKFDTSNEKEISKAFDRLLSLPGIQSIAVDSNEKKFIVIGDMDADEVRLVVGKLINRGML
>Q6L3Z7|PF00931(545...790)|Putative late blight resistance protein homolog R1B-14
MYFNNELSGLKDRFLKSLLAQKYPDRINFFLWELKFLDCFLHLQNFAFASECGMLDVSQKMLKNFKRMCATFRSIRPNAG
SDNAFAYLKEVICKRLCATLLNTRPDACSDDGFAYWNEVIWKTKQEFRAKYSFPKTPLASNKVDDDDINIHSPKFVMEFI
DAVVGNLNVLVKINDPCSLLFVPGPKEQIDQVSKELKLLRFFVCFVSNKCIEPQYGHTTFYIHALIEASHIAMVVWLHLP
VYGNGNQDLAPSEVSRLLSDFISRNSNYIDVLKALKSTIPQAQNKHAAESGIVETPTHNLMVGLSDQMVNLQEMLCLLRD
NLIHLPILDLEFHLQDMDSVILDAGLLIYSLYDIEGEKEDTVLDDMNRALGFDLPRNIEPIKVMVYLVMQKAFQCNLPRV
HGLGYVDFLLKNLNDFQGRYSDSLAFLKNQLQVIQTEFESLQPFLKVVIEEPHNKLKTLNEDCATQIIRKAYEVEYVVDA
CINKVAPHWCLERWLLDIIEEITCIKAKIQEKNTVEDTMKTVITHTSSQLARTPRMNEEIVGFKDVIENLRNRLLNGTKG
QDVISIHGMPGLGKTTLANRLYSDRSVVSHFDICAQCCVSQVYSYKELLLALLCDAVGDDSARRKHNENKLADKLRKTLL
SRRYLILVDDVWDNSAWDDLRGCFPDANNRSRIILTTRHHEVAKYASVHSDPLHLRMFDEDESWKLLEKKVFGEKRCSSL
LLKDVGLRIAKMCGQLPLSIVLVAGILSEMEKEVECWEQVANNLGTHIHNDSRAIVNQSYHVLPCHLKSCFLYFGAFLED
EVIDISRLIRLWISESFIKSSEGRRLEDIAEGYLENLIGRNLVMVTQRADSDGKVKACRLHDVLLDFCKERAAEENFLLW
INRDQISTKAVYSHKQHAHLAFTEMDNLVEWSASCSLVGSVLFKNPDSYLYSPAFSTSLILLNFKFLKVLDLEHQVVIDF
IPTELFYLRYLSASIEQNSIPSSISNLWNLETLILKSTPVGRHNTLLLPSTIWDMVKLRHLHIPKFSPENEEALLENSAR
LYDLETISTPYFSSVEDAELILRKTPNLRKLICEVECLEYPPQYHVLNFPIRLEILKLYRSKAFKTIPFCISAPNLKYLK
LSGFYLDSQYLSETVDHLKHLEVLKLCDLEFGDHREWKVSNGMFPQLKILKLEYLSLMKWIVADDAFPNLEQLVLHGCQD
LMEIPSCFMDILSLKYIEVDMSNKSVVKSAKNIEETQVEDNQNTNFKLVIIKKMVLKFDIYQNHDKGRLETFKKLVPLPG
VKSVRFDMDEKKVTVTGVMDANEVQLVVSKLRKRGML
>Q6L400|PF00931(544...788)|Putative late blight resistance protein homolog R1B-16
MNFNNELSDLEKSFLFWTLRVQEYSYDTMHRIDFFLWELQVLNCFLHLQSFTFASECGMLDISQKMLEICKRFNTPPPHN
AFAYWKELICKRLCAISIRPDDGFAYWKKVIWKTKQEFRAKYSFPKTLLADNKVDDDDTNPEFVMEFIDAVVGNLNVLVK
INDPSSLLFVPGPKEQIEQVLKELKLLRFFVCFVSNKCIEPQYQHTTFYTHALIEASHIAMVVWLNLPIYGNRNQDLASS
EVSCLLSNFMEMKIKSIQPGISRNNIYIDVLQALKSTIPQAQKKHAAESGIVEIPTHSLMVGLSDQMANLQEMLCLLKDN
LIHLPILDLEFQPQDMDSVIIDAGLLIYSFYDMKGEKEDTTLEDINRELGFDLSRNIEPIKVMIYLVMQKAFQCNLPRIH
GLGYVDFLLKNLKDFQGRYSDSFALHKTQIQVIQKEFESLQPFLKVVVEEPHNTFKRLSEDCAIQIIRKAHEVEYVVDAC
INKGIPHWRLKGWLQIIIEDITCIKEKIQEKNTVDDTMKTVIARTSSKLARTPRMNEEIVGFKDVIENLRNQLLNGTKGQ
DAISIHGMPGLGKTTLANTLYSDRSVVSQFDICAQCCVSQVYSYKDLLLALLCDAVGEDSDRRELPDNELADMLRKTLLP
RRYLILVDDVWDNSAWDDLRGCFPDVNNRSRIILTTRHHEVAKYASVHSDPLHLRMFDKDESWKLLEKKVFGEQSCSPLL
KDVGLRIAKMCGQLPLSIVLVAGILSEMEKEVECWEQVANNLGTHIHNDSRAIVNQSYHVLPCHLKSCFLYFGAFLEDEV
IDISRLIRLWISESFIKSSEGRRLEDIAEGYLENLIGRNLVMVTQRADSDGKVKACRLHDVLLDFCKERAAEENFLLWIN
RDQSTNAVYSHKRHAHLAFTEMDSLVEWSASCSLVGSVLLKNYARRPLSSPAFSISHILLNFKFLKVLDLEHQVVIDSIP
TELFYLRYLSARIEQNSIPSSISNLWNLETLILKHVSRCTVLLPSTVWDMVKLRHLHIPNFRPENEEALLENSAKLYDLE
TLSTPYFSRVEDAELMLRKTPNLRKLVCEVECLEYPPQYHVLNFPIRLEILKLYRSKAFNTIPFCISAPNLKYLKLSRSY
MDSQYLSETADHLKNLEVLKLYFVKFADHREWKVSNGMFPQLKILKLEYLALMKWIVADDAFPNLEQLVLHECRHLMEIP
SCFMDIPSLKYIEVENCNESVVKSAMNIQETQVEDYQNTNFKLVLIGIESISTDTKEKKLTVTRDVDADEVQLVVEKQRK
RGML
>Q6L403|PF00931(545...790)|Putative late blight resistance protein homolog R1B-17
MYFNNELSGLKDRFLKSLLAQKYPDRINFFLWELKFLDCFLHLQNFAFASECGMLDVSQKMLKNFKRMCATFRSIRPNAG
SDNAFAYLKEVICKRLCATLLNTRPDACSDDGFAYWNEVIWKTKQEFRAKYSFPKTPLASNKVDDDDINIHSPKFVMEFI
DAVVGNLNVLVKINDPCSLLFVPGPKEQIDQVSKELKLLRFFVCFVSNKCIEPQYGHTTFYIHALIEASHIAMVVWLHLP
VYGNGNQDLAPSEVSRLLSDFISRNSNYIDVLKALKSTIPQAQNKHAAESGIVETPTHNLMVGLSDQMVNLQEMLCLLRD
NLIHLPILDLEFHLQDMDSVILDAGLLIYSLYDIEGEKEDTVLDDMNRALGFDLPRNIEPIKVMVYLVMQKAFQCNLPRV
HGLGYVDFLLKNLNDFQGRYSDSLAFLKNQLQVIQTEFESLQPFLKVVIEEPHNKLKTLNEDCATQIIRKAYEVEYVVDA
CINKVAPHWCLERWLLDIIEEITCIKAKIQEKNTVEDTMKTVITHTSSQLARTPRMNEEIVGFKDVIENLRNRLLNGTKG
QDVISIHGMPGLGKTTLANRLYSDRSVVSHFDICAQCCVSQVYSYKELLLALLCDAVGDDSARRKHNENKLADKLRKTLL
SRRYLILVDDVWDNSAWDDLRGCFPDANNRSRIILTTRHHEVAKYASVHSDPLHLRMFDEDESWKLLEKKVFGEKRCSSL
LLKDVGLRIAKMCEQLPLSIVLVAGILSEMEKEVECWEQVANNLGTHIHNDSRAIVNQSYHVLPCHLKSCFLYFGAFLED
EVIDISRLIRLWISESFIKSSEGRRLEDIAEGYLENLIGRNLVMVTQRADSDGKVKACRLHDVLLDFCKERAAEENFLLW
INRDQISTKAVYSHKQHAHLAFTEMDNLVEWSASCSLVGSVLFKNPDSYLYSPAFSISLILLNFKFLKVLDLERQVVIDF
IPTELFYLRYLSASIEQNSIPSSISNLWNLETLILKGISAKTLLLPSTIWDMVKLRHLHIPKFSPENDEALLENSARLYD
LETISTPYFSSVEHAELILRKTPNLRELICEVECLEYPPQYHVLNFPIRLEILKLYRSKAFKTIPFCISAPNLKYLKLSG
FYLDSQYLSETADHLKHLEVLKLCDLEFGDHREWKVSNGMFPQLKILKLEYLSLMKWIVADDAFPNLEQLVLHGCQDLME
IPSCFMDILSLKYIEVDMSNKSVVKSAKNIEETQVEDNQNTNFKLVVIKKMMWKVDVGVNKGRLETFKRLAPLPGIKSVA
FDFNKKKLTVTGDMDANEVQLVVSKLRKRGML
>Q6L406|PF00931(546...791)|Putative late blight resistance protein homolog R1B-19
MNFNNELSDLKNRFLFRTLRVQEYSDVARDRIDFFIWELKFLNCVLHLQSFTFASECGMLDISQKMLEICKRFNTPPPHN
AFAYWKEVICKRLCAISIRPDASSDDGFACWKKVIWKTKQEFRAKYSFPKTLLADNKVYDDTNPKFVMEFIDAVVGNLNV
LVKINDPSSLHFVPGPKEQIEQVLKELKLLRFFVCFVSNKCTEPQYQYTTFYTHALIEASHIAMVVWLNLPIYGNRNQDL
ASNEVSCLFSDFMEMKIKSIQPGISRNNIYINVLRALKSTIPHAQDKHAAESGIVETPTHNLMVGLSDQMANLQEMLCLL
RDNLIHLPILDLEFHLQDMDSVILDVGLLIYSFYDMKGEKEDTTLEDINRELGFDLPRNIEPIKAMVYLVMQKAFHCNLP
RVHGLGYADFLLKNLKDFQGRYSDSLAFLKNQLQVIQTEFESLQPFLKVVVEEPHNKFKRLNEDCAIQIIRKAHEVEYVV
DACINKGIPHWCLERWLQDIIEEITCIKAKIQEKNTVDDTMKTVIVRTSSKLARTPRMKEEIVGFEDIIENLRKKLLNGT
KGQDVISIHGMPGLGKTTLANRLYSDRSVVSQFDICAQCCVSQVYSYKDLLLSLLCDTIGEESERRELPDNELADMLRKT
LLPRRYLILVDDVWENSVWDDLRGCFPDTNNRSRIILTTRHHEVAKYASVHIDPLHLRMFDENESWKFLEKNVFGEESCS
PLLRDVGQRIAKMCGQLPFSIVLVAGIPSEMEKEVECWEQVANNLGTRIHNDSRAIVDQSYHVLPCHLKSCFLYFAAFLE
DVVIYISRLLRLWISEAFIKSSEGRSLEDIAEGYLENLIGRNLVMVTQRADSDGKVKTCRLHDVLLDFCKKRAAEENFLL
WINRDLITKPFSCVYSHKQHAHLAFTEMHNLVEWSASCSFVGSVVLSKKYEPYFSIDLYSFYDFAISRNLPNFKFLKVLD
LEHQVFIDFIPTELVYLKYFSAHIKQNSIPSSIYNLWNPETLKLKRPRHVRRCTLLLPSTVWDMVKLRHLYIPDFSTENE
EALLENSAKLYDLETLSTPYFSRYHVLNFPIRLEILKLYRSKAFKTIPFCISAPNLKYLKLSGFYLDSQYLSETADHLKN
LEVLKLYYVEFGDHREWKVSNGMFPQLKILKLEYLSLMKWIVADDAFPNLEQLYIKVENCNELVVKSAMNIQETQVEDNQ
NTNFKLVLIEKKTLKLNLSHDEDIPKAFKRLFLCPGIESVSTDRKEKKLTVTGDVDAGSSISCGETEKAWHARVVVPTCQ
HKCGIVILLTSNELGLGREERKKRRKRRKRRAIKEIIVDIVGGDPY
>Q6L438|PF00931(530...775)|Putative late blight resistance protein homolog R1A-6
MYFNNELSDLKDHLLRKLQYYTYSDVVRDRINFILWEFKFLDCFLYLKSFPFASECGMLHVSQKMIEIWKSQWNKLIYIC
MYDEEGSPWDAVVYWKELISQTKQEFRAQYSFPKSPLAANEVIDDDDDDNTHSPEFVMEVIGFFVGNINVLVKINDPCSC
FFVPGLKEQIEQILKELKLLRFLVCFVSNKCIVPQYRCTTFYTRALIEASYIAMVAWLYLPIYGNGNQDLAPSEVSRLLS
DFMEMKIKSIEPGISRNSIYIDVLQALKSTIPQAQKKHVEIPTHSLTVGLSDQMANLQEMLCLLRDNLIHLPILDLEFHL
QDMDSVIVDAGLLIYSLYDIKGQMEDTSLDVINWALGFDLPRNIEPIKVMAYLVMQKAFHCNLPRIHGLGYVDFLLKNLN
DFQDCYSDSLAFLKNQLQVIQTEFESLQPFLKVVAEEPHNKLKTLNEDCATQIIRKAYEVEYVVDACINKEALHWCLERW
LLDIIEEITCIKAKIQEKNTVEDTMKTVIARTSSKLARTPRMKEEIVGFEDVIENLRKKLLSRTKGQDVISIHGMPGLGK
TTLANRLYSDRSVVSQFDFCAQCCVSQVYSCKDLLLSLLRDAIGEESERRELPDNELADMLRKTLLPRRYLILVDDVWDN
SAWDDLRGCFPDVNNRSRIILTTRHHEVAKYASVRSDPLHLRMFDEVESWKLLEKKVFGEQSCPPLLKNIGLRIAKMCGQ
LPLSIVLVAGILSEMEKDVECWEQVANNLGSHIHNDSRAIVDQSYHVLPCHLKSCFLYFGAFLEDRVIDISRLIRLWISE
AFIKSSEGRSLEDIAEGYLENLIGRNLVMVTQRAISDGKVKACRLHDVLLDFCKERAAEENFLLWINRDQITKPSSCVYS
HKQHAHLAFTEMHNLVEWSASCSFVGSVVLSNKYEPYFHDLSSLHDFSISRILPNFKFLKVLDLEHRVFIDFIPTELPYL
RYFSALIDQNSIPSSISNLWNLETLILNRRSADSHNRVLLPSTVWDMVKLRHLHIPNFSPENKKALLKNSPNLDDLETLS
YPYFARVKDAELMLRKTPNLRKLTCKVKCLEYLHQYHALNFPIRLEILKLYRSNAFKAIPFCISAPNLKYLKLSGFYLDS
QYLSKTADHLKNLEVLKLYYVEFGDHREWKVSNGMFPQLKILKLEDVSLMKWIVADDAFPNLEQLVLRGCQDLMEIPSCF
MDILSLQYIEVEDCNESVVKSAMNIQETQVEDYQNTNFKLVLIEKWPKFYKLFSQLSLPRGLVLHLGIESVSSDEKEKKL
TVTGDVDADEVQLVVEKLRKCGMPGL
>Q6L439|PF00931(537...781)|Putative late blight resistance protein homolog R1A-4
MYFNNELSDQKVCLLRELKNLKYSDDARDRINFFLWELKFLDCFLHLKSFPFASECGMLHVSQKMIDIWKSHCSKTINGT
ILYYGKVPLNLFVNWKKVIWKTKQEFRAQYSFPKTPLAANKVIDDDDNTHSPKFVMEVIDVFVENLNVLMKINDPCSWFF
VPGHMKEQIEQVLKELKLLRFFVCFVSNKCSIQPQYRCTTFYTHALIEASHIAMVVWLHLPIYGNVNQDLAPSEVSRLFS
DFMEMKIKSIQPVISRNNIYIDVLQALKSTIPQAQKKHAAESSTVEIPTHSLTVGLSDQMANLQEMLCLLRDNLIHLPIL
DLEFHLQDMDSVIIDAGLLIYSLYDIKREKEDTVLDDMNRALGLDLPRNIEPIKVMVYLVMQKAIQCNLPKVHGLGYVDF
LLKNLKDFQGRYSDSLAFLKNQLQVIQTEFESLQPFLKVVVEEPQNKLKTLNEDCAIQIIRKAHEVEYVVDACINKGIPH
WCLERWLQDIIEEITCIKAKIQEKNTVDDTMKTVIARTSSKLARTPRMNEEIVGFKDVIENLRNQLLNGTKGQDVISIHG
MPGLGKTTLANRLYSDRSVVSHFDICAQCCVSQVYSYKDLLLALLCDAIGEGSVRRELHANELADMLRKTLLPRRYLILV
DDVWENSVWDDLRGCFPDANNRSRIILTTRHHEVAKYASVHSDPLHLRMFDEDESWKLLEKKVFGEQSCSPLLKKVGLRI
AKMCGQLPLSIVLVAGILSEMEKEVECWEQVANDLGTHIRSNSRAIVDQSYHVLPCHLKSCFLYFGAFLGVREIRISRLI
RLWISESFIKSCEGRRLEDIAEGYLENLIGRNLVMVTQRANSNGKVKACRLHDVLLNFCKERAAEENLLLWINRDQSTKA
VYSHKQHAHLAFTKMDNLVEWSASSSLVGSVLIMRYNPYFARCPLYAVSHILLNFKFLKVLDLKHQVVIDFIPTELPYLR
YLTADIGQNSIPSSISNLWNLETLILNRRSVVHKILLPSTVWDMVKLRFLFIPNFSPENKKALLKNSPNLDDLETLSYPY
FARVKDAELMLRKTPNLRKLTCKVKCLEYLHQYHALNFPIRLEILKLYRSNAFKAIPFCISAPNLKYLKLSGFYLDSQYL
SKTADHLKNLEVLKLYYVEFGDHREWKVSNGMFPQLKILKLEDVSLMKWIVADDAFPNLEQLVLRGCQDLMEIPSCFMDI
LSLQYIEVEDCNESVVKSAMNIQETQVEDYQNTNFKLVLIEVHY
>Q6L440|PF00931(26...248)|Putative late blight resistance protein homolog R1A-3
MKTVIARTSSKLARTPRMNEEIVGFEDVIENLRKKLLSETKGQDVISIHGMPGLGKTTLANRLYSDRSVVSQFDICAQCC
VSQVYSYKDLLLSLLRDAIGDESGSRELPDNELADMLRKTLLPRRYLILVDDVWDNSAWDDLRGCFPDVNNRSRIILTTR
HHEVAKYASVHSDPLHLRMFYEDESWKLLEKKVFGEQSCSPLLKDVGLRIAKLCGKLPLSIVFVAGTLSEMEKEVECWEQ
MANNLGGPKLSSFLEDRVIDISRLIRLWISESFIKSSEGRSLEDIAEGYLENLIGRNLVMVTQRADSDGMVKACRLHDVL
LDFCKKRAAEENFLLCIKRDQSTKAVISHKQQAHLAFSKMDNLVEWSASSSLVGSVIFKSYDPYFARCPLSSHAFALSHI
LINFKFLKVLDLEHQVVIDFNPTEHFYLRYLSAHIDQNSIPSSISNLWNLETLILKRTPAGRLNTLLLPSTIWDMVKLRH
LHIPNFRAESEDALLENSAKLYDLETLSTTYFSSVEKAELMLRKTPNLRKLICEVQFLEYPNQYHVLNFPVRLEMLKLYR
FNNSKVIPFYISAPNLKYLKLSGFYLDSHYLSETADHLKHLEVLKLYRVEFGDHGEWKVSNGMFPQLKILKLNYVCLMKW
IVADDAFPNLEQLVLRGCKDLMEIPFCFMDILSLKYIELDNCNKSVVKSAKDIEEAQVEDNQNTNFKLVIIKKMILQFDI
SHDKEIDNAFKRLASLPGVDSISIDMIEKKLTVGGDMNANEVRLVVGKLIDSGML
>Q71BG9|PF00931(162...388)|ToMV resistance protein Tm-2(2)
MAEILLTSVINKSVEIAGNLLIQEGKRLYWLKEDIDWLQREMRHIRSYVDNAKAKEAGGDSRVKNLLKDIQELAGDVEDL
LDDFLPKIQQSNKFNYCLKRSSFADEFAMEIEKIKRRVVDIDRIRKTYNIIDTDNNNDDCVLLDRRRLFLHADETEIIGL
DDDFNMLQAKLLNQDLHYGVVSIVGMPGLGKTTLAKKLYRLIRDQFECSGLVYVSQQPRASEILLDIAKQIGLTEQKMKE
NLEDNLRSLLKIKRYVILLDDIWDVEIWDDLKLVLPECDSKVGSRMIITSRNSNVGRYIGGESSLHALQPLESEKSFELF
TKKIFNFDDNNSWANASPDLVNIGRNIVGRCGGIPLAIVVTAGMLRARERTEHAWNRVLESMGHKVQDGCAKVLALSYND
LPIASRPCFLYFGLYPEDHEIRAFDLINMWIAEKFIVVNSGNRREAEDLAEDVLNDLVSRNLIQLAKRTYNGRISSCRIH
DLLHSLCVDLAKESNFFHTAHDAFGDPGNVARLRRITFYSDNVMIEFFRSNPKLEKLRVLFCFAKDPSIFSHMAYFDFKL
LHTLVVVMSQSFQAYVTIPSKFGNMTCLRYLRLEGNICGKLPNSIVKLTRLETIDIDRRSLIQPPSGVWESKHLRHLCYR
DYGQACNSCFSISSFYPNIYSLHPNNLQTLMWIPDKFFEPRLLHRLINLRKLGILGVSNSTVKMLSIFSPVLKALEVLKL
SFSSDPSEQIKLSSYPHIAKLHLNVNRTMALNSQSFPPNLIKLTLAYFSVDRYILAVLKTFPKLRKLKMFICKYNEEKMD
LSGEANGYSFPQLEVLHIHSPNGLSEVTCTDDVSMPKLKKLLLTGFHCRISLSERLKKLSK
>Q71BH0|PF00931(162...388)|ToMV resistance protein Tm-2(GCR236)
MAEILLTSVINKSVEIAGNLLIQEGKRLYWLKEDIDWLQREMRHIRSYVDNAKAKEAGGDSRVKNLLKDIQELAGDVEDL
LDDFLPKIQQSNKFNYCLKRSSFADEFAMEIEKIKRRVVDIDRIRKTYNIIDTDNNNDDCVLLDRRRLFLHADETEIIGL
DDDFNMLQAKLLNQDLHYGVVSIVGMPGLGKTTLAKKLYRLIRDQFECSGLVYVSQQPRASEILLDIAKQIGLTEQKMKE
NLEDNLRSLLKIKRYVFLLDDIWDVEIWDDLKLVLPECDSKVGSRIIITSRNSNVGRYIGGESSLHALQPLESEKSFELF
TKKIFNFDDNNSWANASPDLVNIGRNIVGRCGGIPLAIVVTAGMLRARERTEHAWNRVLESMGHKVQDGCAKVLALSYND
LPIASRPCFLYFGLYPEDHEIRAFDLINMWIAEKFIVVNSGNRREAEDLAEDVLNDLVSRNLIQLAKRTYNGRISSCRIH
DLLHSLCVDLAKESNFFHTAHDAFGDPGNVARLRRITFYSDNVMIEFFRSNPKLEKLRVLFCFAKDPSIFSHMAYFDFKL
LHTLVVVMSQSFQAYVTIPSKFGNMTCLRYLRLEGNICGKLPNSIVKLTRLETIDIDRRSLIQPPSGVWESKHLRHLCYR
DYGQACNSCFSISSFYPNIYSLHPNNLQTLMWIPDKFFEPRLLHRLINLRKLGILGVSNSTVKMLSIFSPVLKALEVLKL
SFSSDPSEQIKLSSYPHIAKLHLNVNRTMALNSQSFPPNLIKLTLANFTVDRYILAVLKTFPKLRKLKMFICKYNEEKMD
LSGEANGYSFPQLEVLHIHSPNGLSEVTCTDDVSMPKLKKLLLTGFHCRISLSERLKKLSK
>Q71BH1|PF00931(162...388)|ToMV susceptible protein tm-2
MAEILLTSVINKSVEIAGNLLIQEGKRLYWLKEDIDWLQREMRHIRSYVDNAKAKEAGGDSRVKNLLKDIQELAGDVEDL
LDDFLPKIQRSNKFNYCLKTSSFADEFAMEIEKIKRRVVDIDRIRKTYNIIDTDNNNDDCVLLDRRRLFLHADETEIIGL
DDDFNMLQAKLLNQDLHYGVVSIVGMPGLGKTTLAKKLYRLIRDQFECSGLVYVSQQPRAGEILLDIAKQIGLTEQKIKE
NLEDNLRSLLKIKRYVILLDDIWDVEIWDDLKLVLPECDSKVGSRMIITSRNSNVGRYIGGESSLHALQPLESEKSFELF
TKKIFNFDDNNSWANASPDLVNIGRNIAGRCGGIPLAIVVTAGMLRARERTEHAWNRVLESMGHKVQDGCAKVLALSYND
LPIASRPCFLYFSLYPEDHEIRAFDLINMWIAEKFIVVNSGNRREAEDLAEDVLNDLVSRNLIQLAKRTYNGRISSCRIH
DLLHSLCVDLAKESNFFHTAHDVFGDPGNVARLRRITFYSDNVMIEFFGSNPKLEKLRVLFCFTKDPSIFSHMACFDFKL
LHTLVVVMSQSFQAYVTIPSKFGNMTCLRYLKLEGNICGKLPNSIVKLTRLETIDIDRRSLIQLPSGVWESKHLRHLCYR
DYGQACNSCFSISSFYPNIYSLHPNNLQTLMWIPDKFFEPRLLHRLINLRKLGILGVSNSTVKILSTCRPVPKALKVLKL
RFFSDPSEQINLSSYPKIVKLHLNVDRTIALNSEAFPPNIIKLTLVCFMVDSCLLAVLKTLPKLRKLKMVICKYNEEKMA
LSGEANGYSFPQLEVLHIHSPNGLSEVTCTDDVSMPKLKKLLLTGFHCGISLSERLKKLSK
>Q7XA39|PF00931(162...397)|Putative disease resistance protein RGA4
MAEAFLQVLLENLTSFIGDKLVLIFGFEKECEKLSSVFSTIQAVLQDAQEKQLKDKAIENWLQKLNSAAYEVDDILGECK
NEAIRFEQSRLGFYHPGIINFRHKIGRRMKEIMEKLDAISEERRKFHFLEKITERQAAAATRETGFVLTEPKVYGRDKEE
DEIVKILINNVNVAEELPVFPIIGMGGLGKTTLAQMIFNDERVTKHFNPKIWVCVSDDFDEKRLIKTIIGNIERSSPHVE
DLASFQKKLQELLNGKRYLLVLDDVWNDDLEKWAKLRAVLTVGARGASILATTRLEKVGSIMGTLQPYHLSNLSPHDSLL
LFMQRAFGQQKEANPNLVAIGKEIVKKCGGVPLAAKTLGGLLRFKREESEWEHVRDNEIWSLPQDESSILPALRLSYHHL
PLDLRQCFAYCAVFPKDTKMIKENLITLWMAHGFLLSKGNLELEDVGNEVWNELYLRSFFQEIEAKSGNTYFKIHDLIHD
LATSLFSASASCGNIREINVKDYKHTVSIGFAAVVSSYSPSLLKKFVSLRVLNLSYSKLEQLPSSIGDLLHLRYLDLSCN
NFRSLPERLCKLQNLQTLDVHNCYSLNCLPKQTSKLSSLRHLVVDGCPLTSTPPRIGLLTCLKTLGFFIVGSKKGYQLGE
LKNLNLCGSISITHLERVKNDTDAEANLSAKANLQSLSMSWDNDGPNRYESKEVKVLEALKPHPNLKYLEIIAFGGFRFP
SWINHSVLEKVISVRIKSCKNCLCLPPFGELPCLENLELQNGSAEVEYVEEDDVHSRFSTRRSFPSLKKLRIWFFRSLKG
LMKEEGEEKFPMLEEMAILYCPLFVFPTLSSVKKLEVHGNTNTRGLSSISNLSTLTSLRIGANYRATSLPEEMFTSLTNL
EFLSFFDFKNLKDLPTSLTSLNALKRLQIESCDSLESFPEQGLEGLTSLTQLFVKYCKMLKCLPEGLQHLTALTNLGVSG
CPEVEKRCDKEIGEDWHKIAHIPNLDIH
>Q7XA40|PF00931(162...396)|Putative disease resistance protein RGA3
MAEAFLQVLLDNLTFFIQGELGLVFGFEKEFKKLSSMFSMIQAVLEDAQEKQLKYKAIKNWLQKLNVAAYEVDDILDDCK
TEAARFKQAVLGRYHPRTITFCYKVGKRMKEMMEKLDAIAEERRNFHLDERIIERQAARRQTGFVLTEPKVYGREKEEDE
IVKILINNVSYSEEVPVLPILGMGGLGKTTLAQMVFNDQRITEHFNLKIWVCVSDDFDEKRLIKAIVESIEGKSLGDMDL
APLQKKLQELLNGKRYFLVLDDVWNEDQEKWDNLRAVLKIGASGASILITTRLEKIGSIMGTLQLYQLSNLSQEDCWLLF
KQRAFCHQTETSPKLMEIGKEIVKKCGGVPLAAKTLGGLLRFKREESEWEHVRDSEIWNLPQDENSVLPALRLSYHHLPL
DLRQCFAYCAVFPKDTKIEKEYLIALWMAHSFLLSKGNMELEDVGNEVWNELYLRSFFQEIEVKSGKTYFKMHDLIHDLA
TSMFSASASSRSIRQINVKDDEDMMFIVTNYKDMMSIGFSEVVSSYSPSLFKRFVSLRVLNLSNSEFEQLPSSVGDLVHL
RYLDLSGNKICSLPKRLCKLQNLQTLDLYNCQSLSCLPKQTSKLCSLRNLVLDHCPLTSMPPRIGLLTCLKTLGYFVVGE
RKGYQLGELRNLNLRGAISITHLERVKNDMEAKEANLSAKANLHSLSMSWDRPNRYESEEVKVLEALKPHPNLKYLEIID
FCGFCLPDWMNHSVLKNVVSILISGCENCSCLPPFGELPCLESLELQDGSVEVEYVEDSGFLTRRRFPSLRKLHIGGFCN
LKGLQRMKGAEQFPVLEEMKISDCPMFVFPTLSSVKKLEIWGEADAGGLSSISNLSTLTSLKIFSNHTVTSLLEEMFKNL
ENLIYLSVSFLENLKELPTSLASLNNLKCLDIRYCYALESLPEEGLEGLSSLTELFVEHCNMLKCLPEGLQHLTTLTSLK
IRGCPQLIKRCEKGIGEDWHKISHIPNVNIYI
>Q7XA42|PF00931(155...374)|Putative disease resistance protein RGA1
MAEAFIQVVLDNLTSFLKGELVLLFGFQDEFQRLSSMFSTIQAVLEDAQEKQLNDKPLENWLQKLNAATYEVDDILDEYK
TKATRFLQSEYGRYHPKVIPFRHKVGKRMDQVMKKLNAIAEERKKFHLQEKIIERQAATRETGSVLTEPQVYGRDKEKDE
IVKILINTASDAQKLSVLPILGMGGLGKTTLSQMVFNDQRVTERFYPKIWICISDDFNEKRLIKAIVESIEGKSLSDMDL
APLQKKLQELLNGKRYFLVLDDVWNEDQHKWANLRAVLKVGASGAFVLTTTRLEKVGSIMGTLQPYELSNLSPEDCWFLF
MQRAFGHQEEINPNLMAIGKEIVKKCGGVPLAAKTLGGILRFKREEREWEHVRDSPIWNLPQDESSILPALRLSYHHLPL
DLRQCFVYCAVFPKDTKMAKENLIAFWMAHGFLLSKGNLELEDVGNEVWNELYLRSFFQEIEVESGKTYFKMHDLIHDLA
TSLFSANTSSSNIREINANYDGYMMSIGFAEVVSSYSPSLLQKFVSLRVLNLRNSNLNQLPSSIGDLVHLRYLDLSGNFR
IRNLPKRLCKLQNLQTLDLHYCDSLSCLPKQTSKLGSLRNLLLDGCSLTSTPPRIGLLTCLKSLSCFVIGKRKGHQLGEL
KNLNLYGSISITKLDRVKKDTDAKEANLSAKANLHSLCLSWDLDGKHRYDSEVLEALKPHSNLKYLEINGFGGIRLPDWM
NQSVLKNVVSIRIRGCENCSCLPPFGELPCLESLELHTGSADVEYVEDNVHPGRFPSLRKLVIWDFSNLKGLLKMEGEKQ
FPVLEEMTFYWCPMFVIPTLSSVKTLKVIVTDATVLRSISNLRALTSLDISDNVEATSLPEEMFKSLANLKYLKISFFRN
LKELPTSLASLNALKSLKFEFCDALESLPEEGVKGLTSLTELSVSNCMMLKCLPEGLQHLTALTTLTITQCPIVFKRCER
GIGEDWHKIAHIPYLTLYE
>Q7XBQ9|PF00931(155...375)|Disease resistance protein RGA2
MAEAFIQVLLDNLTSFLKGELVLLFGFQDEFQRLSSMFSTIQAVLEDAQEKQLNNKPLENWLQKLNAATYEVDDILDEYK
TKATRFSQSEYGRYHPKVIPFRHKVGKRMDQVMKKLKAIAEERKNFHLHEKIVERQAVRRETGSVLTEPQVYGRDKEKDE
IVKILINNVSDAQHLSVLPILGMGGLGKTTLAQMVFNDQRVTEHFHSKIWICVSEDFDEKRLIKAIVESIEGRPLLGEMD
LAPLQKKLQELLNGKRYLLVLDDVWNEDQQKWANLRAVLKVGASGASVLTTTRLEKVGSIMGTLQPYELSNLSQEDCWLL
FMQRAFGHQEEINPNLVAIGKEIVKKSGGVPLAAKTLGGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLP
LDLKQCFAYCAVFPKDAKMEKEKLISLWMAHGFLLSKGNMELEDVGDEVWKELYLRSFFQEIEVKDGKTYFKMHDLIHDL
ATSLFSANTSSSNIREINKHSYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVHLRYLNLYGSG
MRSLPKQLCKLQNLQTLDLQYCTKLCCLPKETSKLGSLRNLLLDGSQSLTCMPPRIGSLTCLKTLGQFVVGRKKGYQLGE
LGNLNLYGSIKISHLERVKNDKDAKEANLSAKGNLHSLSMSWNNFGPHIYESEEVKVLEALKPHSNLTSLKIYGFRGIHL
PEWMNHSVLKNIVSILISNFRNCSCLPPFGDLPCLESLELHWGSADVEYVEEVDIDVHSGFPTRIRFPSLRKLDIWDFGS
LKGLLKKEGEEQFPVLEEMIIHECPFLTLSSNLRALTSLRICYNKVATSFPEEMFKNLANLKYLTISRCNNLKELPTSLA
SLNALKSLKIQLCCALESLPEEGLEGLSSLTELFVEHCNMLKCLPEGLQHLTTLTSLKIRGCPQLIKRCEKGIGEDWHKI
SHIPNVNIYI
>Q84WD3|PF00931(102...291)|Probable disease resistance protein At4g19060
MDIAKKFISEIDDKLESKSEFDKELEKIKSSFNEEYEKWSSGKQRGSSSKHGNQSTHGDSSPTRNSSGSSKKGRPKANRV
ETSSELPDHLIRGFINEKLFLKNFLLKQKESEEFKTLAIVGKYGVGKTTLCQAVFNDEDVKQVYFPRIWVSMYSKETKED
EDPKIDVVKRILRSLGVEDEMFKHIKTEAEEEKSIKDEAGEREEETVKEKELARLLYALHLNLIGKKYLIVLDDVWEDNE
WDQRLDDEKKQQEKSHLSCGFPKGFGGKVIMTSRDERLAKAIVGEEENLQRLFPRSDAESLWEIYIDAVPTKVDDAAATN
LGDAVATNAGDAVAPKVNPRYPGRYKQELMDKSCGIPLAARMLAKIEPVKVDEIGNIDRKQSF
>Q84WJ0|PF00931(178...305)|Protein DA1-related 5
MPISDVASLVGGAALGAPLSEIFKLVIEEAKKVKDFKPLSQDLASTMERLVPIFNEIDMMQQGSNRGTSELKVLTETMER
AGEMVHKCSRIQWYSIAKKALYTREIKAINQDFLKFCQIELQLIQHRNQLQYMRSMGMASVSTKADLLSDIGNEFSKLCL
VAQPEVVTKFWLKRPLMELKKMLFEDGVVTVVVSAPYALGKTTLVTKLCHDADVKEKFKQIFFISVSKFPNVRLIGHKLL
EHIGCKANEYENDLDAMLYIQQLLKQLGRNGSILLVLDDVWAEEESLLQKFLIQLPDYKILVTSRFEFTSFGPTFHLKPL
IDDEVECRDEIEENEKLPEVNPPLSMCGGCNSAVKHEESVNILGVLWHPGCFCCRSCDKPIAIHELENHVSNSRGKFHKS
CYERYCYVCKEKKMKTYNIHPFWEERYCPVHEADGTPKCCSCERLEPRGTKYGKLSDGRWLCLECGKSAMDSDECQPLYF
DMRDFFESLNMKIEKEFPLILVRKELLNKKEEKIDNHYEVLIRAYCMSEQKIMTYVSEEPRTGQNKQLIDMDTEPQGVVH
ECKVTAILILYGLPRLLTGYILAHEMMHAWLRLNGHMNLNNILEEGICQVLGHLWLESQTYATADTTADAASASSSSSRT
PPAASASKKGEWSDFDKKLVEFCKNQIETDESPVYGLGFRTVNEMVTNSSLQETLKEILRRR
>Q8L3R3|PF00931(161...400)|Disease resistance protein RFL1
MGGCVSVSLSCDREVNQFSQWLCVSGSYIQNLSENLASLQKAMGVLNAKRDDVQGRINREEFTGHRRRLAQVQVWLTRIQ
TIENQFNDLLSTCNAEIQRLCLCGFCSKNVKMSYLYGKRVIVLLREVEGLSSQGVFDIVTEAAPIAEVEELPIQSTIVGQ
DSMLDKVWNCLMEDKVWIVGLYGMGGVGKTTLLTQINNKFSKLGGGFDVVIWVVVSKNATVHKIQKSIGEKLGLVGKNWD
EKNKNQRALDIHNVLRRKKFVLLLDDIWEKVELKVIGVPYPSGENGCKVAFTTHSKEVCGRMGVDNPMEISCLDTGNAWD
LLKKKVGENTLGSHPDIPQLARKVSEKCCGLPLALNVIGETMSFKRTIQEWRHATEVLTSATDFSGMEDEILPILKYSYD
SLNGEDAKSCFLYCSLFPEDFEIRKEMLIEYWICEGFIKEKQGREKAFNQGYDILGTLVRSSLLLEGAKDKDVVSMHDMV
REMALWIFSDLGKHKERCIVQAGIGLDELPEVENWRAVKRMSLMNNNFEKILGSPECVELITLFLQNNYKLVDISMEFFR
CMPSLAVLDLSENHSLSELPEEISELVSLQYLDLSGTYIERLPHGLHELRKLVHLKLERTRRLESISGISYLSSLRTLRL
RDSKTTLDTGLMKELQLLEHLELITTDISSGLVGELFCYPRVGRCIQHIYIRDHWERPEESVGVLVLPAIHNLCYISIWN
CWMWEIMIEKTPWKKNLTNPNFSNLSNVRIEGCDGLKDLTWLLFAPNLINLRVWGCKHLEDIISKEKAASVLEKEILPFQ
KLECLNLYQLSELKSIYWNALPFQRLRCLDILNNCPKLRKLPLDSKSVVKVEEFVIKYKEKKWIERVEWEDEATQYRFLP
TCRLR
>Q8RXS5|PF00931(161...400)|Probable disease resistance protein At5g63020
MGGCVSVSISCDQLTKNVCSCLNRNGDYIHGLEENLTALQRALEQIEQRREDLLRKILSEERRGLQRLSVVQGWVSKVEA
IVPRVNELVRMRSVQVQRLCLCGFCSKNLVSSYRYGKRVMKMIEEVEVLRYQGDFAVVAERVDAARVEERPTRPMVAMDP
MLESAWNRLMEDEIGILGLHGMGGVGKTTLLSHINNRFSRVGGEFDIVIWIVVSKELQIQRIQDEIWEKLRSDNEKWKQK
TEDIKASNIYNVLKHKRFVLLLDDIWSKVDLTEVGVPFPSRENGCKIVFTTRLKEICGRMGVDSDMEVRCLAPDDAWDLF
TKKVGEITLGSHPEIPTVARTVAKKCRGLPLALNVIGETMAYKRTVQEWRSAIDVLTSSAAEFSGMEDEILPILKYSYDN
LKSEQLKLCFQYCALFPEDHNIEKNDLVDYWIGEGFIDRNKGKAENQGYEIIGILVRSCLLMEENQETVKMHDVVREMAL
WIASDFGKQKENFIVQAGLQSRNIPEIEKWKVARRVSLMFNNIESIRDAPESPQLITLLLRKNFLGHISSSFFRLMPMLV
VLDLSMNRDLRHLPNEISECVSLQYLSLSRTRIRIWPAGLVELRKLLYLNLEYTRMVESICGISGLTSLKVLRLFVSGFP
EDPCVLNELQLLENLQTLTITLGLASILEQFLSNQRLASCTRALRIENLNPQSSVISFVATMDSLQELHFADSDIWEIKV
KRNETVLPLHIPTTTTFFPNLSQVSLEFCTRLRDLTWLIFAPNLTVLRVISASDLKEVINKEKAEQQNLIPFQELKELRL
ENVQMLKHIHRGPLPFPCLQKILVNGCSELRKLPLNFTSVPRGDLVIEAHKKWIEILEWEDEATKARFLPTLKAFPENID
ADGYEISF
>Q8W1E0|PF00931(548...793)|Late blight resistance protein R1-A
MNFNNELSDLKNRFLFRTLRAQKCSDVARDRIDFFIWELKFLNCFLHLQSFAFASECGMLDISQKMIEICKRFNTPPPHN
SFAYWKEVICKRLCAISIQPDASSDDGFACWKKVIWKTKQEFRAKYSFPKTLLADNKVYDDDDTNPKFVMEFIDAVVGNL
NVLVKINDPSSLLFVPGPKEQIEQVLKELKLLRFFVCFVSNKCIEPQYQHTTFYTHALIEASHIAMVVWLNLPIYGNRNQ
DLASSEVSCLLSDFMEMKIKSIQPDISRNNIYIDVLRALKSTIPQAQDKHAAESGIVETPTHNLMVGLSDQMANLQEMLC
LLRDNLIHLPILDLEFHLQDMDSVIVDAGLLIYSLYDIKGQKEDTTLEDINQALGFDLPRNIEPIKAMINLVMQKAFQCN
LPRIHGLGYVDFLLKNLKDFQGRYSDSLDFLKNQLQVIQTEFESLQPFLKVVVEEPHNKLKTLNEDCATQIIRKAYEVEY
VVDACINKEVPQWCIERWLLDIIEEITCIKAKIQEKNTVEDTMKTVIARTSSKLARTPRMNEEIVGFEDVIENLRKKLLN
GTKGQDVISIHGMPGLGKTTLANSLYSDRSVFSQFDICAQCCVSQVYSYKDLILALLRDAIGEGSVRRELHANELADMLR
KTLLPRRYLILVDDVWENSVWDDLRGCFPDVNNRSRIILTTRHHEVAKYASVHSDPLHLRMFDEVESWKLLEKKVFGEES
CSPLLKNVGLRIAKMCGQLPLSIVLVAGILSEMEKEVECWEQVANNLGSYIHNDSRAIVDKSYHVLPCHLKSCFLYFGAF
LEDRVIDISRLIRLWISEAFIKSSEGRRLEDIAEGYLENLIGRNLVMVTQRSISDGKAKECRLHDVLLDFCKERAAEENF
LLWINRDQITKPSSCVYSHKQHAHLAFTEMHNLVEWSASCSFVGSVVLSNKYDSYFSTRDISSLHDFSISRILPNFKFLK
VLDLEHRVFIDFIPTELVYLKYFSAHIEQNSIPSSISNLWNLETLILKSPIYALRCTLLLPSTVWDMVKLRHLYIPDFST
RIEAALLENSAKLYNLETLSTLYFSRVEDAELMLRKTPNLRKLICEVECLEYPPQYHVLNFPIRLEILKLYRSKFKTIPF
CISAPNLKYLKLCGFSLDSQYLSETADHLKHLEVLILYKVEFGDHREWKVSNGKFPQLKILKLEYLSLVKWIVADDAFPN
LEQLVLRGCQDLMEIPSCFMDILSLKYIGVEYCNESVVKSALNIQETQVEDYQNTNFKLVLIEFSLQKKAWKLNLTDAED
MHNAVKNILAEIR
>Q8W3K0|PF00931(166...422)|Probable disease resistance protein At1g58602
MAGELVSFAVNKLWDLLSHEYTLFQGVEDQVAELKSDLNLLKSFLKDADAKKHTSALVRYCVEEIKDIVYDAEDVLETFV
QKEKLGTTSGIRKHIKRLTCIVPDRREIALYIGHVSKRITRVIRDMQSFGVQQMIVDDYMHPLRNREREIRRTFPKDNES
GFVALEENVKKLVGYFVEEDNYQVVSITGMGGLGKTTLARQVFNHDMVTKKFDKLAWVSVSQDFTLKNVWQNILGDLKPK
EEETKEEEKKILEMTEYTLQRELYQLLEMSKSLIVLDDIWKKEDWEVIKPIFPPTKGWKLLLTSRNESIVAPTNTKYFNF
KPECLKTDDSWKLFQRIAFPINDASEFEIDEEMEKLGEKMIEHCGGLPLAIKVLGGMLAEKYTSHDWRRLSENIGSHLVG
GRTNFNDDNNNSCNYVLSLSFEELPSYLKHCFLYLAHFPEDYEIKVENLSYYWAAEEIFQPRHYDGEIIRDVGDVYIEEL
VRRNMVISERDVKTSRFETCHLHDMMREVCLLKAKEENFLQITSNPPSTANFQSTVTSRRLVYQYPTTLHVEKDINNPKL
RSLVVVTLGSWNMAGSSFTRLELLRVLDLVQAKLKGGKLASCIGKLIHLRYLSLEYAEVTHIPYSLGNLKLLIYLNLHIS
LSSRSNFVPNVLMGMQELRYLALPSLIERKTKLELSNLVKLETLENFSTKNSSLEDLRGMVRLRTLTIELIEETSLETLA
ASIGGLKYLEKLEIDDLGSKMRTKEAGIVFDFVHLKRLRLELYMPRLSKEQHFPSHLTTLYLQHCRLEEDPMPILEKLLQ
LKELELGHKSFSGKKMVCSSCGFPQLQKLSISGLKEWEDWKVEESSMPLLLTLNIFDCRKLKQLPDEHLPSHLTAISLKK
CGLEDPIPTLERLVHLKELSLSELCGRIMVCTGGGFPQLHKLDLSELDGLEEWIVEDGSMPRLHTLEIRRCLKLKKLPNG
FPQLQNLHLTEVEEWEEGMIVKQGSMPLLHTLYIWHCPKLPGEQHFPSHLTTVFLLGMYVEEDPMRILEKLLHLKNVSLF
QSFSGKRMVCSGGGFPQLQKLSIREIEWEEWIVEQGSMPLLHTLYIGVCPNLKELPDGLRFIYSLKNLIVSKRWKKRLSE
GGEDYYKVQHIPSVEFDD
>Q8W3K3|PF00931(169...419)|Putative disease resistance protein At1g58400
MVEAIVSFGVEKLWDRLTQEYEQFQGVEDRIAELKSNLNLLKSFLKDAEAKKNTSQMVRHCVEEIKEIVYDTENMIETFI
LKEAARKRSGIIRRITKLTCIKVHRWEFASDIGGISKRISKVIQDMHSFGVQQMISDGSQSSHLLQEREREMRQTFSRGY
ESDFVGLEVNVKKLVGYLVEEDDIQIVSVTGMGGLGKTTLARQVFNHEDVKHQFDRLAWVCVSQEFTRKNVWQMILQNLT
SRETKDEILQMEEAELHDELFQLLETSKSLIVFDDIWKEEDWGLINPIFPPKKGWKVLITSRTETIAMHGNRRYVNFKPE
CLTILESWILFQRIAMPRVDESEFKVDKEMEMMGKQMIKYCGGLPLAVKVLGGLLAAKYTFHDWKRLSENIGCHIVGRTD
FSDGNNSSVYHVLSLSFEELPSYLKHCFLYLAHFPEDHNIKVEKLSYCWAAEGILEPRHYHGQTIRDVGESYIEELVRRN
MVIAERDVTTLRFEACHLHDMMREVCLLKAKEENFVQIASILPPTANSQYPGTSRRFVSQNPTTLHVSRDINNPKLQSLL
IVWENRRKSWKLLGSSFIRLELLRVLDLYKAKFEGRNLPSGIGKLIHLRYLNLDLARVSRLPSSLGNLRLLIYLDINVCT
KSLFVPNCLMGMHELRYLRLPFNTSKEIKLGLCNLVNLETLENFSTENSSLEDLRGMVSLRTLTIGLFKHISKETLFASI
LGMRHLENLSIRTPDGSSKFKRIMEDGIVLDAIHLKQLNLRLYMPKLPDEQHFPSHLTSISLDGCCLVEDPLPILEKLLE
LKEVRLDFRAFCGKRMVSSDGGFPQLHRLYIWGLAEWEEWIVEEGSMPRLHTLTIWNCQKLKQLPDGLRFIYSIKDLDMD
KKWKEILSEGGEEYYKVQHIPSVKFEKDYK
>Q8W474|PF00931(168...414)|Probable disease resistance protein At1g58390
MAGELVSFGIKKLWDLLSQECEQFQGVEDQVTGLKRDLNLLSSFLKDADAKKHTTAVVRNVVEEIKEIVYDAEDIIETYL
LKEKLWKTSGIKMRIRRHACIISDRRRNALDVGGIRTRISDVIRDMQSFGVQQAIVDGGYMQPQGDRQREMRQTFSKDYE
SDFVGLEVNVKKLVGYLVDEENVQVVSITGMGGLGKTTLARQVFNHEDVKHQFDRLAWVCVSQEFTRKNVWQMILQNLTS
REKKDEILQMEEAELHDKLFQLLETSKSLIVFDDIWKDEDWDLIKPIFPPNKGWKVLLTSQNESVAVRGDIKYLNFKPEC
LAIEDSWTLFQRIAFPKKDASESKVDEEMEDMGKQMLKHCGGLPLAIKVLGGLLAAKYTMHDWERLSVNIGSDIVGRTSS
NNSSIYHVLSMSFEELPSYLKHCFLYLAHFPEDHKINVEKLSYCWAAEGISTAEDYHNGETIQDVGQSYLEELVRRNMII
WERDATASRFGTCHLHDMMREVCLFKAKEENFLQIAVKSVGVTSSSTGNSQSPCRSRRLVYQCPTTLHVERDINNPKLRS
LVVLWHDLWVENWKLLGTSFTRLKLLRVLDLFYVDFEGMKLPFGIGNLIHLRYLSLQDAKVSHLPSSLGNLMLLIYLNLD
VDTEFIFVPDVFMRMHELRYLKLPLHMHKKTRLSLRNLVKLETLVYFSTWHSSSKDLCGMTRLMTLAIRLTRVTSTETLS
ASISGLRNLEYLYIVGTHSKKMREEGIVLDFIHLKHLLLDLYMPRQQHFPSRLTFVKLSECGLEEDPMPILEKLLHLKGV
ILLKGSYCGRRMVCSGGGFPQLKKLEIVGLNKWEEWLVEEGSMPLLETLSILDCEELKEIPDGLRFIYSLELVMLGTRWK
KKFSVGGEDYYKVQHIPSVEFIGGYLK
>Q8W4J9|PF00931(169...418)|Disease resistance protein RPP8
MAEAFVSFGLEKLWDLLSRESERLQGIDGQLDGLKRQLRSLQSLLKDADAKKHGSDRVRNFLEDVKDLVFDAEDIIESYV
LNKLSGKGKGVKKHVRRLACFLTDRHKVASDIEGITKRISEVIGEMQSFGIQQIIDGGRSLSLQERQRVQREIRQTYPDS
SESDLVGVEQSVKELVGHLVENDVHQVVSIAGMGGIGKTTLARQVFHHDLVRRHFDGFAWVCVSQQFTQKHVWQRILQEL
QPHDGDILQMDEYALQRKLFQLLEAGRYLVVLDDVWKKEDWDVIKAVFPRKRGWKMLLTSRNEGVGIHADPTCLTFRASI
LNPEESWKLCERIVFPRRDETEVRLDEEMEAMGKEMVTHCGGLPLAVKALGGLLANKHTVPEWKRVFDNIGSQIVGGSWL
DDNSLNSVYRILSLSYEDLPTHLKHCFLNLAHFPEDSEISTYSLFYYWAAEGIYDGSTIEDSGEYYLEELVRRNLVIADD
NYLSWQSKYCQMHDMMREVCLSKAKEENFLQIIIDPTCTSTINAQSPSRSRRLSIHSGKAFHILGHKNKTKVRSLIVPRF
EEDYWIRSASVFHNLTLLRVLDLSWVKFEGGKLPCSIGGLIHLRYLSLYEAKVSHLPSTMRNLKLLLYLNLRVDTEEPIH
VPNVLKEMIQLRYLSLPLKMDDKTKLELGDLVNLEYLYGFSTQHSSVTDLLRMTKLRYLAVSLSERCNFETLSSSLRELR
NLETLNFLFSLETYMVDYMGEFVLDHFIHLKQLGLAVRMSKIPDQHQFPPHLVHLFLIYCGMEEDPMPILEKLLHLKSVR
LARKAFLGSRMVCSKGGFPQLCVIEISKESELEEWIVEEGSMPCLRTLTIDDCKKLKELPDGLKYITSLKELKIEGMKRE
WKEKLVPGGEDYYKVQHIPDVQFINCDQ
>Q8YTC2|PF00931(154...370)|Uncharacterized WD repeat-containing protein alr2800
MILQSTSLFCKYINNCRYINREIVATLKASPQGLARIKQARSDRGWSVDDFRWLELASEILGVCWQENGVLAAGISEGTW
KRFLAGKQAINAEAFKAYCQVLGLNWEEVQEGGRTKERKDTGTSRQEKFLSSSHPHTDWGEAPDVSIFYGRSEELDTVKR
WVTQENCRLITLLGMGGIGKTTLSVKLAQEIINSEKIYLSQSPEYIIWRSLRNAPPVEDILAELIQFLSGQQETNLSNHL
QGRISLLLKNLRSSRCLIILDNAESILQAGDRNGRYRAGCEGYGQFLQCIAETSHQSCLILTSREKPQGLAKYEGDSLPV
RSLPLTGLQEQEGRELFNVKGKFAASCDQWQVLISRYGGNPLALKIVASSIRDFFDGDVSQFLEVSQQGTFIFDDIRDLL
DQQFQRLTTLEREIMYWLAINREPVTLAELQADFVANIPPRELLESLSSLQRRSLIEKSAGGFTQQPVVMEYVSNHLIEQ
VCEEMREWGLVRSRGAEEQRSRGEKIHTQYKLNAALPLTALSTPLFTTHALIKAQAKDYVRESQISLILQPLINQLITEF
GSLENISNCLVHILSRLRGKSPQETGYAGGNVLNLLHHAQVDLSGYDFSGLTVWQAYLQGVNLHDVDFANSDLSCCVFTE
TLGNILSAAFSPEGQLLATCDTDCHVRVWEVKSGKLLLICRGHSNWVRFVVFSPDGEILASCGADENVKLWSVRDGVCIK
TLTGHEHEVFSVAFHPDGETLASASGDKTIKLWDIQDGTCLQTLTGHTDWVRCVAFSPDGNTLASSAADHTIKLWDVSQG
KCLRTLKSHTGWVRSVAFSADGQTLASGSGDRTIKIWNYHTGECLKTYIGHTNSVYSIAYSPDSKILVSGSGDRTIKLWD
CQTHICIKTLHGHTNEVCSVAFSPDGQTLACVSLDQSVRLWNCRTGQCLKAWYGNTDWALPVAFSPDRQILASGSNDKTV
KLWDWQTGKYISSLEGHTDFIYGIAFSPDSQTLASASTDSSVRLWNISTGQCFQILLEHTDWVYAVVFHPQGKIIATGSA
DCTVKLWNISTGQCLKTLSEHSDKILGMAWSPDGQLLASASADQSVRLWDCCTGRCVGILRGHSNRVYSAIFSPNGEIIA
TCSTDQTVKIWDWQQGKCLKTLTGHTNWVFDIAFSPDGKILASASHDQTVRIWDVNTGKCHHICIGHTHLVSSVAFSPDG
EVVASGSQDQTVRIWNVKTGECLQILRAKRLYEGMNITGVTGLTKATIFTLQALGALR
>Q940K0|PF00931(156...397)|Disease resistance protein UNI
MGSCFSLQVSDQTLNRIFNCLIGKSYIRTLEKNLRALQREMEDLRAIQHEVQNKVARDEARHQRRLEAVQVWLDRVNSVD
IECKDLLSVTPVELQKLCLCGLCSKYVCSSYKYGKKVFLLLEEVKKLNSEGNFDEVSQPPPRSEVEERPTQPTIGQEDML
EKAWNRLMEDGVGIMGLHGMGGVGKTTLFKKIHNKFAEIGGTFDIVIWIVVSKGVMISKLQEDIAEKLHLCDDLWKNKNE
SDKATDIHRVLKGKRFVLMLDDIWEKVDLEAIGIPYPSEVNKCKVAFTTRSREVCGEMGDHKPMQVNCLEPEDAWELFKN
KVGDNTLSSDPVIVELAREVAQKCRGLPLALNVIGETMSSKTMVQEWEHAIHVFNTSAAEFSDMQNKILPILKYSYDSLG
DEHIKSCFLYCALFPEDGEIYNEKLIDYWICEGFIGEDQVIKRARNKGYAMLGTLTRANLLTKVGTYYCVMHDVVREMAL
WIASDFGKQKENFVVQAGVGLHEIPKVKDWGAVRKMSLMDNDIEEITCESKCSELTTLFLQSNKLKNLPGAFIRYMQKLV
VLDLSYNRDFNKLPEQISGLVSLQFLDLSNTSIEHMPIGLKELKKLTFLDLTYTDRLCSISGISRLLSLRLLRLLGSKVH
GDASVLKELQQLQNLQELAITVSAELISLDQRLAKLISNLCIEGFLQKPFDLSFLASMENLSSLRVENSYFSEIKCRESE
TESSYLRINPKIPCFTNLSRLEIMKCHSMKDLTWILFAPNLVVLLIEDSREVGEIINKEKATNLTSITPFLKLEWLILYN
LPKLESIYWSPLPFPVLLTMDVSNCPKLRKLPLNATSVSKVEEFEIHMYPPPEQENELEWEDDDTKNRFLPSIKPYKYFV
YPGMSFLTV
>Q9C646|PF00931(166...413)|Probable disease resistance protein RXW24L
MELVSFGVEKLWDRLSQEYDQFKGVEDQVTELKSNLNLLKSFLKDADAKKHISEMVRHCVEEIKDIVYDTEDIIETFILK
EKVEMKRGIMKRIKRFASTIMDRRELASDIGGISKRISKVIQDMQSFGVQQIITDGSRSSHPLQERQREMRHTFSRDSEN
DFVGMEANVKKLVGYLVEKDDYQIVSLTGMGGLGKTTLARQVFNHDVVKDRFDGFAWVSVSQEFTRISVWQTILQNLTSK
ERKDEIQNMKEADLHDDLFRLLESSKTLIVLDDIWKEEDWDLIKPIFPPKKGWKVLLTSRTESIAMRGDTTYISFKPKCL
SIPDSWTLFQSIAMPRKDTSEFKVDEEMENMGKKMIKHCGGLSLAVKVLGGLLAAKYTLHDWKRLSENIGSHIVERTSGN
NSSIDHVLSVSFEELPNYLKHCFLYLAHFPEDHEIDVEKLHYYWAAEGISERRRYDGETIRDTGDSYIEELVRRNMVISE
RDVMTSRFETCRLHDMMREICLFKAKEENFLQIVSNHSPTSNPQTLGASRRFVLHNPTTLHVERYKNNPKLRSLVVVYDD
IGNRRWMLSGSIFTRVKLLRVLDLVQAKFKGGKLPSDIGKLIHLRYLSLKDAKVSHLPSSLRNLVLLIYLDIRTDFTDIF
VPNVFMGMRELRYLELPRFMHEKTKLELSNLEKLEALENFSTKSSSLEDLRGMVRLRTLVIILSEGTSLQTLSASVCGLR
HLENFKIMENAGVNRMGEERMVLDFTYLKKLTLSIEMPRLPKIQHLPSHLTVLDLSYCCLEEDPMPILEKLLELKDLSLD
YLSFSGRKMVCSAGGFPQLRKLALDEQEEWEEWIVEEGSMSRLHTLSIWSSTLKELPDGLRFIYSLKNLIMGKSWMERLS
ERGEEFYKVQNIPFIKFSS
>Q9C7X0|PF00931(193...411)|Disease resistance protein ADR2
MASSSSSPRNWRYNVFTSFHGPDVRIKFLSHLRQQFVYNGITMFDDNGIERSQIIAPALKKAIGESRVAIVLLSKNYASS
SWCLDELLEILKCKEYIGQIVMTVFYEVDPSHVRKQTGDFGIAFKETCAHKTEEERSKWSQALTYVGNIAGEDFIHWKDE
AKMIEKIARDVSTKINVTPCRDFDDMVGLERHLKEMVSLLDLDKEGVKMVGISGPAGIGKSTIAKALHSRHSSTFQHNCF
VDNLWENYKICTGEHGVKLRLHEQFVSKILKQNGLELTHLSVIKDRLQDKKVLIILDDVESLAQLETLADMTWFGPGSRV
IVTTENKEILQQHGIGDIYQVGYPSESEALTIFCLSAFKQASPPDGFMDLADEVVRICDKLPLALCVLGSSLLRKSQTDW
EDELPRLRNCLDGIESVLKVGFESLNEKDQALFLYITVFFNYECADHVTLMLAKSNLNVRLGLKNLANRYLIHIDHDQKK
RVVVHRLLRVMAIQVCTKQKPWKSQILVDAEKIAYVLEEATGNRSIKGVSFDTAEIDELMISPKAFEKMCNLLFLKVYDA
GWHTGKRKLDIPEDIKFPRTIRLFHWDAYSGKRLPSSFFAENLVEVNMQDSELQKLWEGTQCLANLKKIDLSRSSCLTEL
PDLSNATNLEDLYVGSCTALVELPSSIGNLHKLAHIMMYSCESLEVIPSLINLTSLTFLNMNKCSRLRRFPDIPTSIEDV
QVTGTTLEELPASLTHCSGLQTIKISGSVNLKIFYTELPVSVSHINISNSGIEWITEDCIKGLHNLHDLCLSGCKRLVSL
PELPRSLKILQADDCDSLESLNGHLNTPNAELYFANCFKLDAEARRAIIQQSFVSGWALLPGLEVPPEFGHRARGNSLII
PYSASNRFKVCVVMSLNHHQPFELVPRNLLYRWTVIGDSVSSDEKTFHLSHMFNADSVNSKLQKPHLFIFHSCLPFIFHS
CLPFIFDISNIMLEFSSEYKDFDILECGVQILTDETDERNIWGSLVF
>Q9C8K0|PF00931(160...398)|Probable disease resistance protein At1g51480
MADWLLLIPWNKIFTAACGCFFSDRNYIHKMEANLDDLHTTMEELKNGRDDLLRRVSIEEDKGLQQLAQVKGWISRVEIV
ESRFKDLLEDKSTETGRLCLFGFCSENCISSYNYGEKVMKNLEEVKELLSKKHFEVVAHKIPVPKVEEKNIHTTVGLYAM
VEMAWKSLMNDEIRTLCLHGMGGVGKTTLLACINNKFVELESEFDVVIWVVVSKDFQLEGIQDQILGRLRLDKEWERETE
NKKASLINNNLKRKKFVLLLDDLWSEVDLNKIGVPPPTRENGAKIVFTKRSKEVSKYMKADMQIKVSCLSPDEAWELFRI
TVDDVILSSHEDIPALARIVAAKCHGLPLALIVIGEAMACKETIQEWHHAINVLNSPAGHKFPGMEERILLVLKFSYDSL
KNGEIKLCFLYCSLFPEDFEIEKEKLIEYWICEGYINPNRYEDGGTNQGYDIIGLLVRAHLLIECELTTKVKMHYVIREM
ALWINSDFGKQQETICVKSGAHVRMIPNDINWEIVRQVSLISTQIEKISCSSKCSNLSTLLLPYNKLVNISVGFFLFMPK
LVVLDLSTNMSLIELPEEISNLCSLQYLNLSSTGIKSLPGGMKKLRKLIYLNLEFSYKLESLVGISATLPNLQVLKLFYS
NVCVDDILMEELQHMDHLKILTVTIDDAMILERIQGIDRLASSIRGLCLTNMSAPRVVLSTTALGGLQQLAILSCNISEI
KMDWKSKERREVSPMEIHPSTSTSSPGFKQLSSVNIMKLVGPRDLSWLLFAQNLKSLHVGFSPEIEEIINKEKGSSITKE
IAFGKLESLVIYKLPELKEICWNYRTLPNSRYFDVKDCPKLPEDIANFPMHAEE
>Q9C8T9|PF00931(156...397)|Putative disease resistance protein At1g63350
MGISFSIPFDPCVNKVSQWLDMKVSYTHNLEKNLVALETTMEELKAKRDDLLRKLKREEDRGLQTLGEIKVWLNRVETIE
SRVNDLLNARNAELQRLCLCGFCSKSLTTSYRYGKSVFLKLREVEKLERRVFEVISDQASTSEVEEQQLQPTIVGQETML
DNAWNHLMEDGVGIMGLYGMGGVGKTTLLTQINNKFSKYMCGFDSVIWVVVSKEVNVENILDEIAQKVHISGEKWDTKYK
YQKGVYLYNFLRKMRFVLFLDDIWEKVNLVEIGVPFPTIKNKCKVVFTTRSLDVCTSMGVEKPMEVQCLADNDAYDLFQK
KVGQITLGSDPEIRELSRVVAKKCCGLPLALNVVSETMSCKRTVQEWRHAIYVLNSYAAKFSGMDDKILPLLKYSYDSLK
GEDVKMCLLYCALFPEDAKIRKENLIEYWICEEIIDGSEGIDKAENQGYEIIGSLVRASLLMEEVELDGANIVCLHDVVR
EMALWIASDLGKQNEAFIVRASVGLREILKVENWNVVRRMSLMKNNIAHLDGRLDCMELTTLLLQSTHLEKISSEFFNSM
PKLAVLDLSGNYYLSELPNGISELVSLQYLNLSSTGIRHLPKGLQELKKLIHLYLERTSQLGSMVGISCLHNLKVLKLSG
SSYAWDLDTVKELEALEHLEVLTTTIDDCTLGTDQFLSSHRLMSCIRFLKISNNSNRNRNSSRISLPVTMDRLQEFTIEH
CHTSEIKMGRICSFSSLIEVNLSNCRRLRELTFLMFAPNLKRLHVVSSNQLEDIINKEKAHDGEKSGIVPFPKLNELHLY
NLRELKNIYWSPLPFPCLEKINVMGCPNLKKLPLDSKSGKHGGNGLIITHREMEWITRVEWEDEATKTRFLANRSSFSSS
LICFSNDLVSRDMNCFHL
>Q9CAK1|PF00931(191...430)|Disease resistance protein RML1B
MASPSSFSSQNYKFNVFASFHGPDVRKTLLSHIRLQFNRNGITMFDDQKIVRSATIGPSLVEAIKESRISIVILSKKYAS
SSWCLDELVEILECKKAMGQIVMTIFYGVDPSDVRKQIGKFGIAFNETCARKTEEERQKWSKALNQVSNIAGEDFLRWDN
EAIMIEKIARDVLDKLNATPSRDFDGMVGIEAHLREIKSLLDLDNVEVKIVAIAGPAGIGKTTIARALYGLLSKRFQLSC
FVDNLRGSYHSGFDEYGFKLHLQEQFLSKVLNQSGMRICHLGAIKENLSDQRVLIILDDVNKLKQLEALANETTWFGPGS
RIVVTTENKELLQQHGINNTYHVGFPSDEDALKILCSYAFKQTSPRHGFEELSESVTKLCGKLPLGLCVVGSSLRGKKED
EWEDVVTRLETILDQDIEDVLRVGYESLDENAQTLFLHIAIFFNKEDGDLVKTMFAESDLDVKYGLKILENRSLIKMKIF
SNGDTKIVMHRLLQQMGKRAIQKQEPWERQILIDAREICHVLEHAKGTGWNVHGMSFDISRISEVSIRKKAFKRMPNLQF
LKVYKSKDDGNNRMHVPEEMDFPCLLRLLDWKAYPSKSLPPTFNPEHLVELNMHSSQLEYLWQGTQPLKNLKKMDLSQSK
NLKQLPDLSNATNLEYLYLMGCESLIEIPSSISHLHKLEMLATVGCINLEVIPAHMNLESLQTVYLGGCSRLRNIPVMST
NIRYLFITNTAVEGVPLCPGLKTLDVSGSRNFKGLLTHLPTSLTTLNLCYTDIERIPDCFKSLHQLKGVNLRGCRRLASL
PELPRSLLTLVADDCESLETVFCPLNTLKASFSFANCFKLDREARRAIIQQSFFMGKAVLPGREVPAVFDHRAKGYSLTI
RPDGNPYTSFVFCVVVSRNQKSDKTIPPSLLWRRIIAQDEGYPVEVWNRIGDVFKYRTEHLLIFHFDFLEFDNRDIVFEF
SSESHDFDIIECGAKVLAEKSIKESYESGSDQAFEDDVVFEPSKAFGDEKYGDCCIL
>Q9EPV5|PF00931(130...374)|Apoptotic protease-activating factor 1
MDAKARNCLLQHKEALEKDIKTSYIMDHMISNGVLTVVEEEKVKSQATQYQRAAALIKMILNKDNYAYISFYNALLHEGY
KDLAGLLHSGLPLVSSSSGKDTDGGNTSFVRTVLCEGGVPQRPVIFVTRKKLVSAIQQKLWKLNGEPGWVTIYGMAGCGK
SVLAAEAVRDHALLEGCFSGGVHWVSIGKQDKSGLLMKLQNLCTRLGQEESFSQRLPLNIEEAKDRLRVLMLRKHPRSLL
ILDDVWDPWVLKAFDNQCQILLTTRDKSVTDSVMGPKYVIPVESGLGKEKGLEILSLFVNMKKEDLPVEAHSIIKECKGS
PLVVSLVGALLRDFPNRWAYYLRQLQNKQFKRIRKSSSYDYEALDEAMSISVEMLREDIKDYYTDLSILQKDVKVPTKVL
CVLWDLETEEVEDILQEFVNKSLLFCNRNGKSFCYYLHDLQVDFLTEKNRSQLQDLHRKMVTQFQRYHQPHTLSPGQEDC
MYWYNFLAYHMASAGMHKELCALMFSLDWIKAKTELVGPAHLIHEFVEYRHILDEKDCAVCENFQEFLSLNGHLLGRQPF
PNIVQLGLCEPETSEVYQQAKLQAKQEVDTGRLYLEWINKKTIKNLSRLVVRPHTDAVYHACFSQDGQRIASCGADKTLQ
VFKAETGEKLLDIKAHEDEVLCCAFSSDDSYIATCSVDKKVKIWDSGTGKLVHTYEEHSEQVNCCHFTNKSNHLLLATGS
NDSFLKLWDLNQKECRNTMFGHTNSVTHCRFSPDDELLASCSADGTLKLWDVRSANEKKSINVKRFFLSSEDPPEDVEVI
VKCCSWSADGDRIIVAAKNKVLLLDIHTSGLLTEIHTGHHSTIQYCDFSPYDHLAVIALSQYCVELWNIDSRVKVADCRG
HLSWVHGVMFSPDGSSFLTASDDQTIRVWETRKVCKNSAIVLKQEIDVVFQENEMMVLAVDNIRGLQLIAGKTGQIDYLP
EAQVSCCCLSPHLEYVAFGDEEGAIKIIELPNNRVFSSGIGHKKAVRHIQFTADGKTLISSSEDSVIQVWNWQTEEYVFL
QAHQETVKDFRLLRDSRLLSWSFDGTVKVWNVITGRIERDFTCHQGTVLSCAISSDATKFSSTSADKTAKIWSFELPSPL
HELKGHNSCVRCSAFSLDGILLATGDDNGEIRIWNVSDGQLLHLCAPISIEEGTATHGGWVTDVCFSPDRKMLVSAGGYL
KWWNVVTGESSQTFYTNGTNLKKIHVSPDFRTYVTVDNLGILYILQVLE
>Q9FG90|PF00931(157...395)|Probable disease resistance protein At5g43740
MLGWLVIPWNQIFTAACGCFLSDRNYIHMMESNLDALQKTMEELKNGRDDLLGRVSIEEDKGLQRLAQVNGWLSRVQIVE
SEFKDLLEAMSIETGRLCLLGYCSEDCISSYNYGEKVSKMLEEVKELLSKKDFRMVAQEIIHKVEKKLIQTTVGLDKLVE
MAWSSLMNDEIGTLGLYGMGGVGKTTLLESLNNKFVELESEFDVVIWVVVSKDFQFEGIQDQILGRLRSDKEWERETESK
KASLIYNNLERKKFVLLLDDLWSEVDMTKIGVPPPTRENGSKIVFTTRSTEVCKHMKADKQIKVACLSPDEAWELFRLTV
GDIILRSHQDIPALARIVAAKCHGLPLALNVIGKAMSCKETIQEWSHAINVLNSAGHEFPGMEERILPILKFSYDSLKNG
EIKLCFLYCSLFPEDSEIPKEKWIEYWICEGFINPNRYEDGGTNHGYDIIGLLVRAHLLIECELTDNVKMHDVIREMALW
INSDFGKQQETICVKSGAHVRMIPNDINWEIVRTMSFTCTQIKKISCRSKCPNLSTLLILDNRLLVKISNRFFRFMPKLV
VLDLSANLDLIKLPEEISNLGSLQYLNISLTGIKSLPVGLKKLRKLIYLNLEFTGVHGSLVGIAATLPNLQVLKFFYSCV
YVDDILMKELQDLEHLKILTANVKDVTILERIQGDDRLASSIRSLCLEDMSTPRVILSTIALGGLQQLAILMCNISEIRI
DWESKERRELSPTEILPSTGSPGFKQLSTVYINQLEGQRDLSWLLYAQNLKKLEVCWSPQIEEIINKEKGMNITKLHRDI
VVPFGNLEDLALRQMADLTEICWNYRTLPNLRKSYINDCPKLPEDIFVPLLPEKSPSRFFFF
>Q9FG91|PF00931(157...396)|Probable disease resistance protein At5g43730
MVDWLSLLPWNKIFTAACGCFLSDSNYIHLMESNLDALQKTMEELKNGRDDLLARVSIEEDKGLQRLALVNGWLSRVQIV
ESEFKDLLEAMSIETGRLCLFGYCSEDCISSYNYGGKVMKNLEEVKELLSKKNFEVVAQKIIPKAEKKHIQTTVGLDTMV
GIAWESLIDDEIRTLGLYGMGGIGKTTLLESLNNKFVELESEFDVVIWVVVSKDFQLEGIQDQILGRLRPDKEWERETES
KKASLINNNLKRKKFVLLLDDLWSEVDLIKIGVPPPSRENGSKIVFTTRSKEVCKHMKADKQIKVDCLSPDEAWELFRLT
VGDIILRSHQDIPALARIVAAKCHGLPLALNVIGKAMVCKETVQEWRHAINVLNSPGHKFPGMEERILPILKFSYDSLKN
GEIKLCFLYCSLFPEDFEIEKDKLIEYWICEGYINPNRYEDGGTNQGYDIIGLLVRAHLLIECELTDKVKMHDVIREMAL
WINSDFGNQQETICVKSGAHVRLIPNDISWEIVRQMSLISTQVEKIACSPNCPNLSTLLLPYNKLVDISVGFFLFMPKLV
VLDLSTNWSLIELPEEISNLGSLQYLNLSLTGIKSLPVGLKKLRKLIYLNLEFTNVLESLVGIATTLPNLQVLKLFYSLF
CVDDIIMEELQRLKHLKILTATIEDAMILERVQGVDRLASSIRGLCLRNMSAPRVILNSVALGGLQQLGIVSCNISEIEI
DWLSKERRDHRSTSSPGFKQLASITVIGLVGPRDLSWLLFAQNLKDIQVQYSPTIEEIINKQKGMSITKVHRDIVVPFGK
LESLHLYQLAELTEICWNYQTLPNLRESYVNYCPKLLEDIANFPKLKG
>Q9FHF0|PF00931(212...435)|Disease resistance protein RPS4B
MAASSSSTGLPPQHQVFINFRGEDLRLGFVSHLVEALENDNIKVFIDNYADKGEPLETLLTKIHDSKIALAIFSGKYTES
TWCLRELAMIKDCVEKGKLVAIPIFYKVDPSTVRGVRGQFGDAFRDLEERDVIKKKEWKQALKWIPGLIGITVHDKSPES
EILNEIVKEVKKVLKKVSLEGSQKVVSVDPSQSIDTLSSVGGEKDKTFGIKQRLKELEEKLDLVKYKGTRVIGVVGMPGI
GKTTLVKELYKTWQGKFSRYALIDQIRGKSNNFRLECLPTLLLEKLLPELNNPQLDSIEEPYKTHKGLLRERKVLVVLDD
VSRREQIYALLGKYDLHSKHEWIKDGSRIIIATNDISSLKGLVHDTYVVRQLNHRDGLQLFRYHAFHYDQATPPKVDFMK
LSDEFVHYARGHPLALKILGRELYEKNMKHWETKLIILAQSPTTYIGEVVQVSYDELSLAQKDAFLDIACFRSQDVDYVE
SLLVSSDPGSAEAIKALKNKFLIDTCDGRVEMHDLLYRFSRELDLKASTQGGSKQRRLWVRQDIINVQQKTMGAANVRGI
FLDLSEVKVETSLDREHFKNMRNLRYLKLYNSHCPHECLTNNKINMPDGLELPLKEVRCLHWLKFPLEELPNDFDPINLV
DLKLPYSEIERLWDGVKDTPVLKWVDLNHSSKLCSLSGLSKAQNLQRLNLEGCTSLESLRDVNLTSLKTLTLSNCSNFKE
FPLIPENLKALYLDGTSISQLPDNVGNLKRLVLLNMKDCKVLETIPTCVSELKTLQKLVLSGCSKLKEFPEINKSSLKIL
LLDGTSIKTMPQLPSVQYLCLSRNDHLIYLPAGINQVSQLTRLDLKYCTKLTYVPELPPTLQYLDAHGCSSLKNVAKPLA
RIMSTVQNHYTFNFTNCGNLEQAAKEEITSYAQRKCQLLSDARKHYNEGSEALFSTCFPGCEVPSWFGHEAVGSLLQRKL
LPHWHDKRLSGIALCAVVSFPDSQDQLSCFSVTCTFKIKAEDKSWVPFTCPVGIWTREGNKKDRIESDHVFIAYISSPHS
IRCLEEKNSDKCNFSEASLEFTVTSDTSGIGVFKVLKCGLSLVYENDKNKNSSLEAKYDVPVEVSFQEPEHGIMEEERYI
NKRRSDDRRPKKKRKTKRDDIMIISTVTQTCVPSVNARIEDKVTG
>Q9FHI7|PF00931(71...320)|Probable disease resistance protein At5g45490
MPSKNLQQAVLTNEFTTNFITTCKDWLDVNGLAKGNLEKKRDDNEEEERLKTESKLPGHDIHGFDNEIKSLQHFLLDQKV
RREFKSLVIVGEYGVGKTALCQKIFNDEAVKSVYAPRVWVSMENKESKEGLDGKICVLKKILKGLGVEELILETISTDAK
QEFKDNEEVASNQEAGEIDRETEKEKELSALLYALHLNLRWKKYLIVFDDVRENDNWDEKLDAKLKEDEKWGKYLSDGFP
KGSGGRVIYTTRDENLAKNLVAQKHEIHRLWPLSDHQSVWKIYDAVVKDKQKESPRNDKKCIDELMNKSRGLPLAARLLA
ERDPVFVDDEVGPVGSTHGQTDSSNRQPANQASS
>Q9FHJ2|PF00931(60...310)|Probable disease resistance protein At5g45440
MTQEDSSRGLTSVGRVDFTNRFADRYNEWLGTTGDETKQVEDRVETDSGLPGHDIYGFENEIKSLQHFLLDQKSYKLFKS
LVVVGEYGVGKTALCQQIFNDYDVRNAYAPRIWVSMHSNESKEGLDGKICVLKTILKGLGVEESMFESIHREVVEEVSNR
QEAGEIDGETAKEKEISALLYALHLNLRWKKYLIVFDDVQEIDNWDEKLDAKLNEGEKWGKYLSDGFPKGSGGRVIYTTR
DENLAKNLVVQKHEIHRLWPLSDSNSVWKIYEAMIQKREKESPRNDKKCIDELMNKSRGLPLAARLLAELDPMLFDDGKA
NQNGSKDGKTDSVDNPNSEESKTKPL
>Q9FI14|PF00931(231...457)|Disease resistance protein TAO1
MDSSCFLVYRIFRFRKRNKNISSSLSSSSPPSSLSQNWLHPVFLSFRGEDVRKGLLSHIQKEFQRNGITPFIDNEMKRGG
SIGPELLQAIRGSKIAIILLSRNYGSSKWCLDELVEIMKCREELGQTVMTVFYDVDPSDVRKQKGDFGKVFKKTCVGRPE
EMVQRWKQALTSAANILGEDSRNWENEADMIIKISKDVSDVLSFTPSKDFDEFVGIEAHTTEITSLLQLDLEEVRMIGIW
GPAGIGKTTISRVLYNKLFHQFQLGAIIDNIKVRYPRPCHDEYSAKLQLQKELLSQMINQKDMVVPHLGVAQERLKDKKV
LLVLDDVDGLVQLDAMAKDVQWFGLGSRIIVVTQDLKLLKAHGIKYIYKVDFPTSDEALEIFCMYAFGEKSPKVGFEQIA
RTVTTLAGKLPLGLRVMGSYLRRMSKQEWAKSIPRLRTSLDDDIESVLKFSYNSLAEQEKDLFLHITCFFRRERIETLEV
FLAKKSVDMRQGLQILADKSLLSLNLGNIEMHNLLVQLGLDIVRKQSIHKPGKRQFLVDTEDICEVLTDDTGTRTLIGID
LELSGVIEGVINISERAFERMCNLQFLRFHHPYGDRCHDILYLPQGLSHISRKLRLLHWERYPLTCLPPKFNPEFLVKIN
MRDSMLEKLWDGNEPIRNLKWMDLSFCVNLKELPDFSTATNLQELRLINCLSLVELPSSIGNATNLLELDLIDCSSLVKL
PSSIGNLTNLKKLFLNRCSSLVKLPSSFGNVTSLKELNLSGCSSLLEIPSSIGNIVNLKKVYADGCSSLVQLPSSIGNNT
NLKELHLLNCSSLMECPSSMLNLTRLEDLNLSGCLSLVKLPSIGNVINLQSLYLSDCSSLMELPFTIENATNLDTLYLDG
CSNLLELPSSIWNITNLQSLYLNGCSSLKELPSLVENAINLQSLSLMKCSSLVELPSSIWRISNLSYLDVSNCSSLLELN
LVSHPVVPDSLILDAGDCESLVQRLDCFFQNPKIVLNFANCFKLNQEARDLIIQTSACRNAILPGEKVPAYFTYRATGDS
LTVKLNQKYLLQSLRFKACLLLVEGQNKWPNWGMNLVTSREPDGHIVLYTPSSHLQGPLLMENLYTFEFELVVTSSEFVL
EFRADRYKCALGRFDKFGVHVVWCHLDQYESKSPSCKPFWRDFPIVISNGQNILDAILKTPMPSINQ
>Q9FJB5|PF00931(167...412)|Disease resistance RPP8-like protein 3
MAEGVVSFGVQKLWALLNRESERLNGIDEQVDGLKRQLRGLQSLLKDADAKKHGSDRVRNFLEDVKDLVFDAEDIIESYV
LNKLRGEGKGVKNHVRRLACFLTDRHKVASDIEGITKRISKVIGEMQSLGIQQQIIDGGRSLSLQDIQREIRQTFPNSSE
SDLVGVEQSVEELVGPMVEIDNIQVVSISGMGGIGKTTLARQIFHHDLVRRHFDGFAWVCVSQQFTQKHVWQRILQELRP
HDGEILQMDEYTIQGKLFQLLETGRYLVVLDDVWKEEDWDRIKEVFPRKRGWKMLLTSRNEGVGLHADPTCLSFRARILN
PKESWKLFERIVPRRNETEYEEMEAIGKEMVTYCGGLPLAVKVLGGLLANKHTASEWKRVSENIGAQIVGKSCLDDNSLN
SVYRILSLSYEDLPTDLKHCFLYLAHFPEDYKIKTRTLYSYWAAEGIYDGLTILDSGEDYLEELVRRNLVIAEKSNLSWR
LKLCQMHDMMREVCISKAKVENFLQIIKVPTSTSTIIAQSPSRSRRLTVHSGKAFHILGHKKKVRSLLVLGLKEDLWIQS
ASRFQSLPLLRVLDLSSVKFEGGKLPSSIGGLIHLRFLSLHQAVVSHLPSTIRNLKLMLYLNLHVAIGVPVHVPNVLKEM
LELRYLSLPLDMHDKTKLELGDLVNLEYLWCFSTQHSSVTDLLRMTKLRFFGVSFSERCTFENLSSSLRQFRKLETLSFI
YSRKTYMVDYVGEFVLDFIHLKKLSLGVHLSKIPDQHQLPPHIAHIYLLFCHMEEDPMPILEKLLHLKSVELRRKAFIGR
RMVCSKGGFPQLRALQISEQSELEEWIVEEGSMPCLRDLIIHSCEKLEELPDGLKYVTSLKELKIEGMKREWKEKLVGED
YYKVQHIPDVQFFNCDDEQRE
>Q9FJK8|PF00931(169...418)|Probable disease resistance RPP8-like protein 4
MAEGFVSFGLEKLWDLLSRESERLQGIDEQLDGLKRQLRSLQSLLKDADAKKHGSDRVRNFLEDVKDLVFDAEDIIESYV
LNKLRGEGKGVKKHVRRLARFLTDRHKVASDIEGITKRISDVIGEMQSFGIQQIIDGVRSLSLQERQRVQREIRQTYPDS
SESDLVGVEQSVEELVGHLVENDIYQVVSIAGMGGIGKTTLARQVFHHDLVRRHFDGFAWVCVSQQFTLKHVWQRILQEL
QPHDGNILQMDESALQPKLFQLLETGRYLLVLDDVWKKEDWDRIKAVFPRKRGWKMLLTSRNEGVGIHADPTCLTFRASI
LNPEESWKLCERIVFPRRDETEVRLDEEMEAMGKEMVTHCGGLPLAVKALGGLLANKHTVPEWKRVSDNIGSQIVGGSCL
DDNSLNSVNRILSLSYEDLPTHLKHRFLYLAHFPEDSKIYTQDLFNYWAAEGIYDGSTIQDSGEYYLEELVRRNLVIADN
RYLSLEFNFCQMHDMMREVCLSKAKEENFLQIIKDPTSTSTINAQSPSRSRRFSIHSGKAFHILGHRNNPKVRSLIVSRF
EEDFWIRSASVFHNLTLLRVLDLSRVKFEGGKLPSSIGGLIHLRYLSLYGAVVSHLPSTMRNLKLLLFLNLRVDNKEPIH
VPNVLKEMLELRYLSLPQEMDDKTKLELGDLVNLEYLWYFSTQHSSVTDLLRMTKLRNLGVSLSERCNFETLSSSLRELR
NLEMLNVLFSPEIVMVDHMGEFVLDHFIHLKQLGLAVRMSKIPDQHQFPPHLAHIHLVHCVMKEDPMPILEKLLHLKSVA
LSYGAFIGRRVVCSKGGFPQLCALGISGESELEEWIVEEGSMPCLRTLTIHDCEKLKELPDGLKYITSLKELKIREMKRE
WKEKLVPGGEDYYKVQHIPDVQFINCDL
>Q9FKN7|PF00931(178...379)|Protein DA1-related 4
MEPPAARVTPSIKADCSHSVNIICEETVLHSLVSHLSAALRREGISVFVDACGLQETKFFSIKQNQPLTDGARVLVVVIS
DEVEFYDPWFPKFLKVIQGWQNNGHVVVPVFYGVDSLTRVYGWANSWLEAEKLTSHQSKILSNNVLTDSELVEEIVRDVY
GKLYPAERVGIYARLLEIEKLLYKQHRDIRSIGIWGMPGIGKTTLAKAVFNHMSTDYDASCFIENFDEAFHKEGLHRLLK
ERIGKILKDEFDIESSYIMRPTLHRDKLYDKRILVVLDDVRDSLAAESFLKRLDWFGSGSLIIITSVDKQVFAFCQINQI
YTVQGLNVHEALQLFSQSVFGINEPEQNDRKLSMKVIDYVNGNPLALSIYGRELMGKKSEMETAFFELKHCPPLKIQDVL
KNAYSALSDNEKNIVLDIAFFFKGETVNYVMQLLEESHYFPRLAIDVLVDKCVLTISENTVQMNNLIQDTCQEIFNGEIE
TCTRMWEPSRIRYLLEYDELEGSGETKAMPKSGLVAEHIESIFLDTSNVKFDVKHDAFKNMFNLKFLKIYNSCSKYISGL
NFPKGLDSLPYELRLLHWENYPLQSLPQDFDFGHLVKLSMPYSQLHKLGTRVKDLVMLKRLILSHSLQLVECDILIYAQN
IELIDLQGCTGLQRFPDTSQLQNLRVVNLSGCTEIKCFSGVPPNIEELHLQGTRIREIPIFNATHPPKVKLDRKKLWNLL
ENFSDVEHIDLECVTNLATVTSNNHVMGKLVCLNMKYCSNLRGLPDMVSLESLKVLYLSGCSELEKIMGFPRNLKKLYVG
GTAIRELPQLPNSLEFLNAHGCKHLKSINLDFEQLPRHFIFSNCYRFSSQVIAEFVEKGLVASLARAKQEELIKAPEVII
CIPMDTRQRSSFRLQAGRNAMTDLVPWMQKPISGFSMSVVVSFQDDYHNDVGLRIRCVGTWKTWNNQPDRIVERFFQCWA
PTEAPKVVADHIFVLYDTKMHPSDSEENHISMWAHEVKFEFHTVSGENNPLGASCKVTECGVEVITAATGDTSVSGIIRE
SETITIIEKEDTIIDEEDTPLLSRKPEETNRSRSSSELQKLSSTSSKVRSKGNVFWKWLGCFPLQPKNLRSRSRRTTALE
EALEEALKEREKLEDTRELQIALIESKKIKKIKQADERDQIKHADEREQRKHSKDHEEEEIESNEKEERRHSKDYVIEEL
VLKGKGKRKQLDDDKADEKEQIKHSKDHVEEEVNPPLSKCKDCKSAIEDGISINAYGSVWHPQCFCCLRCREPIAMNEIS
DLRGMYHKPCYKELRHPNCYVCEKKIPRTAEGLKYHEHPFWMETYCPSHDGDGTPKCCSCERLEHCGTQYVMLADFRWLC
RECMDSAIMDSDECQPLHFEIREFFEGLHMKIEEEFPVYLVEKNALNKAEKEEKIDKQGDQCLMVVRGICLSEEQIVTSV
SQGVRRMLNKQILDTVTESQRVVRKCEVTAILILYGLPRLLTGYILAHEMMHAYLRLNGYRNLNMVLEEGLCQVLGYMWL
ECQTYVFDTATIASSSSSSRTPLSTTTSKKVDPSDFEKRLVNFCKHQIETDESPFFGDGFRKVNKMMASNNHSLKDTLKE
IISISKTPQYSKL
>Q9FKZ0|PF00931(182...403)|Probable disease resistance protein At5g66910
MVVVDWLGLGLGSVAGALVSEGLKVLISEAKKVLAFKSVSNELASTMESLLPVIKEIESMQDGMELQDLKDTIDKALLLV
EKCSHVEKWNIILKSKYTRKVEEINRKMLKFCQVQLQLLLFRNQLKSMPSMEAILNNYFQNINKKLDRLSGSPAPPLVSK
RCSVPKLDNMVLVGLDWPLVELKKKLLDNSVVVVSGPPGCGKTTLVTKLCDDPEIEGEFKKIFYSVVSNTPNFRAIVQNL
LQDNGCGAITFDDDSQAETGLRDLLEELTKDGRILLVLDDVWQGSEFLLRKFQIDLPDYKILVTSQFDFTSLWPTYHLVP
LKYEYARSLLIQWASPPLHTSPDEYEDLLQKILKRCNGFPLVIEVVGISLKGQALYLWKGQVESWSEGETILGNANPTVR
QRLQPSFNVLKPHLKECFMDMGSFLQDQKIRASLIIDIWMELYGRGSSSTNKFMLYLNELASQNLLKLVHLGTNKREDGF
YNELLVTQHNILRELAIFQSELEPIMQRKKLNLEIREDNFPDECLNQPINARLLSIYTDDLFSSKWLEMDCPNVEALVLN
ISSLDYALPSFIAEMKKLKVLTIANHGFYPARLSNFSCLSSLPNLKRIRFEKVSVTLLDIPQLQLGSLKKLSFFMCSFGE
VFYDTEDIDVSKALSNLQEIDIDYCYDLDELPYWIPEVVSLKTLSITNCNKLSQLPEAIGNLSRLEVLRMCSCMNLSELP
EATERLSNLRSLDISHCLGLRKLPQEIGKLQKLENISMRKCSGCELPDSVRYLENLEVKCDEVTGLLWERLMPEMRNLRV
HTEETEHNLKLLLTF
>Q9FKZ1|PF00931(176...405)|Probable disease resistance protein At5g66900
MNDWASLGIGSIGEAVFSKLLKVVIDEAKKFKAFKPLSKDLVSTMEILFPLTQKIDSMQKELDFGVKELKELRDTIERAD
VAVRKFPRVKWYEKSKYTRKIERINKDMLKFCQIDLQLLQHRNQLTLLGLTGNLVNSVDGLSKRMDLLSVPAPVFRDLCS
VPKLDKVIVGLDWPLGELKKRLLDDSVVTLVVSAPPGCGKTTLVSRLCDDPDIKGKFKHIFFNVVSNTPNFRVIVQNLLQ
HNGYNALTFENDSQAEVGLRKLLEELKENGPILLVLDDVWRGADSFLQKFQIKLPNYKILVTSRFDFPSFDSNYRLKPLE
DDDARALLIHWASRPCNTSPDEYEDLLQKILKRCNGFPIVIEVVGVSLKGRSLNTWKGQVESWSEGEKILGKPYPTVLEC
LQPSFDALDPNLKECFLDMGSFLEDQKIRASVIIDMWVELYGKGSSILYMYLEDLASQNLLKLVPLGTNEHEDGFYNDFL
VTQHDILRELAICQSEFKENLERKRLNLEILENTFPDWCLNTINASLLSISTDDLFSSKWLEMDCPNVEALVLNLSSSDY
ALPSFISGMKKLKVLTITNHGFYPARLSNFSCLSSLPNLKRIRLEKVSITLLDIPQLQLSSLKKLSLVMCSFGEVFYDTE
DIVVSNALSKLQEIDIDYCYDLDELPYWISEIVSLKTLSITNCNKLSQLPEAIGNLSRLEVLRLCSSMNLSELPEATEGL
SNLRFLDISHCLGLRKLPQEIGKLQNLKKISMRKCSGCELPESVTNLENLEVKCDEETGLLWERLKPKMRNLRVQEEEIE
HNLNLLQMF
>Q9FL92|PF00931(153...362)|Disease resistance protein RRS1B
MTESEQIVYISCIEEVRYSFVSHLSKALQRKGVNDVFIDSDDSLSNESQSMVERARVSVMILPGNRTVSLDKLVKVLDCQ
KNKDQVVVPVLYGVRSSETEWLSALDSKGFSSVHHSRKECSDSQLVKETVRDVYEKLFYMERIGIYSKLLEIEKMINKQP
LDIRCVGIWGMPGIGKTTLAKAVFDQMSGEFDAHCFIEDYTKAIQEKGVYCLLEEQFLKENAGASGTVTKLSLLRDRLNN
KRVLVVLDDVRSPLVVESFLGGFDWFGPKSLIIITSKDKSVFRLCRVNQIYEVQGLNEKEALQLFSLCASIDDMAEQNLH
EVSMKVIKYANGHPLALNLYGRELMGKKRPPEMEIAFLKLKECPPAIFVDAIKSSYDTLNDREKNIFLDIACFFQGENVD
YVMQLLEGCGFFPHVGIDVLVEKSLVTISENRVRMHNLIQDVGRQIINRETRQTKRRSRLWEPCSIKYLLEDKEQNENEE
QKTTFERAQVPEEIEGMFLDTSNLSFDIKHVAFDNMLNLRLFKIYSSNPEVHHVNNFLKGSLSSLPNVLRLLHWENYPLQ
FLPQNFDPIHLVEINMPYSQLKKLWGGTKDLEMLKTIRLCHSQQLVDIDDLLKAQNLEVVDLQGCTRLQSFPATGQLLHL
RVVNLSGCTEIKSFPEIPPNIETLNLQGTGIIELPLSIVKPNYRELLNLLAEIPGLSGVSNLEQSDLKPLTSLMKISTSY
QNPGKLSCLELNDCSRLRSLPNMVNLELLKALDLSGCSELETIQGFPRNLKELYLVGTAVRQVPQLPQSLEFFNAHGCVS
LKSIRLDFKKLPVHYTFSNCFDLSPQVVNDFLVQAMANVIAKHIPRERHVTGFSQKTVQRSSRDSQQELNKTLAFSFCAP
SHANQNSKLDLQPGSSSMTRLDPSWRNTLVGFAMLVQVAFSEGYCDDTDFGISCVCKWKNKEGHSHRREINLHCWALGKA
VERDHTFVFFDVNMRPDTDEGNDPDIWADLVVFEFFPVNKQRKPLNDSCTVTRCGVRLITAVNCNTSIENISPVLSLDPM
EVSGNEDEEVLRVRYAGLQEIYKALFLYIAGLFNDEDVGLVAPLIANIIDMDVSYGLKVLAYRSLIRVSSNGEIVMHYLL
RQMGKEILHTESKKTDKLVDNIQSSMIATKEIEITRSKSRRKNNKEKRVVCVVDRGSRSSDLWVWRKYGQKPIKSSPYPR
SYYRCASSKGCFARKQVERSRTDPNVSVITYISEHNHPFPTLRNTLAGSTRSSSSKCSDVTTSASSTVSQDKEGPDKSHL
PSSPASPPYAAMVVKEEDMEQWDNMEFDVDVEEDTFIPELFPEDTFADMDKLEENSQTMFLSRRSSGGNMEAQGKNSSDD
REVNLPSKILNR
>Q9FLB4|PF00931(160...381)|Putative disease resistance protein At5g05400
MGACFSVAISCDQAVNNLTSCLSRNQNRFRNLVDHVAALKKTVRQLEARRDDLLKRIKVQEDRGLNLLDEVQQWLSEVES
RVCEAHDILSQSDEEIDNLCCGQYCSKRCKYSYDYSKSVINKLQDVENLLSKGVFDEVAQKGPIPKVEERLFHQEIVGQE
AIVESTWNSMMEVGVGLLGIYGMGGVGKTTLLSQINNKFRTVSNDFDIAIWVVVSKNPTVKRIQEDIGKRLDLYNEGWEQ
KTENEIASTIKRSLENKKYMLLLDDMWTKVDLANIGIPVPKRNGSKIAFTSRSNEVCGKMGVDKEIEVTCLMWDDAWDLF
TRNMKETLESHPKIPEVAKSIARKCNGLPLALNVIGETMARKKSIEEWHDAVGVFSGIEADILSILKFSYDDLKCEKTKS
CFLFSALFPEDYEIGKDDLIEYWVGQGIILGSKGINYKGYTIIGTLTRAYLLKESETKEKVKMHDVVREMALWISSGCGD
QKQKNVLVVEANAQLRDIPKIEDQKAVRRMSLIYNQIEEACESLHCPKLETLLLRDNRLRKISREFLSHVPILMVLDLSL
NPNLIELPSFSPLYSLRFLNLSCTGITSLPDGLYALRNLLYLNLEHTYMLKRIYEIHDLPNLEVLKLYASGIDITDKLVR
QIQAMKHLYLLTITLRNSSGLEIFLGDTRFSSYTEGLTLDEQSYYQSLKVPLATISSSRFLEIQDSHIPKIEIEGSSSNE
SEIVGPRVRRDISFINLRKVRLDNCTGLKDLTWLVFAPHLATLYVVCLPDIEHIISRSEESRLQKTCELAGVIPFRELEF
LTLRNLGQLKSIYRDPLLFGKLKEINIKSCPKLTKLPLDSRSAWKQNVVINAEEEWLQGLQWEDVATKERFFPS
>Q9FT77|PF00931(185...407)|Disease resistance protein RLM3
MKSSSSQSYDVFPNFRGEDVRHSLVSHLRKELDRKFINTFNDNRIERSRKITPELLLAIENSRISLVVFSKNYASSTWCL
DELVKIQECYEKLDQMVIPIFYKVDPSHVRKQTGEFGMVFGETCKGRTENEKRKWMRALAEVAHLAGEDLRNWRSEAEML
ENIAKDVSNKLFPPSNNFSDFVGIEAHIEALISMLRFDSKKARMIGICGPSETGKTTIGRALYSRLKSDFHHRAFVAYKR
KIRSDYDQKLYWEEQFLSEILCQKDIKIEECGAVEQRLKHTKVLIVLDDVDDIELLKTLVGRIRWFGSESKIVVITQKRE
LLKAHNIAHVYEVGFPSEELAHQMFCRYAFGKNSPPHGFNELADEAAKIAGNRPKALKYVGSSFRRLDKEQWVKMLSEFR
SNGNKLKISYDELDGKGQDYVACLTNGSNSQVKAEWIHLALGVSILLNIRSDGTTILKHLSYNRSMAQQAKIWWYENLER
VCKKYNICGIDSSTDGGGSTYGQCSNSQFQRNMDASPGGNKTSNQSTKDSPRASQVEKEKIEYCEPHVYITPAIFSDGTR
APKYVESSSRRVTQVHHAKTWWPENCEKVYENHNNIYGIDRSIDGGDKFEGKSKVSDGGLDGKDQGSMYGQSSNSELQIN
MDADNRRCEPVSEMLFKNYNVCSPNGLTDVNCSNPQSQRKLDASLKKDKIVHEWIRTGSGFFFDFQGPKSIVSAAQVDEK
NFEYCEQGVYITLGILSGGIIVLKHLEFSRRMAQQAKVWWSENWIKVYQEHNICGIDKSFDGRFDDRRVIRQLRPN
>Q9FW44|PF00931(232...365)|Disease resistance protein ADR1
MASFIDLFAGDITTQLLKLLALVANTVYSCKGIAERLITMIRDVQPTIREIQYSGAELSNHHQTQLGVFYEILEKARKLC
EKVLRCNRWNLKHVYHANKMKDLEKQISRFLNSQILLFVLAEVCHLRVNGDRIERNMDRLLTERNDSLSFPETMMEIETV
SDPEIQTVLELGKKKVKEMMFKFTDTHLFGISGMSGSGKTTLAIELSKDDDVRGLFKNKVLFLTVSRSPNFENLESCIRE
FLYDGVHQRKLVILDDVWTRESLDRLMSKIRGSTTLVVSRSKLADPRTTYNVELLKKDEAMSLLCLCAFEQKSPPSPFNK
YLVKQVVDECKGLPLSLKVLGASLKNKPERYWEGVVKRLLRGEAADETHESRVFAHMEESLENLDPKIRDCFLDMGAFPE
DKKIPLDLLTSVWVERHDIDEETAFSFVLRLADKNLLTIVNNPRFGDVHIGYYDVFVTQHDVLRDLALHMSNRVDVNRRE
RLLMPKTEPVLPREWEKNKDEPFDAKIVSLHTGEMDEMNWFDMDLPKAEVLILNFSSDNYVLPPFIGKMSRLRVLVIINN
GMSPARLHGFSIFANLAKLRSLWLKRVHVPELTSCTIPLKNLHKIHLIFCKVKNSFVQTSFDISKIFPSLSDLTIDHCDD
LLELKSIFGITSLNSLSITNCPRILELPKNLSNVQSLERLRLYACPELISLPVEVCELPCLKYVDISQCVSLVSLPEKFG
KLGSLEKIDMRECSLLGLPSSVAALVSLRHVICDEETSSMWEMVKKVVPELCIEVAKKCFTVDWLDD
>Q9I9H8|PF00931(137...374)|Apoptotic protease-activating factor 1
MEERARSRLLRSKATLEQDIKASYLMDHMISDGVLTNDEEAKVLSKATRKEQAVALLETLLRKDNRAYISFYNALIRESY
GDLASLLHSDLPLLSPEGEKSFADGVSPSVQAILSVGGVPQRPVVFVSRPPLLNLIREMLYQLRDTPGWVTVFGMAGSGK
SVMAAEVVRDRSLIKECFPDGVHWLSVGQCERADLLVRMQSLCFRLEQCQSSDTSQRPPSTVEEAKERLRFLMLRRFPRS
LLILDDVWDSSSLRSFDIQCRVLLTTRNRALTDSVSGVRYEVPVENGLDEEKALEILALYVNGKMHKLPEQARSIVSECK
GSPLVVSLIGALLREFPDRWSYYLRQLQQKQFKRIRKSSSYDYEALDQAMDASLQVLEAEHQELYRDLSVMQKDIKVPAK
VLSVLWGLELEEVEDVLQEFVNKSLLFRDCNQRPYRYYLHDLQLDFLAEQNRDQIAELHKKMVRQYQRFYSKRPPDSADK
DSLYWYQFIPYHMAKAGLSKELYSLMFSLDWVKEKARIMGSAHLINDYVEYGEILDKENSEVRVQFQEFLSLNGHHLEQR
PFPDVVQLALSQPDRSEVYRQALMQAQKRASRGQIYLNWVNKNIEEGLSRLVMHPHQGAVYYACFSKDGSKIASCGASKA
LRVFKSTSGEKLLELQAHEEDVLCCAFSPDDRHIATCASDRKVKLWNVERGVLIREFEVEHEEQINHCQFTNTGRRVLLA
TCSNDKFTNTRLWNPNKKTSQNTMFGHMEPVNHCCFSPNDLYLATSSSDGSLKLFEVSSANEWKSIDVDSFFPESDEEIK
AMVKCSTWSADGSQIICAARNTVFVFDVETSDLLLKLKTSRLSTIQFCHACPNSSLLAVALSHYTVELWNFESSKKKAEC
SGHLSWVHCVQFSPDGSLLLSSSDDQTIRLWETDRVHTSSAVALKRDTDVLSSHSDATIIAPDSSNRLQVLSGSTGAVVL
ESEELSSRIRCSCISRNAAFVALGSEDGTVQVIEVPSSKASVKLSGHTKTVHHCQFTDDCEILITSSEDSTIRVWKWRTG
ECMVLQGHMEPVRKFHLLSSSSSPHLFSWSFDGTVKVWDLTRGQMLQDLVCHEGAVLSCDVSSDGRLFATTSANRTAKVW
SSASWKMLFLLEGHKDCVRSCRFSWDNKRLATGDDNGEIRLWSMLDGALLKICPRDTKDSMNSYHAGWVTDLHFSPDNRV
LVSTAGYIKWWSVESGEALQTFYTMGGNLKKIHVSPDFSTFITVDSIGILYILKRLEGEGT
>Q9LMP6|PF00931(159...399)|Probable disease resistance protein At1g15890
MGNCVALEISCDQTLNHACGCLFGDRNYILKMEANLEALQNTMQELEERRDDLLRRVVIEEDKGLQRLAQVQGWLSRVKD
VCSQVNDLLKAKSIQTERLCLCGYCSKNFISGRNYGINVLKKLKHVEGLLAKGVFEVVAEKIPAPKVEKKHIQTTVGLDA
MVGRAWNSLMKDERRTLGLYGMGGVGKTTLLASINNKFLEGMNGFDLVIWVVVSKDLQNEGIQEQILGRLGLHRGWKQVT
EKEKASYICNILNVKKFVLLLDDLWSEVDLEKIGVPPLTRENGSKIVFTTRSKDVCRDMEVDGEMKVDCLPPDEAWELFQ
KKVGPIPLQSHEDIPTLARKVAEKCCGLPLALSVIGKAMASRETVQEWQHVIHVLNSSSHEFPSMEEKILPVLKFSYDDL
KDEKVKLCFLYCSLFPEDYEVRKEELIEYWMCEGFIDGNEDEDGANNKGHDIIGSLVRAHLLMDGELTTKVKMHDVIREM
ALWIASNFGKQKETLCVKPGVQLCHIPKDINWESLRRMSLMCNQIANISSSSNSPNLSTLLLQNNKLVHISCDFFRFMPA
LVVLDLSRNSSLSSLPEAISKLGSLQYINLSTTGIKWLPVSFKELKKLIHLNLEFTDELESIVGIATSLPNLQVLKLFSS
RVCIDGSLMEELLLLEHLKVLTATIKDALILESIQGVDRLVSSIQALCLRNMSAPVIILNTVALGGLQHLEIVGSKISEI
KIDWERKGRGELKCTSSPGFKHLSVVEIFNLEGPRDLTWLLFAQNLRRLSVTLSLTIEEIINKEKGMSITNVHPNIVVPF
GKLEFLEVRGLDELKRICWNPPALPNLRQFDVRSCLKLPEAATEFPRHANE
>Q9LQ54|PF00931(143...392)|Probable disease resistance protein At1g59620
MAETLLSFGVEKLWDLLVRESDRFQGVKKQFNELRSDLNKLRCFLEDADAKKHQSAMVSNTVKEVKEIVYDTEDIIETFL
RKKQLGRTRGMKKRIKEFACVLPDRRKIAIDMEGLSKRIAKKDKRNMRQTFSNNNESVLVGLEENVKKLVGHLVEVEDSS
QVVSITGMGGIGKTTLARQVFNHETVKSHFAQLAWVCVSQQFTRKYVWQTILRKVGPEYIKLEMTEDELQEKLFRLLGTR
KALIVLDDIWREEDWDMIEPIFPLGKGWKVLLTSRNEGVALRANPNGFIFKPDCLTPEESWTIFRRIVFPGENTTEYKVD
EKMEELGKQMIKHCGGLPLALKVLGGLLVVHFTLDEWKRIYGNIKSHIVGGTSFNDKNMSSVYHILHLSFEELPIYLKHC
FLYLAQFPEDFTIDLEKLSYYWAAEGMPRPRYYDGATIRKVGDGYIEELVKRNMVISERDARTRRFETCHLHDIVREVCL
KAEEENLIETENSKSPSKPRRLVVKGGDKTDMEGKLKNPKLRSLLFIEELGGYRGFEVWFTRLQLMRVLDLHGVEFGGEL
PSSIGLLIHLRYLSLYRAKASHLPSSMQNLKMLLYLNLCVQESCYIYIPNFLKEMLELKYLSLPLRMDDKVKLELGNLVN
LEKLENFSTEHGGVGDLQFMTRLRALSIYIRGRLNMKTLSSSLSKLRDLENLTICYYPMYAPMSGIEGLVLDCDQLKHLN
LRIYMPRLPDEQHFPWHLRNISLAECCLKEDPMPILEKLLQLNEVSLSHQSFCGKRMVCSDGGFPQLQKLDLCGLEEWEE
WIVEEGSMPRLHKLTIRNDPKLKELPDGLKFITSLKEVHVILNNWDFKKKLSRGGEDYYKVQHIPLVRFL
>Q9LRR4|PF00931(176...398)|Putative disease resistance RPP13-like protein 1
MTGIGEMFLAAFLQALFQTLVSEPFRSFFKRRELNENLLERLSTALLTITAVLIDAEEKQITNPVVEKWVNELRDVVYHA
EDALDDIATEALRLNIGAESSSSNRLRQLRGRMSLGDFLDGNSEHLETRLEKVTIRLERLASQRNILGLKELTAMIPKQR
LPTTSLVDESEVFGRDDDKDEIMRFLIPENGKDNGITVVAIVGIGGVGKTTLSQLLYNDQHVRSYFGTKVWAHVSEEFDV
FKITKKVYESVTSRPCEFTDLDVLQVKLKERLTGTGLPFLLVLDDLWNENFADWDLLRQPFIHAAQGSQILVTTRSQRVA
SIMCAVHVHNLQPLSDGDCWSLFMKTVFGNQEPCLNREIGDLAERIVHKCRGLPLAVKTLGGVLRFEGKVIEWERVLSSR
IWDLPADKSNLLPVLRVSYYYLPAHLKRCFAYCSIFPKGHAFEKDKVVLLWMAEGFLQQTRSSKNLEELGNEYFSELESR
SLLQKTKTRYIMHDFINELAQFASGEFSSKFEDGCKLQVSERTRYLSYLRDNYAEPMEFEALREVKFLRTFLPLSLTNSS
RSCCLDQMVSEKLLPTLTRLRVLSLSHYKIARLPPDFFKNISHARFLDLSRTELEKLPKSLCYMYNLQTLLLSYCSSLKE
LPTDISNLINLRYLDLIGTKLRQMPRRFGRLKSLQTLTTFFVSASDGSRISELGGLHDLHGKLKIVELQRVVDVADAAEA
NLNSKKHLREIDFVWRTGSSSSENNTNPHRTQNEAEVFEKLRPHRHIEKLAIERYKGRRFPDWLSDPSFSRIVCIRLREC
QYCTSLPSLGQLPCLKELHISGMVGLQSIGRKFYFSDQQLRDQDQQPFRSLETLRFDNLPDWQEWLDVRVTRGDLFPSLK
KLFILRCPELTGTLPTFLPSLISLHIYKCGLLDFQPDHHEYSYRNLQTLSIKSSCDTLVKFPLNHFANLDKLEVDQCTSL
YSLELSNEHLRGPNALRNLRINDCQNLQLLPKLNALPQNLQVTITNCRYLRQPMEQQPQYHHPQFHLPRSNVSGSPKSHG
SHRSYDSRSSSRYD
>Q9LRR5|PF00931(194...421)|Putative disease resistance protein At3g14460
MANSYLSSCANVMVERINTSQELVELCKGKSSSALLKRLKVALVTANPVLADADQRAEHVREVKHWLTGIKDAFFQAEDI
LDELQTEALRRRVVAEAGGLGGLFQNLMAGREAIQKKIEPKMEKVVRLLEHHVKHIEVIGLKEYSETREPQWRQASRSRP
DDLPQGRLVGRVEDKLALVNLLLSDDEISIGKPAVISVVGMPGVGKTTLTEIVFNDYRVTEHFEVKMWISAGINFNVFTV
TKAVLQDITSSAVNTEDLPSLQIQLKKTLSGKRFLLVLDDFWSESDSEWESFQVAFTDAEEGSKIVLTTRSEIVSTVAKA
EKIYQMKLMTNEECWELISRFAFGNISVGSINQELEGIGKRIAEQCKGLPLAARAIASHLRSKPNPDDWYAVSKNFSSYT
NSILPVLKLSYDSLPPQLKRCFALCSIFPKGHVFDREELVLLWMAIDLLYQPRSSRRLEDIGNDYLGDLVAQSFFQRLDI
TMTSFVMHDLMNDLAKAVSGDFCFRLEDDNIPEIPSTTRHFSFSRSQCDASVAFRSICGAEFLRTILPFNSPTSLESLQL
TEKVLNPLLNALSGLRILSLSHYQITNLPKSLKGLKLLRYLDLSSTKIKELPEFVCTLCNLQTLLLSNCRDLTSLPKSIA
ELINLRLLDLVGTPLVEMPPGIKKLRSLQKLSNFVIGRLSGAGLHELKELSHLRGTLRISELQNVAFASEAKDAGLKRKP
FLDGLILKWTVKGSGFVPGSFNALACDQKEVLRMLEPHPHLKTFCIESYQGGAFPKWLGDSSFFGITSVTLSSCNLCISL
PPVGQLPSLKYLSIEKFNILQKVGLDFFFGENNSRGVPFQSLQILKFYGMPRWDEWICPELEDGIFPCLQKLIIQRCPSL
RKKFPEGLPSSTEVTISDCPLRAVSGGENSFRRSLTNIPESPASIPSMSRRELSSPTGNPKSDASTSAQPGFASSSQSND
DNEVTSTSSLSSLPKDRQTEDFDQYETQLGSLPQQFEEPAVISARYSGYISDIPSTLSPYMSRTSLVPDPKNEGSILPGS
SSYQYHQYGIKSSVPSPRSSEAIKPSQYDDDETDMEYLKVTDISHLMELPQNLQSLHIDSCDGLTSLPENLTESYPNLHE
LLIIACHSLESFPGSHPPTTLKTLYIRDCKKLNFTESLQPTRSYSQLEYLFIGSSCSNLVNFPLSLFPKLRSLSIRDCES
FKTFSIHAGLGDDRIALESLEIRDCPNLETFPQGGLPTPKLSSMLLSNCKKLQALPEKLFGLTSLLSLFIIKCPEIETIP
GGGFPSNLRTLCISLCDKLTPRIEWGLRDLENLRNLEIDGGNEDIESFPEEGLLPKSVFSLRISRFENLKTLNRKGFHDT
KAIETMEISGCDKLQISIDEDLPPLSCLRISSCSLLTETFAEVETEFFKVLNIPYVEIDGEIFS
>Q9LUJ8|PF00931(188...401)|Disease resistance protein CHL1
MSSASSSSAASLLLGREVDVFLSFCCQTSHGYFQNILIRNGIRTFLSYRCLEKRFGPIGQRTLKALEESRVAVVMTSTTK
PCSVGFLEELLVILEFQEKGSLMVIPIFLTDLSFNVEEICRQHPEKAPSWRTALTKLTNLAAEYPLSQNLAGMDQSDLLN
QIARDISLVVFYSGSNDSNALVAMDRHMKVVYDLLALEVNKEVRTIGIWGSAGVGKTTLARYIYAEIFVNFQTHVFLDNV
ENMKDKLLKFEGEEDPTVIISSYHDGHEITEARRKHRKILLIADDVNNMEQGKWIIEYANWFAPGSRVILISQNKNLLVD
AGVMDVYEVRSLRYDEALQVFSHFAFKQPYPPSDFEELAVRAVHLAGFLPLGLRLLGSFLAGKGREEWVAALLKLKAKQG
GHIMEVWKLMEATDDKGLEEWETAADIVERKESSQDKSQQESEVAADILIGKESSQDKQ
>Q9LVT1|PF00931(6...196)|Putative disease resistance protein At5g47280
MLFNLNDEARIIGISGMIGSGKTILAKELARDEEVRGHFANRVLFLTVSQSPNLEELRSLIRDFLTGHEAGFGTALPESV
GHTRKLVILDDVRTRESLDQLMFNIPGTTTLVVSQSKLVDPRTTYDVELLNEHDATSLFCLSAFNQKSVPSGFSKSLVKQ
VVGESKGLPLSLKVLGASLNDRPETYWAIAVERLSRGEPVDETHESKVFAQIEATLENLDPKTKECFLDMGAFPEGKKIP
VDVLINMLVKIHDLEDAAAFDVLVDLANRNLLTLVKDPTFVAMGTSYYDIFVTQHDVLRDVALHLTNRGKVSRRDRLLMP
KRETMLPSEWERSNDEPYNARVVSIHTGEMTEMDWFDMDFPKAEVLIVNFSSDNYVLPPFIAKMGMLRVFVIINNGTSPA
HLHDFPIPTSLTNLRSLWLERVHVPELSSSMIPLKNLHKLYLIICKINNSFDQTAIDIAQIFPKLTDITIDYCDDLAELP
STICGITSLNSISITNCPNIKELPKNISKLQALQLLRLYACPELKSLPVEICELPRLVYVDISHCLSLSSLPEKIGNVRT
LEKIDMRECSLSSIPSSAVSLTSLCYVTCYREALWMWKEVEKAVPGLRIEATEKWFNMTWPDE
>Q9LVT3|PF00931(155...390)|Probable disease resistance protein At5g47260
MGNNFSVESPSLAPFLCGKRKYLYNLERNLEALHKVMQDLNAMRNDLLKRLSKEEEIGLQGLQEVKEWISMVEEIEPKAN
RLLDESVSEIQRLSRYGYCSLIPASTYRYSEKVLTTMEGVETLRSKGVFEAVVHRALPPLVIKMPPIQLTVSQAKLLDTA
WARLMDINVGTLGIYGRGGVGKTTLLTKLRNKLLVDAFGLVIFVVVGFEEVESIQDEIGKRLGLQWRRETKERKAAEILA
VLKEKRFVLLLDGIQRELDLEEIGVPFPSRDNGCKIVFTTQSLEACDESKWVDAKVEITCLSPEEAWDLFQETVGENTLR
SHQDIPKLARVVASTCRGLPLALNLIGEAMSGKRTVREWRYTIHVLASSTAEFPDMEDGTLPILKSIYDNMSDEIIRLCF
LYCALFPENLDIGKEDLVNYWICEGILAKEDREEAEIQGYEIICDLVRMRLLMESGNGNCVKMHGMVREMALWIASEHFV
VVGGERIHQMLNVNDWRMIRRMSVTSTQIQNISDSPQCSELTTLVFRRNRHLKWISGAFFQWMTGLVVLDLSFNRELAEL
PEEVSSLVLLRFLNLSWTCIKGLPLGLKELKSLIHLDLDYTSNLQEVDVIASLLNLQVLRLFHSVSMDLKLMEDIQLLKS
LKELSLTVRGSSVLQRLLSIQRLASSIRRLHLTETTIVDGGILSLNAIFSLCELDILGCNILEITIDWRCTIQREIIPQF
QNIRTMTIHRCEYLRDLTWLLLAPCLGELSVSECPQMEEVISKDKAMAKLGNTSEQPFQNLTKLVLDGLPKLESIYWTPL
PFPVLEYLVIRRCPELRRLPFNSESTIGNQVETIIEEQVIKIVEWEDEATKQRFSHFNNRDFVQMAEDPKMDGLTSESHP
IQTIDLVGTTGSGETATANNIQGKKVVQSGTHATVVTMECQTYKVFTPDCPINNMIDTPGTNFLLCYT
>Q9LVT4|PF00931(161...398)|Probable disease resistance protein At5g47250
MNCCWQVVEPCYKSALSYLCVKVGNICMLKENLVLLKSAFDELKAEKEDVVNRVNAGELKGGQRLAIVATWLSQVEIIEE
NTKQLMDVASARDASSQNASAVRRRLSTSGCWFSTCNLGEKVFKKLTEVKSLSGKDFQEVTEQPPPPVVEVRLCQQTVGL
DTTLEKTWESLRKDENRMLGIFGMGGVGKTTLLTLINNKFVEVSDDYDVVIWVESSKDADVGKIQDAIGERLHICDNNWS
TYSRGKKASEISRVLRDMKPRFVLLLDDLWEDVSLTAIGIPVLGKKYKVVFTTRSKDVCSVMRANEDIEVQCLSENDAWD
LFDMKVHCDGLNEISDIAKKIVAKCCGLPLALEVIRKTMASKSTVIQWRRALDTLESYRSEMKGTEKGIFQVLKLSYDYL
KTKNAKCFLYCALFPKAYYIKQDELVEYWIGEGFIDEKDGRERAKDRGYEIIDNLVGAGLLLESNKKVYMHDMIRDMALW
IVSEFRDGERYVVKTDAGLSQLPDVTDWTTVTKMSLFNNEIKNIPDDPEFPDQTNLVTLFLQNNRLVDIVGKFFLVMSTL
VVLDLSWNFQITELPKGISALVSLRLLNLSGTSIKHLPEGLGVLSKLIHLNLESTSNLRSVGLISELQKLQVLRFYGSAA
ALDCCLLKILEQLKGLQLLTVTVNNDSVLEEFLGSTRLAGMTQGIYLEGLKVSFAAIGTLSSLHKLEMVNCDITESGTEW
EGKRRDQYSPSTSSSEITPSNPWFKDLSAVVINSCIHLKDLTWLMYAANLESLSVESSPKMTELINKEKAQGVGVDPFQE
LQVLRLHYLKELGSIYGSQVSFPKLKLNKVDIENCPNLHQRPL
>Q9LW09|PF00931(157...364)|Putative disease resistance protein At3g15700
MGKDFKSMVTRCIYVGKENDNVKKLKTATEELKDLRNIVMKRVKMYEDQQKLKRLEKVQVWLRQADVAIKEAEEMLITLM
SSSSSNGSSMMSFHKLDKKLCKKLKEVQEIKSRGTFDVVVENSGIGSGSMMISNVDRDDQTVGLEAVSGLVWRCMTVDNT
GIIGLYGVEGVGKTTVLTQVNNRLLQHKLNGFDFVIWVFVSKNVNLEKIQDTIREKIGFLDRSWMSKTEEEKAGKIFEIL
SKRRFALFLDDVWEKVDLVKAGVPPPDGLNRSKIVFTTCSDEVCQEMGAQTKIKMEKLPWERAWDLFKMNAGEEIVKSHP
DITKVAQEVAAKCDGLPLALVTIGRAMASKKTPQEWRDALYILSTSPPNFSGPIL
>Q9LZ25|PF00931(186...384)|Probable disease resistance protein At5g04720
MADIIGGEVVTELVRQLYAVSQKTLRCRGIAKNLATMIDGLQPTIKEIQYSGVELTPHRQAQLRMFSETLDKCRKLTEKV
LKSSRWNMVRQLLHVRKMENLQSKVSSFLNGQLLVHVLADVHHVRADSEFRFDRIDRKVDSLNEKLGSMKLRGSESLREA
LKTAEATVEMVTTDGADLGVGLDLGKRKVKEMLFKSIDGERLIGISGMSGSGKTTLAKELARDEEVRGHFGNKVLFLTVS
QSPNLEELRAHIWGFLTSYEAGVGATLPESRKLVILDDVWTRESLDQLMFENIPGTTTLVVSRSKLADSRVTYDVELLNE
HEATALFCLSVFNQKLVPSGFSQSLVKQVVGECKGLPLSLKVIGASLKERPEKYWEGAVERLSRGEPADETHESRVFAQI
EATLENLDPKTRDCFLVLGAFPEDKKIPLDVLINVLVELHDLEDATAFAVIVDLANRNLLTLVKDPRFGHMYTSYYDIFV
TQHDVLRDVALRLSNHGKVNNRERLLMPKRESMLPREWERNNDEPYKARVVSIHTGEMTQMDWFDMELPKAEVLILHFSS
DKYVLPPFIAKMGKLTALVIINNGMSPARLHDFSIFTNLAKLKSLWLQRVHVPELSSSTVPLQNLHKLSLIFCKINTSLD
QTELDIAQIFPKLSDLTIDHCDDLLELPSTICGITSLNSISITNCPRIKELPKNLSKLKALQLLRLYACHELNSLPVEIC
ELPRLKYVDISQCVSLSSLPEKIGKVKTLEKIDTRECSLSSIPNSVVLLTSLRHVICDREALWMWEKVQKAVAGLRVEAA
EKSFSRDWLDD
>Q9M667|PF00931(170...394)|Disease resistance protein RPP13
MVDAITEFVVGKIGNYLIEEASMFMAVKEDLEELKTELTCIHGYLKDVEAREREDEVSKEWSKLVLDFAYDVEDVLDTYH
LKLEERSQRRGLRRLTNKIGRKMDAYSIVDDIRILKRRILDITRKRETYGIGGLKEPQGGGNTSSLRVRQLRRARSVDQE
EVVVGLEDDAKILLEKLLDYEEKNRFIISIFGMGGLGKTALARKLYNSRDVKERFEYRAWTYVSQEYKTGDILMRIIRSL
GMTSGEELEKIRKFAEEELEVYLYGLLEGKKYLVVVDDIWEREAWDSLKRALPCNHEGSRVIITTRIKAVAEGVDGRFYA
HKLRFLTFEESWELFEQRAFRNIQRKDEDLLKTGKEMVQKCRGLPLCIVVLAGLLSRKTPSEWNDVCNSLWRRLKDDSIH
VAPIVFDLSFKELRHESKLCFLYLSIFPEDYEIDLEKLIHLLVAEGFIQGDEEMMMEDVARYYIEELIDRSLLEAVRRER
GKVMSCRIHDLLRDVAIKKSKELNFVNVYNDHVAQHSSTTCRREVVHHQFKRYSSEKRKNKRMRSFLYFGEFDHLVGLDF
ETLKLLRVLDFGSLWLPFKINGDLIHLRYLGIDGNSINDFDIAAIISKLRFLQTLFVSDNYFIEETIDLRKLTSLRHVIG
NFFGGLLIGDVANLQTLTSISFDSWNKLKPELLINLRDLGISEMSRSKERRVHVSWASLTKLESLRVLKLATPTEVHLSL
ESEEAVRSMDVISRSLESVTLVGITFEEDPMPFLQKMPRLEDLILLSCNYSGKMSVSEQGFGRLRKLDLLMRSLDELQIE
EEAMPNLIELEISVSKRETKLIIPNRLRAFGQIYC
>Q9S0Y6|PF00931(303...500)|Regulatory protein AfsR
MDRDNGPRVRVPEQRTPSIPATADALRFTVLGPVRAWRGSELLSSGSPQQRALLTALLLREGRTATAGELIDAFWGEDPP
SQALATIRTYASRLRKILGQDTLVSESGGYAIRTERSALDLTLAQDLAAEAEKARAAGDRCQARTLINKVLGLWDGEALA
SVPGPYADNQRTRLEEWRLQLTETRLDLDLEVGCHAEAVSELTALTAAHPLRERLRELLMVALYRSGRQAEALAVYADTR
RLLAEELGVDPRPELAELQQRILRADEELARPADEPAPAPAPLKPAQLPATVPDFTGRSAFVTELGSRLATAEGSVMAVS
AVAGIGGVGKTTLAVHVAHQARRHFPDGQLYVDLQGAGARAAEPETVLGSFLRALGTADSAIPDTLDERAALYRSTLDGR
RILILLDNAHDAAQIRPLLPGTPGCAALVTSRVRMVDLAGAHLVDLDVMSPEEALQLFTRIVGAERVGAEREAALDVVAA
CGFLPLAIRIAASRLAARRTWTVSVLAAKLADERRRLDELQAGDLTVKATFELGYGQLEPAQAHAFRLLGLADGPDISLA
AAAALLDLDPHVAEDLLEALVDTSLVESAAPGRYRYHDLVRLYARACAERDEQPPVRRELALSRLLDFYLATAAGVYALE
RPGERVLDHFTPTEYPGLTFPAREAALDWLFTESSGLLACARQSAAIGMPQRAADLLMAVVDLGESGANSHQFATAAKAV
SEAAKAAGVPRAEARARTMLSHVHSVSGRFAEAEAEAMRALDLGRLAQDAVSQGQAPNQRGIIALYENRHDDAEAHLTQA
LTAFRADGNKPGEAAALCNLSRVHLATGRTATAVRLAEEGVAIYDSDASGLALIGSGRTDPARHVLLEALQIFRESRQQL
WHGMTLFRLSELHLTEQEGAQAAAHAEQSLVVLRGIGGDWRRANVLTVLGRALTVIGQTDRAQVCWGEALTVFEELGSPE
AEAVRQLLDPAGVG
>Q9SCX6|PF00931(211...449)|Disease resistance protein RPS4
METSSISTVEDKPPQHQVFINFRGADLRRRFVSHLVTALKLNNINVFIDDYEDRGQPLDVLLKRIEESKIVLAIFSGNYT
ESVWCVRELEKIKDCTDEGTLVAIPIFYKLEPSTVRDLKGKFGDRFRSMAKGDERKKKWKEAFNLIPNIMGIIIDKKSVE
SEKVNEIVKAVKTALTGIPPEGSHNAVVGALGNSNAGTSSGDKKHETFGNEQRLKDLEEKLDRDKYKGTRIIGVVGMPGI
GKTTLLKELYKTWQGKFSRHALIDQIRVKSKHLELDRLPQMLLGELSKLNNPHVDNLKDPYSQLHERKVLVVLDDVSKRE
QIDALREILDWIKEGKEGSRVVIATSDMSLTNGLVDDTYMVQNLNHRDSLQLFHYHAFIDDQANPQKKDFMKLSEGFVHY
ARGHPLALKVLGGELNKKSMDHWNSKMKKLAQSPSPNIVSVFQVSYDELTTAQKDAFLDIACFRSQDKDYVESLLASSDL
GSAEAMSAVKSLTDKFLINTCDGRVEMHDLLYKFSREVDLKASNQDGSRQRRLWLHQHIIKGGIINVLQNKMKAANVRGI
FLDLSEVEDETSLDRDHFINMGNLRYLKFYNSHCPQECKTNNKINIPDKLKLPLKEVRCLHWLKFPLETLPNDFNPINLV
DLKLPYSETEQLWEGDKDTPCLRWVDLNHSSKLCSLSGLSKAEKLQRLNLEGCTTLKAFPHDMKKMKMLAFLNLKGCTSL
ESLPEMNLISLKTLTLSGCSTFKEFPLISDNIETLYLDGTAISQLPMNMEKLQRLVVLNMKDCKMLEEIPGRVGELKALQ
ELILSDCLNLKIFPEIDISFLNILLLDGTAIEVMPQLPSVQYLCLSRNAKISCLPVGISQLSQLKWLDLKYCTSLTSVPE
FPPNLQCLDAHGCSSLKTVSKPLARIMPTEQNHSTFIFTNCENLEQAAKEEITSYAQRKCQLLSYARKRYNGGLVSESLF
STCFPGCEVPSWFCHETVGSELEVKLLPHWHDKKLAGIALCAVISCLDPQDQVSRLSVTCTFKVKDEDKSWVPYTCPVGS
WTRHGGGKDKIELDHVFIGYTSCPHTIKCHEEGNSDECNPTEASLKFTVTGGTSENGKYKVFKCGLSLVYAKDKDKNSAL
ETKYDMLIGKSFQETSEGVDGRVKKTKGKYVMPVEKNFQETTEGVDGRVKKKKKTRMDNGRPKKKQRSGRDDNQTRMQVE
LQEGNINSVIMHTVKNF
>Q9SCX7|PF00931(211...449)|Inactive disease resistance protein RPS4
METSSISTVEDKPPQHQVFINFRGADLRRRFVSHLVTALKLNNINVFIDDYEDRGQPLDVLLKRIEESKIVLAIFSGNYT
ESVWCVRELEKIKDCTDEGTLVAIPIFYKLEPSTVRDLKGKFGDRFRSMAKGDERKKKWKEAFNLIPNIMGIIIDKKSVE
SEKVNEIVKAVKTALTGIPPEGSHNAVVGALGNSDAGTSSGDKKHETFGNEQRLKDLEEKLDRDKYKGTRIIGVVGMPGI
GKTTLLKELYKTWQGKFSRHALIDQIRVKSKHLELDRLPQMLLGELSKLNNPHVDNLKDPYSQLHERKVLVVLDDVSKRE
QIDALREILDWIKEGKEGSRVVIATSDMSLTNGLVDDTYMVQNLNHRDSLQLFHYHAFIDDQANPQKKDFMKLSEGFVHY
ARGHPLALKVLGGELNKKSMDHWNSKMKKLAQSPSPNIVSVFQVSYDELTTAQKDAFLDIACFRSQDKDYVESLLASSDL
GSAEAMSAVKSLTDKFLINTCDGRVEMHDLLYKFSREVDLKASNQDGSRQRRLWLHQHIIKGGIINVLQNKMKAANVRGI
FLDLSEVEDETSLDRDHFINMGNLRYLKFYNSHCPQECKTNNKINIPDKLKLPLKEVRCLHWLKFPLETLPNDFNPINLV
DLKLPYSEMEQLWEGDKDTPCLRWVDLNHSSKLCSLSGLSKAEKLQRLNLEGCTTLKAFPHDMKKMKMLAFLNLKGCTSL
ESLPEMNLISLKTLTLSGCSTFKEFPLISDNIETLYLDGTAISQLPMNMEKLQRLVVLNMKDCKMLEEIPGRVGELKALQ
ELILSDCLNLKIFPEIDISFLNILLLDGTAIEVMPQLPSVQYLCLSRNAKISCLPVGISQLSQLKWLDLKYCTSLTSVPE
FPPNLQCLDAHGCSSLKTVSKPLARIMPTEQNHSTFIFTNCENLEQAAKEEITSYAQRKCQLLSYARKRHNGGLVSESLF
STCFPGCEVPSWFCHETVGSELEVKLLPHWHDKKLAGIALCAVVSCLDPQDQVSRLSVTCTFKVKDEDKSWVPYTCPVGS
WTRHGGGKDKIELDHVFIGYTSCPHTIKCHEEGNSDECNPTEASLKFTVTGGTSENGKYKVLKCGLSLVYAKDKDKNSAL
ETKYDMLIGKSFQETSEGVDGRVKKTKGKYVMPVEKNFQETTEGVDGRVKKKKKTRMDNGRPKKKQRSGRDDNQTRMQVE
LQEGNINSVIMHTVKNF
>Q9SH22|PF00931(157...398)|Probable disease resistance protein At1g63360
MGISFSIPFDPCVNKVSQWLDMKVSYTHNLEKNLAALEKTMKELKAKRDDLERRLKREEARGLQRLSEFQVWLDSVATVE
DIIITLLRDRNVEIQRLCLCRFCSKSLTRSYRYGKSVFLRLREVEKLKGEVFGVITEQASTSAFEERPLQPTIVGQDTML
DKAGKHLMEDGVGIMGMYGMGGVGKTTLLTQLYNMFNKDKCGFDIGIWVVVSQEFHVEKVQDEIAQKLGLGGDEWTQKDK
SQKGICLYNILREKSFVLFLDDIWEKVDLAEIGVPDPRTKKGRKLAFTTRSQEVCARMGVEHPMEVQCLEENVAFDLFQK
KVGQTTLGSDPGIPQLARIVAKKCCGLPLALNVIGETMSCKRTIQEWRHAIHVLNSYAAEFIGMEDKVLPLLKYSYDNLK
GEQVKSSLLYCALYPEDAKILKEDLIEHWICEEIIDGSEGIEKAEDKGYEIIGCLVRASLLMEWDDGDGRRAVCMHDVVR
EMALWIASELGIQKEAFIVRAGVGVREIPKIKNWNVVRRMSLMENKIHHLVGSYECMELTTLLLGKREYGSIRSQLKTIS
SEFFNCMPKLAVLDLSHNKSLFELPEEISNLVSLKYLNLLYTEISHLPKGIQELKKIIHLNLEYTRKLESITGISSLHNL
KVLKLFRSRLPWDLNTVKELETLEHLEILTTTIDPRAKQFLSSHRLLSHSRLLEIYGSSVSSLNRHLESLSVSTDKLREF
QIKSCSISEIKMGGICNFLSLVDVNIFNCEGLRELTFLIFAPKIRSLSVWHAKDLEDIINEEKACEGEESGILPFPELNF
LTLHDLPKLKKIYWRPLPFLCLEEINIRECPNLRKLPLDSTSGKQGENGCIIRNKDSRWFEGVKWADEATKKRFLPSCQL
ISLK
>Q9SI85|PF00931(156...398)|Probable disease resistance protein At1g62630
MGISFSIPFDPCVNKVSQWLDMKGSYTHNLEKNLVALETTMEELKAKRDDLLRRLKREEDRGLQRLSEFQVWLNRVATVE
DIIITLLRDRDVEIQRLCLCRFCSKNLTTSYRYGKSVFLRLREVEKLKGEVFGVITEQASTSAFEERPLQPTIVGQKKML
DKAWKHLMEDGTGIMGMYGMGGVGKTTLLTQLFNMFNKDKCGFDIGIWVVVSQEVNVEKIQDEIAQKLGLGGHEWTQRDI
SQKGVHLFNFLKNKKFVLFLDDLWDKVELANIGVPDPRTQKGCKLAFTSRSLNVCTSMGDEEPMEVQCLEENVAFDLFQK
KVGQKTLGSDPGIPQLARIVAKKCCGLPLALNVIGETMSCKRTIQEWRNAIHVLNSYAAEFIGMEDKILPLLKYSYDNLK
GEHVKSSLLYCALYPEDAKIRKEDLIEHWICEEIIDGSEGIEKAEDKGYDIIGSLVRASLLMECVDLKGKSSVIMHDVVR
EMALWIASELGIQKEAFIVRAGVGVREIPKVKNWNVVRRMSLMGNKIHHLVGSYECMELTTLLLGEGEYGSIWRWSEIKT
ISSEFFNCMPKLAVLDLSHNQSLFELPEEISNLVSLKYLNLSHTGIRHLSKGIQELKKIIHLNLEHTSKLESIDGISSLH
NLKVLKLYGSRLPWDLNTVKELETLEHLEILTTTIDPRAKQFLSSHRLMSRSRLLQIFGSNIFSPDRQLESLSVSTDKLR
EFEIMCCSISEIKMGGICNFLSLVDVTIYNCEGLRELTFLIFAPKLRSLSVVDAKDLEDIINEEKACEGEDSGIVPFPEL
KYLNLDDLPKLKNIYRRPLPFLCLEKITIGECPNLRKLPLDSRSGKQGENGCIIHYKDSRWLKGVKWADEATKKRFLPSC
EHRLERCETIFED
>Q9SSR8|PF00931(151...365)|Probable disease resistance protein At1g52660
MGKDFKSLVTRCIYVGKMNDNAKKLKIATEELKDLGNNVMKRVKLCEEQQQMKRLDKVQTWLRQADTVIKEAEEYFLMSS
SSSSSGLISSSHKMEKKICKKLKEVQEIKSRGMFEVVAESTGGIGGGAGGGLTIKDSDEQTIGLEAVSGLVWRCLTMENT
GIIGLYGVEGVGKTTVLTQVNNRLLQQKANGFDFVLWVFVSKNLNLQKIQDTIREKIGFLDRTWTSKSEEEKAAKIFEIL
SKRRFALFLDDVWEKVDLVKAGVPPPDAQNRSKIVFTTCSEEVCKEMSAQTKIKVEKLAWERAWDLFKKNVGEDTIKSHP
DIAKVAQEVAARCDGLPLALVTIGRAMASKKTPQEWRDALYILSNSPPNFSGQIS
>Q9STE5|PF00931(173...392)|Putative disease resistance RPP13-like protein 2
MVDAITEFVVGKIDNYLIEEAPMLIGVKDDLEELKTELTCIQVYLKNVEVCDKEDEVSKEWTKLVLDIAYDVEDVLDTYF
LKLEKRLHRLGLMRLTNIISDKKDAYNILDDIKTLKRRTLDVTRKLEMYGIGNFNEHRVVASTSRVREVRRARSDDQEER
VVGLTDDAKVLLTKLLDDDGDNKIYMISIFGMEGLGKTSLARKLFNSSDVKESFEYRVWTNVSGECNTRDILMRIISSLE
ETSEGELEKMAQQELEVYLHDILQEKRYLVVVDDIWESEALESLKRALPCSYQGSRVIITTSIRVVAEGRDKRVYTHNIR
FLTFKESWNLFEKKAFRYILKVDQELQKIGKEMVQKCGGLPRTTVVLAGLMSRKKPNEWNDVWSSLRVKDDNIHVSSLFD
LSFKDMGHELKLCFLYLSVFPEDYEVDVEKLIQLLVAEGFIQEDEEMTMEDVARYYIEDLVYISLVEVVKRKKGKLMSFR
IHDLVREFTIKKSKELNFVNVYDEQHSSTTSRREVVHHLMDDNYLCDRRVNTQMRSFLFFGKRRNDITYVETITLKLKLL
RVLNLGGLHFICQGYSPWSLPDVIGGLVHLRYLGIADTVVNNLPDFISNLRFLQTLDASGNSFERMTDLSNLTSLRHLTG
RFIGELLIGDAVNLQTLRSISSYSWSKLKHELLINLRDLEIYEFHILNDQIKVPLDLVSLSKLKNLRVLKIEVVSFSLFS
EETVRFELLVKLTLHCDVRRLPRDMDLIFPSLESLTLVTNLQEDPMPTLQKLQRLENLVLYSCVYPGAKMFINAQGFGRL
RKLKVIIKRLDELEIEEEAMPCLMKLNLDNKDGATKLMIPDRMRAFV
>Q9STE7|PF00931(170...397)|Putative disease resistance RPP13-like protein 3
MVDAVTGFVLNKIGGYLINEVLALMGVKDDLEELKTELTCIHGYLKDVEAREREDEVSKEWTKLVLDIAYDIEDVLDTYF
LKLEERSLRRGLLRLTNKIGKKRDAYNIVEDIRTLKRRILDITRKRETFGIGSFNEPRGENITNVRVRQLRRAPPVDQEE
LVVGLEDDVKILLVKLLSDNEKDKSYIISIFGMGGLGKTALARKLYNSGDVKRRFDCRAWTYVSQEYKTRDILIRIIRSL
GIVSAEEMEKIKMFEEDEELEVYLYGLLEGKNYMVVVDDVWDPDAWESLKRALPCDHRGSKVIITTRIRAIAEGVEGTVY
AHKLRFLTFEESWTLFERKAFSNIEKVDEDLQRTGKEMVKKCGGLPLAIVVLSGLLSRKRTNEWHEVCASLWRRLKDNSI
HISTVFDLSFKEMRHELKLCFLYFSVFPEDYEIKVEKLIHLLVAEGFIQEDEEMMMEDVARCYIDELVDRSLVKAERIER
GKVMSCRIHDLLRDLAIKKAKELNFVNVYNEKQHSSDICRREVVHHLMNDYYLCDRRVNKRMRSFLFIGERRGFGYVNTT
NLKLKLLRVLNMEGLLFVSKNISNTLPDVIGELIHLRYLGIADTYVSILPASISNLRFLQTLDASGNDPFQYTTDLSKLT
SLRHVIGKFVGECLIGEGVNLQTLRSISSYSWSKLNHELLRNLQDLEIYDHSKWVDQRRVPLNFVSFSKPKNLRVLKLEM
RNFKLSSESRTTIGLVDVNFPSLESLTLVGTTLEENSMPALQKLPRLEDLVLKDCNYSGVKIMSISAQGFGRLKNLEMSM
ERRGHGLDELRIEEEAMPSLIKLTVKGRLELTKLMIPDRLKAFVRRN
>Q9SX38|PF00931(168...419)|Putative disease resistance protein At1g50180
MAEAIVSVTVQKLGQLLLEEPLFLFGIGDQVKQLQDELKRLNCFLKDADEKQHESERVRNWVAGIREASYDAEDILEAFF
LKAESRKQKGMKRVLRRLACILNEAVSLHSVGSEIREITSRLSKIAASMLDFGIKESMGREGLSLSDSLREQRQSFPYVV
EHNLVGLEQSLEKLVNDLVSGGEKLRVTSICGMGGLGKTTLAKQIFHHHKVRRHFDRFAWVYVSQDCRRRHVWQDIFLNL
SYKDENQRILSLRDEQLGEELHRFLKRNKCLIVLDDIWGKDAWDCLKHVFPHETGSEIILTTRNKEVALYADPRGVLHEP
QLLTCEESWELLEKISLSGRENIEPMLVKKMEEIGKQIVVRCGGLPLAITVLGGLLATKSTWNEWQRVCENIKSYVSNGG
SSNGSKNMLVADVLCLSYEYLPPHVKQCFLYFAHYPEDYEVHVGTLVSYCIAEGMVMPVKHTEAGTTVEDVGQDYLEELV
KRSMVMVGRRDIVTSEVMTCRMHDLMREVCLQKAKQESFVQVIDSRDQDEAEAFISLSTNTSRRISVQLHGGAEEHHIKS
LSQVSFRKMKLLRVLDLEGAQIEGGKLPDDVGDLIHLRNLSVRLTNVKELTSSIGNLKLMITLDLFVKGQLYIPNQLWDF
PVGKCNPRDLLAMTSLRRLSINLSSQNTDFVVVSSLSKVLKRLRGLTINVPCEPMLPPVDVTQLVSAFTNLCELELFLKL
EKLPGEQSFSSDLGALRLWQCGLVDDPFMVLEKLPNLKILQLFEGSFVGSKLCCSKNLENLEEWTVEDGAMMRLVTVELK
CCNKLKSVPEGTRFLKNLQEVEIGNRTKAFKDKLISGGEDFYKVQHVPCVVFENCEL
>Q9SZ66|PF00931(197...427)|Disease resistance-like protein DSC1
MESSSPSSAEFDVFLSFRGFDTRNNFTGHLQKALRLRGIDSFIDDRLRRGDNLTALFDRIEKSKIAIIVFSTNYANSAWC
LRELVKILECRNSNQQLVVPIFYKVDKSDVEKQRNSFAVPFKLPELTFPGVTPEEISSWKAALASASNILGYVVKEISTS
EAKLVDEIAVDTFKKLNDLAPSGNEGLVGIESRLKNLEKLLSWEDLDTVHIIGIVGMVGIGKTTLADCLYGRMRGQFDGS
CFLTNIRENSGRSGLESLLQKLFSTVLNDRDLEIGAPGNAHERFERRLKSKRLLIVLDDVNDEKQIRYLMGHCKWYQGGS
RIIITTRDSKLIETIKGRKYVLPKLNDREALKLFSLNAFSNSFPLKEFEGLTNMVLDYAKGHPLALKVLGSDLCERDDLY
WEAKLDRLKSRSHGDIYEVLETSYEELTTEQKNVFLDIACFFRSENVDYVTSLLNSHGVDVSGVVKDLVDKCLITLSDNR
IEMHDMLQTMAKEISLKVETIGIRDCRWLSRHGNQCQWHIRLWDSEDICDLLTEGLGTDKIRGIFLDTSKLRAMRLSAKA
FQGMYNLKYLKIYDSHCSRGCEAEFKLHLRRGLSFLPNELTYLHWHGYPLQSIPLDFDPKNLVDLKLPHSQLEEIWDDEK
DVGMLKWVDLSHSINLRQCLGLANAHNLERLNLEGCTSLKKLPSTINCLEKLIYLNLRDCTSLRSLPKGIKTQSLQTLIL
SGCSSLKKFPLISENVEVLLLDGTVIKSLPESIQTFRRLALLNLKNCKKLKHLSSDLYKLKCLQELILSGCSQLEVFPEI
KEDMESLEILLMDDTSITEMPKMMHLSNIKTFSLCGTSSHVSVSMFFMPPTLGCSRLTDLYLSRCSLYKLPDNIGGLSSL
QSLCLSGNNIENLPESFNQLNNLKWFDLKFCKMLKSLPVLPQNLQYLDAHECESLETLANPLTPLTVGERIHSMFIFSNC
YKLNQDAQASLVGHARIKSQLMANASAKRYYRGFVPEPLVGICYPATEIPSWFCHQRLGRSLEIPLPPHWCDINFVGLAL
SVVVSFKDYEDSAKRFSVKCCGNFENKDSSFTRFDFTLAGWNEPCGSLSHESRKLTSDHVFMGYNSCFLVKNVHGESNSC
CYTKASFEFYVTDDETRKKIETCEVIKCGMSLMYVPEDDDCMLLKKTNIVQLSLKSGPSCSYDLDDVMDDVRPKRGLCQF
VGGEEPGCKRRKEEKITVR
>Q9SZ67|PF00931(822...1031)|Probable WRKY transcription factor 19
MSEKEELPLTLTSIGAATATSDYHQRVGSSGEGISSSSSDVDPRFMQNSPTGLMISQSSSMCTVPPGMAATPPISSGSGL
SQQLNNSSSSKLCQVEGCQKGARDASGRCISHGGGRRCQKPDCQKGAEGKTVYCKAHGGGRRCEYLGCTKGAEGSTDFCI
AHGGGRRCNHEDCTRSAWGRTEFCVKHGGGARCKTYGCGKSASGPLPFCRAHGGGKKCSHEDCTGFARGRSGLCLMHGGG
KRCQRENCTKSAEGLSGLCISHGGGRRCQSIGCTKGAKGSKMFCKACITKRPLTIDGGGNMGGVTTGDALNYLKAVKDKF
EDSEKYDTFLEVLNDCKHQGVDTSGVIARLKDLFKGHDDLLLGFNTYLSKEYQITILPEDDFPIDFLDKVEGPYEMTYQQ
AQTVQANANMQPQTEYPSSSAVQSFSSGQPQIPTSAPDSSLLAKSNTSGITIIEHMSQQPLNVDKQVNDGYNWQKYGQKK
VKGSKFPLSYYKCTYLGCPSKRKVERSLDGQVAEIVYKDRHNHEPPNQGKDGSTTYLSGSSTHINCMSSELTASQFSSNK
TKIEQQEAASLATTIEYMSEASDNEEDSNGETSEGEKDEDEPEPKRRITEVQVSELADASDRTVREPRVIFQTTSEVDNL
DDGYRWRKYGQKVVKGNPYPRFSSSKDYDVVIRYGRADISNEDFISHLRASLCRRGISVYEKFNEVDALPKCRVLIIVLT
STYVPSNLLNILEHQHTEDRVVYPIFYRLSPYDFVCNSKNYERFYLQDEPKKWQAALKEITQMPGYTLTDKSESELIDEI
VRDALKVLCSADKVNMIGMDMQVEEILSLLCIESLDVRSIGIWGTVGIGKTTIAEEIFRKISVQYETCVVLKDLHKEVEV
KGHDAVRENFLSEVLEVEPHVIRISDIKTSFLRSRLQRKRILVILDDVNDYRDVDTFLGTLNYFGPGSRIIMTSRNRRVF
VLCKIDHVYEVKPLDIPKSLLLLDRGTCQIVLSPEVYKTLSLELVKFSNGNPQVLQFLSSIDREWNKLSQEVKTTSPIYI
PGIFEKSCCGLDDNERGIFLDIACFFNRIDKDNVAMLLDGCGFSAHVGFRGLVDKSLLTISQHNLVDMLSFIQATGREIV
RQESADRPGDRSRLWNADYIRHVFINDTGTSAIEGIFLDMLNLKFDANPNVFEKMCNLRLLKLYCSKAEEKHGVSFPQGL
EYLPSKLRLLHWEYYPLSSLPKSFNPENLVELNLPSSCAKKLWKGKKARFCTTNSSLEKLKKMRLSYSDQLTKIPRLSSA
TNLEHIDLEGCNSLLSLSQSISYLKKLVFLNLKGCSKLENIPSMVDLESLEVLNLSGCSKLGNFPEISPNVKELYMGGTM
IQEIPSSIKNLVLLEKLDLENSRHLKNLPTSIYKLKHLETLNLSGCISLERFPDSSRRMKCLRFLDLSRTDIKELPSSIS
YLTALDELLFVDSRRNSPVVTNPNANSTELMPSESSKLEILGTPADNEVVVGGTVEKTRGIERTPTILVKSREYLIPDDV
VAVGGDIKGLRPPVLQLQPAMKLSHIPRGSTWDFVTHFAPPETVAPPSSSSEAREEEVETEETGAMFIPLGDKETCSFTV
NKGDSSRTISNTSPIYASEGSFITCWQKGQLLGRGSLGSVYEGISADGDFFAFKEVSLLDQGSQAHEWIQQVEGGIALLS
QLQHQNIVRYRGTTKDESNLYIFLELVTQGSLRKLYQRNQLGDSVVSLYTRQILDGLKYLHDKGFIHRNIKCANVLVDAN
GTVKLADFGLAKVMSLWRTPYWNWMAPEVILNPKDYDGYGTPADIWSLGCTVLEMLTGQIPYSDLEIGTALYNIGTGKLP
KIPDILSLDARDFILTCLKVNPEERPTAAELLNHPFVNMPLPSSGSGSVSSLLRG
>Q9SZA7|PF00931(191...390)|Probable disease resistance protein At4g33300
MAITDFFAGEIATELLKQLFTISTTAWRYKNTAKQLLTLIDSIRPTIKEIQYSGVELPAHRQAQIGMLFDTLEKGKKLTD
KVLSSKRWNLYRQLTLARKMEKLEKTISNFLKNEVFTHILADVHHLRADTSVRLDRVDMSLDRVIQQVGSMKIGGGGLIS
EAMKRAEAMEIETNDDSEKFGVGLELGKVKVKKMMFESQGGVFGISGMGGVGKTTLAKELQRDHEVQCHFENRILFLTVS
QSPLLEELRELIWGFLSGCEAGNPVPDCNFPFDGARKLVILDDVWTTQALDRLTSFKFPGCTTLVVSRSKLTEPKFTYDV
EVLSEDEAISLFCLCAFGQKSIPLGFCKDLVKQVANECKGLPLALKVTGASLNGKPEMYWKGVLQRLSKGEPADDSHESR
LLRQMEASLDNLDQTTKDCFLDLGAFPEDRKIPLDVLINIWIELHDIDEGNAFAILVDLSHKNLLTLGKDPRLGSLYASH
YDIFVTQHDVLRDLALHLSNAGKVNRRKRLLMPKRELDLPGDWERNNDEHYIAQIVSIHTGEMNEMQWFDMEFPKAEILI
LNFSSDKYVLPPFISKMSRLKVLVIINNGMSPAVLHDFSIFAHLSKLRSLWLERVHVPQLSNSTTPLKNLHKMSLILCKI
NKSFDQTGLDVADIFPKLGDLTIDHCDDLVALPSSICGLTSLSCLSITNCPRLGELPKNLSKLQALEILRLYACPELKTL
PGEICELPGLKYLDISQCVSLSCLPEEIGKLKKLEKIDMRECCFSDRPSSAVSLKSLRHVICDTDVAFMWEEVEKAVPGL
KIEAAEKCFSLDWLDE
>Q9T048|PF00931(150...388)|Disease resistance protein At4g27190
MECCAPVIGEILRLMYESTFSRVANAIKFKSNVKALNESLERLTELKGNMSEDHETLLTKDKPLRLKLMRWQREAEEVIS
KARLKLEERVSCGMSLRPRMSRKLVKILDEVKMLEKDGIEFVDMLSVESTPERVEHVPGVSVVHQTMASNMLAKIRDGLT
SEKAQKIGVWGMGGVGKTTLVRTLNNKLREEGATQPFGLVIFVIVSKEFDPREVQKQIAERLDIDTQMEESEEKLARRIY
VGLMKERKFLLILDDVWKPIDLDLLGIPRTEENKGSKVILTSRFLEVCRSMKTDLDVRVDCLLEEDAWELFCKNAGDVVR
SDHVRKIAKAVSQECGGLPLAIITVGTAMRGKKNVKLWNHVLSKLSKSVPWIKSIEEKIFQPLKLSYDFLEDKAKFCFLL
CALFPEDYSIEVTEVVRYWMAEGFMEELGSQEDSMNEGITTVESLKDYCLLEDGDRRDTVKMHDVVRDFAIWIMSSSQDD
SHSLVMSGTGLQDIRQDKLAPSLRRVSLMNNKLESLPDLVEEFCVKTSVLLLQGNFLLKEVPIGFLQAFPTLRILNLSGT
RIKSFPSCSLLRLFSLHSLFLRDCFKLVKLPSLETLAKLELLDLCGTHILEFPRGLEELKRFRHLDLSRTLHLESIPARV
VSRLSSLETLDMTSSHYRWSVQGETQKGQATVEEIGCLQRLQVLSIRLHSSPFLLNKRNTWIKRLKKFQLVVGSRYILRT
RHDKRRLTISHLNVSQVSIGWLLAYTTSLALNHCQGIEAMMKKLVSDNKGFKNLKSLTIENVIINTNSWVEMVSTNTSKQ
SSDILDLLPNLEELHLRRVDLETFSELQTHLGLKLETLKIIEITMCRKLRTLLDKRNFLTIPNLEEIEISYCDSLQNLHE
ALLYHQPFVPNLRVLKLRNLPNLVSICNWGEVWECLEQVEVIHCNQLNCLPISSTCGRIKKIKGELSWWERLEWDDPSAL
TTVQPFFNPVREVPLLIADATTQML
>Q9XGM3|PF00931(211...449)|Disease resistance protein RPS4
METSSISTVEDKPPQHQVFINFRGADLRRRFVSHLVTALKLNNINVFIDDYEDRGQPLDVLLKRIEESKIVLAIFSGNYT
ESVWCVRELEKIKDCTDEGTLVAIPIFYKLEPSTVRDLKGKFGDRFRSMAKGDERKKKWKEAFNLIPNIMGIIIDKKSVE
SEKVNEIVKAVKTALTGIPPEGSHNAVVGALGNSNAGTSSGDKKHETFGNEQRLKDLEEKLDRDKYKGTRIIGVVGMPGI
GKTTLLKELYKTWQGKFSRHALIDQIRVKSKHLELDRLPQMLLGELSKLNHPHVDNLKDPYSQLHERKVLVVLDDVSKRE
QIDALREILDWIKEGKEGSRVVIATSDMSLTNGLVDDTYMVQNLNHRDSLQLFHYHAFIDDQANPQKKDFMKLSEGFVHY
ARGHPLALKVLGGELNKKSMDHWNSKMKKLAQSPSPNIVSVFQVSYDELTTAQKDAFLDIACFRSQDKDYVESLLASSDL
GSAEAMSAVKSLTDKFLINTCDGRVEMHDLLYKFSREVDLKASNQDGSRQRRLWLHQHIIKGGIINVLQNKMKAANVRGI
FLDLSEVEDETSLDRDHFINMGNLRYLKFYNSHCPQECKTNNKINIPDKLKLPLKEVRCLHWLKFPLETLPNDFNPINLV
DLKLPYSEMEQLWEGDKDTPCLRWVDLNHSSKLCSLSGLSKAEKLQRLNLEGCTTLKAFPHDMKKMKMLAFLNLKGCTSL
ESLPEMNLISLKTLTLSGCSTFKEFPLISDNIETLYLDGTAISQLPMNMEKLQRLVVLNMKDCKMLEEIPGRVGELKALQ
ELILSDCLNLKIFPEIDISFLNILLLDGTAIEVMPQLPSVQYLCLSRNAKISCLPVGISQLSQLKWLDLKYCTSLTSVPE
FPPNLQCLDAHGCSSLKTVSKPLARIMPTEQNHSTFIFTNCENLEQAAKEEITSYAQRKCQLLSYARKRYNGGLVSESLF
STCFPGCEVPSWFCHETVGSELEVKLLPHWHDKKLAGIALCAVVSCLDPQDQVSRLSVTCTFKVKDEDKSWVAYTCPVGS
WTRHGGGKDKIELDHVFIGYTSCPHTIKCHEEGNSDECNPTEASLKFTVTGGTSENGKYKVLKCGLSLVYAKDKDKNSAL
ETKYDMLIGKSFQETSEGVDGRVKKTKGKYVMPVEKNFQETTEGVDGRVNKKKKTRMDNGRPKKKQRSGRDDNQTRMQVE
LQEGNINSVIMHTVKNF
>Q9XIF0|PF00931(164...410)|Putative disease resistance protein At1g59780
MQDLYMVDSIVSFGVEKLWKLLSQEYERFQGVEEQITELRDDLKMLMAFLSDADAKKQTRALARNCLEEIKEITYDAEDI
IEIFLLKGSVNMRSLACFPGGRREIALQITSISKRISKVIQVMQNLGIKSDIMDGVDSHAQLERKRELRHTFSSESESNL
VGLEKNVEKLVEELVGNDSSHGVSITGLGGLGKTTLARQIFDHDKVKSHFDGLAWVCVSQEFTRKDVWKTILGNLSPKYK
DSDLPEDDIQKKLFQLLETKKALIVFDDLWKREDWYRIAPMFPERKAGWKVLLTSRNDAIHPHCVTFKPELLTHDECWKL
LQRIAFSKQKTITGYIIDKEMVKMAKEMTKHCKRLPLAVKLLGGLLDAKHTLRQWKLISENIISHIVVGGTSSNENDSSS
VNHVLSLSFEGLPGYLKHCLLYLASYPEDHEIEIERLSYVWAAEGITYPGNYEGATIRDVADLYIEELVKRNMVISERDA
LTSRFEKCQLHDLMREICLLKAKEENFLQIVTDPTSSSSVHSLASSRSRRLVVYNTSIFSGENDMKNSKLRSLLFIPVGY
SRFSMGSNFIELPLLRVLDLDGAKFKGGKLPSSIGKLIHLKYLSLYQASVTYLPSSLRNLKSLLYLNLRINSGQLINVPN
VFKEMLELRYLSLPWERSSLTKLELGNLLKLETLINFSTKDSSVTDLHRMTKLRTLQILISGEGLHMETLSSALSMLGHL
EDLTVTPSENSVQFKHPKLIYRPMLPDVQHFPSHLTTISLVYCFLEEDPMPTLEKLLQLKVVSLWYNAYVGRRMVCTGGG
FPPLHRLEIWGLDALEEWIVEEGSMPLLHTLHIVDCKKLKEIPDGLRFISSLKELAIRTNEKVFQKKVSKGGEDYYKMQH
VPLIRYNWPQEPENNEVIYSFPSPII
>V9M2S5|PF00931(201...440)|Disease resistance protein RPV1
MASTSSFRASSSSSTPSIPRTTTYDVFLSFRGEDTRYNFTDHLYSALGRRGIRTFRDDRLRRGEAIAPELLKAIEESRSS
VIVFSENYAHSRWCLDELVKIMECQKDLGHAVFPIFYHVDPSHVRKQEGSFGEAFAGYEENWKDKIPRWRTALTEAANLS
GWHLLDDRYESNQIKEITNSIFRQLKCKRLDVGANLVGIDSHVKEMILRLHLESSDVRMVGIYGVGGIGKTTIAKVIYNE
LSCEFEYMSFLENIREGSNPQVLFHLQNQLLGDILEGEGSQNISSVAHRASMIKDILLSRRVFIVLDDVDDLSQLEYLLG
HREWLGEGSRVIITTRNKHVLAVQEVDDLYEVEGLNFEEACELFSLYAFKQNLPKSDYRNLTCRVVGYCQGLPLALKVLG
SLLCKKTIPQWEGELKKLDSEPKADIHKVLKRSYDGLDRIDKNIFLDLACFFKGEGRDFVLRILDGCDFPAETGISNLND
LCLITLPYNQICMHDLIQQMGWEIVRENFPVEPNKWSRLWDPCDFERALTADEGIKSVETMSLDLSKLKRVCSNSNVFAK
MTKLRLLKVYSSSDIDSAHGDSDEDIEEVYDVVMKDASKMQLGQSFKFPSYELRYLRWDGYPLDSLPLNFDGGKLVELHL
KCSNIKQLWQGHKDLERLKVIDLSYSRKLSQMSEFSSMPNLERLCLSGCVSLIDIHPSVGNMKKLTTLSLRSCNKLKNLP
DSIGDLESLESLYLSNCSKFEKFPEKGGNMKSLTELDLKNTAIKDLPDSIGDLESLESLYLSNCSKFEKFPEKGGNMKSL
TELDLKNTAIKDLPDSIGDLESLEILNLSDCAKFEKFPEKGGNMKSLKELDLQNTAIKDLPDSIGDLKSLKYLSLSDCSK
FEKFPEKGGNMKRLLQLILSNTAIKDLPDSIGDLESLKYLYLSDCSKFEKFPEKGGNMKSLTELDLKNTAIKDLPDSIGD
LESLEILNLSDCAKFEKFPEKGGNMKSLKELDLQNTAIKDLPDSIGDLESLKYLYLSDCSKFEKFPEKGGNMKSLLQLIL
SNTAIKDLPDSIGDLESLEYLHLSVCSKFEKFPEKGGNMKSLRELGLRNTAIKDLPDSIGDLESLEMLSLSNCPKFEVLP
LSLKAIDAHLCTSKEDLSRLLWLCHRNWLKSTTEEFDRWQLSAFIPESSGIPEWITYQNLGSEVTEKLPINWCEDPDFPG
FVLSCVYRPSCDYSSAYIFCHDFKCELNLHGNGFRFRDVCYHECWCDCHVNFKDSRDLVCVYWYPKTAIPEEDHHKYTHI
NASFKSDEVKIKKCGINVIFLGDQRNHMPMLEHPQNSGDNGSALQDANGNVHGANQDDEHYHIPLLDLLRNLSLGDNGSV
VLEDTLGNRKRRRNDSLPDVVEEPLYKRLGGPHTEISL
>V9M398|PF00931(206...434)|Disease resistance protein RUN1
MASTSSSRASSSSSSSSTPSIPRTITYDVFLSFRGEDTRFNFTDHLYSALGRRGIRTFRDDKLRRGEAIAPELLKAIEES
RSSVIVFSENYARSRWCLDELVKIMECHKDKKDPGHAVFPIFYHVDPSHVRKQEGSFGEAFAGYGENLKDKIPRWRTALT
EAANLSGWPLQDGYESNQIKEITDSIFRRLKCKRLDAGANLVGIDSHVKEMIWRLHMESSDVRMVGMYGVGGIGKTTIAK
VIYNELSREFEYMSFLENIREKFNTQGVSPLQNQLLDDILKGEGSQNINSVAHGASMIKDILSSKIVFIVLDDVDDQSQL
EYLLRHREWLGEGSRVIITTRNKHVLDVQKVDDLYEVKGLNFEEACELFSLYAFEQNLPKSDYRNLSHRVVGYCQGLPLA
LKVLGCLLLKKTIPEWESELRKLDREPEAEILSVLKRSYDGLGRTEKSIFLDVACFFKGEDRDFVSKILDACDFHAEIGI
KNLNDKCLITLQYNRIRMHDLIQQMGWEIVREKFPDEPNKWSRLWDTCDFERALTAYKGIKRVETISLDLSKLKRVCSNS
NAFAKMTRLRLLKVQSSLDIDFEPEYIDADDKVELYDVVMKNASKMRLGRGFKFPSYELRYLRWDGYPLDFLPSNFDGGK
LVELHLKCSNIKQLRLGNKDLEMLKVIDLSYSRKLSQMSEFSSMPNLERLFLRGCVSLIDIHPSVGNMKKLTTLSLKSCK
KLKNLPDSIGDLESLEILDLAYCSKFEKFPEKGGNMKSLTELDLQNTAIKDLPDSIGDLESLKYLDLSDCSKFEKFPEKG
GNMKSLRELDLRNTAIKDLPDSIRDLESLERLYLSYCSKFEKFPEKGGNMKSLMELDLQNTAIKDLPDSIGDLESLKYLD
LSNCSKFEKFPEKGGNMKSLTELFLENTAIKDLPDSIGDLESLVSLNLSDCSKFEKFPEKGGNMKSLNWLYLNNTAIKDL
PDSIGDLESLMRLYLSNSSKFEKLPEKVGNMKSLELLDLRNTAIKDLPDSIGDLEPLEKLSLSNCPKFEVLPLSLKAIDA
HLCTSKEDLSRLLWLCHRNWLKSTTEEFDRWQLSAFIPESSGIPEWITYQNLGSEVTEKLPINWCEDPDFPGFVLSCLYR
PSDYSSAYNFCHDFKCELNLHGNGFTFTDECSHSCWCDCHVNFKDSRDLVCVYWYPKTAIPEEDHHKYTHINASFTHRFE
GHPFFCEDIKKIKCGINVIFLGDQRNHMPMLEHPQNSGDNGSALQDANGNVHGANQDDEHYHIPTLGLLGNFHDNGSAVL
EDTLGNRKRRRDDSLPDVVEEPHYKKIGSHPTPISCFELHHQYQSEQNHMW
